Table of Contents

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 24, 2017April 1, 2018
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to 
Commission file number: 001-35065
WRIGHT MEDICAL GROUP N.V.
(Exact name of registrant as specified in its charter)
The Netherlands 98-0509600
(State or other jurisdiction
of incorporation or organization)
 
(I.R.S. Employer
Identification No.)
Prins Bernhardplein 200
1097 JB Amsterdam, The Netherlands
(Address of principal executive offices)
 
None
(Zip Code)
(+31) 20 521 4777
(Registrant’s telephone number, including area code)
Not applicable
(Former name, former address and former fiscal year, if changed since last report)
_________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     þ Yes o No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). þ Yes o No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company" and "emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer þ
 
Accelerated filer o
Non-accelerated filer o
(Do not check if a smaller reporting company)
 
Smaller reporting company o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes þ No
As of October 27, 2017,May 4, 2018, there were 105,015,417105,969,807 ordinary shares outstanding.
 

WRIGHT MEDICAL GROUP N.V.

QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 24, 2017APRIL 1, 2018

TABLE OF CONTENTS
 Page
PART I — FINANCIAL INFORMATION
 
  
Item 1. Financial Statements (unaudited).
5
  Condensed Consolidated Balance Sheets as of September 24, 2017April 1, 2018 and December 25, 201631, 2017
5
Condensed Consolidated Statements of Operations for the threeThree Months ended April 1, 2018 and nine months ended September 24,March 26, 2017 and September 25, 2016
6
Condensed Consolidated Statements of Comprehensive Loss for the threeThree Months ended April 1, 2018 and nine months ended September 24,March 26, 2017 and September 25, 2016
7
Condensed Consolidated Statements of Cash Flows for the nine monthsThree Months ended September 24,April 1, 2018 and March 26, 2017 and September 25, 2016
8
  Notes to Condensed Consolidated Financial Statements
9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
4037
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
5347
Item 4. Controls and Procedures.
5649
  
PART II — OTHER INFORMATION
 
  
Item 1. Legal Proceedings.
5650
Item 1A. Risk Factors.
6054
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
6256
Item 3. Defaults Upon Senior Securities.
6256
Item 4. Mine Safety Disclosures.
6257
Item 5. Other Information.
6257
Item 6. Exhibits.
6258
  
SIGNATURES
6359


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This document may contain certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act), and that are subject to the safe harbor created by those sections. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current view of future performance, results, and trends. Forward-lookingForward looking statements may be identified by their use of terms such as anticipate, believe, could, estimate, expect, intend, may, plan, predict, project, will, and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The reader should not place undue reliance on forward-looking statements. Such statements are made as of the date of this report, and we undertake no obligation to update such statements after this date. Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements are discussed in our filings with the U.S. Securities and Exchange Commission (SEC) (including our most recent Annual Report on Form 10-K, which was filed with the SEC on February 23, 2017)27, 2018). By way of example and without implied limitation, such risks and uncertainties include:
inability to achieve or sustain profitability;
failure to realize the anticipated benefits from previous acquisitions and dispositions;
•
failure to obtain anticipated commercial sales of our AUGMENT® Bone Graft products in the United States;
failure to realize the anticipated benefits of the 2017 additions to our direct U.S. lower extremities and biologics sales force;
liability for product liability claims on hip/knee (OrthoRecon) products sold by Wright Medical Technology, Inc. (WMT) prior to the divestiture of the OrthoRecon business;
risks and uncertainties associated with our metal-on-metal master settlement agreements and the settlement agreements with certain of our insurance companies, including without limitation, the resolution of the remaining unresolved claims, the effect of the broad release of certain insurance coverage for present and future claims, and the resolution of WMT’s dispute with the remaining carriers;
adverse outcomes in existing product liability litigation;
copycat claims against our modular hip systems resulting from a competitor’s recall of its modular hip product;
the ability of a creditor of any one particular entity within our corporate structure to reach the assets of the other entities within our corporate structure not liable for the underlying claims of the one particular entity, despite our corporate structure which is intended to ring-fence liabilities;
new product liability claims;
pending and future other litigation, which could have an adverse effect on our business, financial condition, or operating results;
challenges to our intellectual property rights or inability to defend our products against the intellectual property rights of others;
the possibility of private securities litigation or shareholder derivative suits;
inadequate insurance coverage;
inability to generate sufficient cash flow to satisfy our capital requirements, including future milestone payments, and existing debt, including the conversion features of our convertible senior notes, or refinance our existing debt as it matures;
risks associated with our credit, security and guaranty agreement for our senior secured asset based line of credit;
inability to raise additional financing when needed and on favorable terms;
the loss of key suppliers, which may result in our inability to meet customer orders for our products in a timely manner or within our budget;
the incurrence of significant expenditures of resources to maintain relatively high levels of inventory, which could reduce our cash flows and increase the risk of inventory obsolescence, which could harm our operating results;
our inability to timely manufacture products or instrument sets to meet demand;
our private label manufacturers failing to provide us with sufficient supply of their products, or failing to meet appropriate quality requirements;
our plans to bring the manufacturing of certain of our products in-house and possible disruptions we may experience in connection with such transition;
our plans to increase our gross margins by taking certain actions designed to do so;
inventory reductions or fluctuations in buying patterns by wholesalers or distributors;
not successfully competing against our existing or potential competitors and the effect of significant recent consolidations amongst our competitors;
not successfully developing and marketing new products and technologies and implementing our business strategy;
insufficient demand for and market acceptance of our new and existing products;
the reliance of our business plan on certain market assumptions;
lack of suitable business development opportunities;
inability to capitalize on business development opportunities;

future actions of the SEC, the United States Attorney’s office, the U.S. Food and Drug Administration (FDA), the Department of Health and Human Services, or other U.S. or foreign government authorities, including those resulting from increased scrutiny under the U.S. Foreign Corrupt Practices Act and similar laws, that could delay, limit, or suspend our development, manufacturing, commercialization, and sale of products, or result in seizures, injunctions, monetary sanctions, or criminal or civil liabilities;
failure or delay in obtaining FDA or other regulatory approvals for our products;
the compliance of our products and activities with the laws and regulations of the countries in which they are marketed, which compliance may be costly and time-consuming;
the use, misuse or off-label use of our products that may harm our image in the marketplace or result in injuries that may lead to product liability suits, which could be costly to our business or result in governmental sanctions;
recently enacted healthcare laws and changes in product reimbursements, which could generate downward pressure on our product pricing;
the potentially negative effect of our ongoing compliance efforts on our relationships with customers and on our ability to deliver timely and effective medical education, clinical studies, and new products;
failures of, interruptions to, or unauthorized tampering with, our information technology systems;
our inability to maintain effective internal controls;
product quality or patient safety issues;
geographic and product mix impact on our sales;
deriving a significant portion of our revenues from operations in certain geographic markets that are subject to political, economic, and social instability, including in particular France, and risks and uncertainties involved in launching our products in certain new geographic markets;
the negative impact of the commercial and credit environment on us, our customers, and our suppliers;
inability to retain key sales representatives, independent distributors, and other personnel or to attract new talent;
consolidation in the healthcare industry that could lead to demands for price concessions or the exclusion of some suppliers from certain of our markets, which could have an adverse effect on our business, financial condition, or operating results;
our clinical trials and their results and our reliance on third parties to conduct them;
risks associated with the merger between Tornier N.V. (Tornier or legacy Tornier) and Wright Medical Group, Inc. (WMG or legacy Wright), including the failure to realize intended benefits and anticipated synergies and cost-savings from the transaction or delay in realization thereof; our businesses may not be combined successfully, or such combination may take longer, be more difficult, time-consuming or costly to accomplish than expected; and business disruption after the transaction, including adverse effects on employee retention, our sales and distribution channel, especially in light of territory transitions, and business relationships with third parties;
risks associated with the divestiture of the U.S. rights to certain of legacy Tornier's ankle and silastic toe replacement products;
liability for product liability claims on hip/knee (OrthoRecon) products sold by Wright Medical Technology, Inc. (WMT) prior to the divestiture of the OrthoRecon business;
risks and uncertainties associated with the metal-on-metal master settlement agreement, the settlement agreement with the three insurance companies, and the recent metal-on-metal settlement agreements, including without limitation, the final settlement amounts and the final number of claims settled under such agreements, the resolution of the remaining unresolved claims, the contingency of receipt of new insurance payments, the effect of the broad release of certain insurance coverage for present and future claims, and the resolution of WMT’s dispute with the remaining carriers;
failure to realize the anticipated benefits from previous acquisitions and dispositions;
adverse outcomes in existing product liability litigation;
new product liability claims;
inadequate insurance coverage;
copycat claims against our modular hip systems resulting from a competitor’s recall of its modular hip product;
the ability of a creditor of any one particular entity within our corporate structure to reach the assets of the other entities within our corporate structure not liable for the underlying claims of the one particular entity, despite our corporate structure which is intended to ring-fence liabilities;
•
failure to obtain anticipated commercial sales of our AUGMENT® Bone Graft in the United States;
challenges to our intellectual property rights or inability to defend our products against the intellectual property rights of others;
adverse effects of diverting resources and attention to transition services provided to the purchaser of our Large Joints business;
failures of, interruptions to, or unauthorized tampering with, our information technology systems;
failure or delay in obtaining FDA or other regulatory approvals for our products;
the potentially negative effect of our ongoing compliance efforts on our relationships with customers and on our ability to deliver timely and effective medical education, clinical studies, and new products;
the possibility of private securities litigation or shareholder derivative suits;
insufficient demand for and market acceptance of our new and existing products;
recently enacted healthcare laws and changes in product reimbursements, which could generate downward pressure on our product pricing;
potentially burdensome tax measures;
lack of suitable business development opportunities;
inability to capitalize on business development opportunities;
product quality or patient safety issues;

geographic and product mix impact on our sales;
inability to retain key sales representatives, independent distributors, and other personnel or to attract new talent;
inventory reductions or fluctuations in buying patterns by wholesalers or distributors;
inability to generate sufficient cash flow to satisfy our capital requirements, including future milestone payments, and existing debt, including the conversion features of our convertible senior notes, or refinance our existing debt as it matures;
risks associated with our credit, security and guaranty agreement for our senior secured asset-based line of credit;
inability to raise additional financing when needed and on favorable terms;
the negative impact of the commercial and credit environment on us, our customers, and our suppliers;
deriving a significant portion of our revenues from operations in certain geographic markets that are subject to political, economic, and social instability, including in particular France, and risks and uncertainties involved in launching our products in certain new geographic markets;
fluctuations in foreign currency exchange rates;
not successfully developing and marketing new products and technologies and implementing our business strategy;
not successfully competing against our existing or potential competitors and the effect of significant recent consolidations amongst our competitors;
the reliance of our business plan on certain market assumptions;
our private label manufacturers failing to provide us with sufficient supply of their products, or failing to meet appropriate quality requirements;
our inability to timely manufacture products or instrument sets to meet demand;
our plans to bring the manufacturing of certain of our products in-house and possible disruptions we may experience in connection with such transition;
our plans to increase our gross margins by taking certain actions designed to do so;
the loss of key suppliers, which may result in our inability to meet customer orders for our products in a timely manner or within our budget;
the incurrence of significant expenditures of resources to maintain relatively high levels of inventory, which could reduce our cash flows and increase the risk of inventory obsolescence, which could harm our operating results;
consolidation in the healthcare industry that could lead to demands for price concessions or the exclusion of some suppliers from certain of our markets, which could have an adverse effect on our business, financial condition, or operating results;
our clinical trials and their results and our reliance on third parties to conduct them;
the compliance of our products and activities with the laws and regulations of the countries in which they are marketed, which compliance may be costly and time-consuming;
the use, misuse or off-label use of our products that may harm our image in the marketplace or result in injuries that may lead to product liability suits, which could be costly to our business or result in governmental sanctions;
pending and future other litigation, which could have an adverse effect on our business, financial condition, or operating results; and
risks that we may identify future material weaknesses in our internal control over financial reporting.rates.
For more information regarding these and other uncertainties and factors that could cause our actual results to differ materially from what we have anticipated in our forward-looking statements or otherwise could materially adversely affect our business, financial condition, or operating results, see ““Part I. Item 1A. Risk Factors”Factors” of our most recent Annual Report on Form 10-K.10-K and “Part II. Item 1A. Risk Factors” of this report. The risks and uncertainties described above and in “Part I. Item 1A. Risk Factors” of our most recent Annual Report on Form 10-K and “Part II. Item 1A. Risk Factors” of this report are not exclusive and further information concerning us and our business, including factors that potentially could materially affect our financial results or condition, may emerge from time to time. We assume no obligation to update, amend, or clarify forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements. We advise you, however, to consult any further disclosures we make on related subjects in our future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K we file with or furnish to the SEC.



PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (unaudited).
Wright Medical Group N.V.
Condensed Consolidated Balance Sheets
(In thousands, except share data)
(unaudited)
Wright Medical Group N.V.
Condensed Consolidated Balance Sheets
(In thousands, except share data)
(unaudited)
Wright Medical Group N.V.
Condensed Consolidated Balance Sheets
(In thousands, except share data)
(unaudited)
September 24, 2017 December 25, 2016April 1, 2018 December 31, 2017
Assets:      
Current assets:      
Cash and cash equivalents$238,867
 $262,265
$138,051
 $167,740
Restricted cash38,922
 150,000
Accounts receivable, net114,948
 130,602
130,597
 130,610
Inventories172,311
 150,849
174,381
 168,144
Prepaid expenses14,159
 11,678
13,885
 13,555
Other current assets61,912
 54,231
67,812
 86,845
Total current assets641,119
 759,625
524,726
 566,894
      
Property, plant and equipment, net211,785
 201,732
212,331
 212,379
Goodwill860,860
 851,042
942,579
 933,662
Intangible assets, net226,617
 231,797
227,278
 231,001
Deferred income taxes1,690
 1,498
955
 937
Other assets258,612
 244,892
168,672
 183,851
Total assets$2,200,683
 $2,290,586
$2,076,541
 $2,128,724
Liabilities and Shareholders’ Equity:      
Current liabilities:      
Accounts payable$43,481
 $32,866
$43,334
 $41,831
Accrued expenses and other current liabilities387,561
 407,704
267,351
 314,558
Current portion of long-term obligations56,783
 33,948
59,340
 58,906
Total current liabilities487,825
 474,518
370,025
 415,295
      
Long-term debt and capital lease obligations818,873
 780,407
851,522
 836,208
Deferred income taxes27,813
 27,550
15,367
 15,780
Other liabilities327,656
 321,247
256,452
 272,745
Total liabilities1,662,167
 1,603,722
1,493,366
 1,540,028
Commitments and contingencies (Note 12)
   
Commitments and contingencies (Note 13)

 
Shareholders’ equity:      
Ordinary shares, €0.03 par value, authorized: 320,000,000 shares; issued and outstanding: 105,011,678 shares at September 24, 2017 and 103,400,995 shares at December 25, 20163,868
 3,815
Ordinary shares, €0.03 par value, authorized: 320,000,000 shares; issued and outstanding: 105,949,645 shares at April 1, 2018 and 105,807,424 shares at December 31, 20173,901
 3,896
Additional paid-in capital1,947,717
 1,908,749
1,978,877
 1,971,347
Accumulated other comprehensive income (loss)24,901
 (19,461)
Accumulated other comprehensive income34,748
 22,290
Accumulated deficit(1,437,970) (1,206,239)(1,434,351) (1,408,837)
Total shareholders’ equity538,516
 686,864
583,175
 588,696
Total liabilities and shareholders’ equity$2,200,683
 $2,290,586
$2,076,541
 $2,128,724
The accompanying notes are an integral part of these condensed consolidated financial statements.

Wright Medical Group N.V.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(unaudited)
Wright Medical Group N.V.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(unaudited)
Wright Medical Group N.V.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(unaudited)
Three months ended Nine months endedThree months ended
September 24, 2017 September 25, 2016 September 24, 2017 September 25, 2016April 1, 2018 March 26, 2017
Net sales$170,503
 $157,332
 $527,387
 $497,339
$198,537
 $177,191
Cost of sales 1, 2
38,421
 46,149
 113,669
 141,824
Cost of sales 1
41,139
 37,126
Gross profit132,082
 111,183
 413,718
 355,515
157,398
 140,065
Operating expenses:          
Selling, general and administrative 1
131,421
 129,840
 392,073
 401,069
137,248
 129,834
Research and development 1
11,992
 12,481
 36,971
 36,705
13,899
 12,432
Amortization of intangible assets7,178
 7,466
 21,574
 21,407
7,141
 7,397
Total operating expenses150,591
 149,787
 450,618
 459,181
158,288
 149,663
Operating loss(18,509) (38,604) (36,900) (103,666)(890) (9,598)
Interest expense, net18,978
 16,795
 55,512
 41,673
19,812
 18,195
Other expense (income), net5,457
 (365) 6,875
 (3,494)
Other (income) expense, net(1,000) 7,975
Loss from continuing operations before income taxes(42,944) (55,034) (99,287) (141,845)(19,702) (35,768)
Benefit for income taxes(8,822) (2,325) (7,498) (6,913)
Provision for income taxes205
 939
Net loss from continuing operations(34,122) (52,709) (91,789) (134,932)(19,907) (36,707)
Loss from discontinued operations, net of tax(97,748) (57,436) (139,942) (252,571)(5,607) (21,992)
Net loss$(131,870) $(110,145) $(231,731) $(387,503)$(25,514) $(58,699)
          
Net loss from continuing operations per share-basic and diluted (Note 11):
$(0.33) $(0.51) $(0.88) $(1.31)
Net loss from discontinued operations per share-basic and diluted (Note 11):
$(0.93) $(0.56) $(1.34) $(2.46)
Net loss per share-basic and diluted (Note 11):
$(1.26) $(1.07) $(2.22) $(3.77)
Net loss from continuing operations per share-basic and diluted (Note 12):
$(0.19) $(0.35)
Net loss from discontinued operations per share-basic and diluted (Note 12):
$(0.05) $(0.21)
Net loss per share-basic and diluted (Note 12):
$(0.24) $(0.57)
          
Weighted-average number of ordinary shares outstanding-basic and diluted:104,836
 103,072
 104,292
 102,854
105,904
 103,663
___________________________
1 
These line items include the following amounts of non-cash, share-based compensation expense for the periods indicated:
Three months ended Nine months endedThree months ended
September 24, 2017 September 25, 2016 September 24, 2017 September 25, 2016April 1, 2018 March 26, 2017
Cost of sales$152
 $146
 $403
 $321
$165
 $119
Selling, general and administrative4,960
 3,168
 12,939
 9,070
4,522
 3,656
Research and development333
 214
 789
 510
331
 179
2
Cost of sales includes amortization of inventory step-up adjustment of $10.3 million and $30.9 million for the three and nine months ended September 25, 2016, respectively.
The accompanying notes are an integral part of these condensed consolidated financial statements.

Wright Medical Group N.V.
Condensed Consolidated Statements of Comprehensive Loss
(In thousands)
(unaudited)
Three months ended Nine months endedThree months ended
September 24, 2017 September 25, 2016 September 24, 2017 September 25, 2016April 1, 2018 March 26, 2017
Net loss$(131,870) $(110,145) $(231,731) $(387,503)$(25,514) $(58,699)
          
Other comprehensive income:          
Changes in foreign currency translation25,132
 4,480
 44,362
 11,763
12,458
 8,445
Other comprehensive income25,132
 4,480
 44,362
 11,763
12,458
 8,445
          
Comprehensive loss$(106,738) $(105,665) $(187,369) $(375,740)$(13,056) $(50,254)
The accompanying notes are an integral part of these condensed consolidated financial statements.


Wright Medical Group N.V.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(unaudited)
Wright Medical Group N.V.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(unaudited)
Wright Medical Group N.V.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(unaudited)
Nine months endedThree months ended
September 24, 2017 September 25, 2016April 1, 2018 March 26, 2017
Operating activities:      
Net loss$(231,731) $(387,503)$(25,514) $(58,699)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation42,124
 42,066
14,499
 13,446
Share-based compensation expense14,131
 9,901
5,018
 3,954
Amortization of intangible assets21,574
 21,746
7,141
 7,397
Amortization of deferred financing costs and debt discount37,373
 28,676
13,302
 12,184
Deferred income taxes(2,059) (9,534)(780) —
Provision for excess and obsolete inventory13,770
 16,171
5,020
 3,650
Write-off of deferred financing costs—
 12,343
Amortization of inventory step-up adjustment—
 34,346
Non-cash adjustment to derivative fair values(4,163) (26,460)1,694
 365
Impairment loss on large joints assets held for sale (Note 3)
—
 21,876
Mark-to-market adjustment for CVRs (Note 5)
6,721
 8,968
Mark-to-market adjustment for CVRs (Note 6)
(3,924) 6,160
Other2,093
 3,494
215
 651
Changes in assets and liabilities:      
Accounts receivable18,807
 9,900
565
 12,584
Inventories(28,210) (3,662)(10,403) (7,281)
Prepaid expenses and other current assets5,851
 20,066
22,034
 4,579
Accounts payable8,260
 (6,659)975
 2,636
Accrued expenses and other liabilities(21,343) (9,820)(20,478) (26,497)
Metal-on-metal product liabilities (Note 12)
(12,506) 188,732
Metal-on-metal product liabilities (Note 13)
(28,172) 10,393
Net cash used in operating activities(129,308) (25,353)(18,808) (14,478)
Investing activities:      
Capital expenditures(49,476) (37,800)(11,886) (12,149)
Purchase of intangible assets(1,408) (4,761)(553) (875)
Net cash used in investing activities(50,884) (42,561)(12,439) (13,024)
Financing activities:      
Issuance of ordinary shares24,828
 5,654
2,639
 14,648
Proceeds from stock warrants—
 54,629
Payment of notes hedge options—
 3,892
Repurchase of stock warrants—
 (3,319)
Payment of notes premium—
 (1,619)
Proceeds from notes hedge options—
 (99,816)
Proceeds from convertible senior notes—
 395,000
Proceeds from other debt32,000
 821
Proceeds from debt2,042
 —
Payments of debt(10,722) —
(1,266) (12,792)
Redemption of convertible senior notes—
 (102,974)
Payments of deferred financing costs and equity issuance costs—
 (8,318)
Payment of contingent consideration(1,429) (664)(919) (987)
Payments of capital lease obligations(1,863) (1,822)(1,388) (482)
Net cash provided by financing activities42,814
 241,464
1,108
 387
Effect of exchange rates on cash, cash equivalents and restricted cash2,902
 960
Net (decrease) increase in cash, cash equivalents and restricted cash(134,476) 174,510
Cash, cash equivalents and restricted cash, beginning of period412,265
 139,804
Cash, cash equivalents and restricted cash, end of period$277,789
 $314,314
Effect of exchange rates on cash and cash equivalents450
 832
Net decrease in cash and cash equivalents(29,689) (26,283)
Cash and cash equivalents, beginning of period167,740
 412,265
Cash and cash equivalents, end of period$138,051
 $385,982
The accompanying notes are an integral part of these condensed consolidated financial statements.

8
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)




1. Organization and Description of Business
Wright Medical Group N.V. (Wright or we) is a global medical device company focused on extremities and biologics products. We are committed to delivering innovative, value-added solutions improving quality of life for patients worldwide and are a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics. We market our products in overapproximately 50 countries worldwide.
Our global corporate headquarters are located in Amsterdam, the Netherlands. We also have significant operations located in Memphis, Tennessee (U.S. headquarters, research and development, sales and marketing administration, and administrative activities); Bloomington, Minnesota (upper extremities sales and marketing and warehousing operations); Arlington, Tennessee (manufacturing and warehousing operations); Franklin, Tennessee (manufacturing and warehousing operations); Montbonnot, France (manufacturing and warehousing operations); Plouzané, France (research and development); and Macroom, Ireland (manufacturing). In addition, we have local sales and distribution offices in Canada, Australia, Asia, Latin America, and throughout Europe. For purposes of this report, references to "international" or "foreign" relate to non-U.S. matters while references to "domestic" relate to U.S. matters.
Our fiscal year-end is generally determined on a 52-week basis and runs from the Monday nearest to the 31st of December of a year, and ends on the Sunday nearest to the 31st of December of the following year. Every few years, it is necessary to add an extra week to the year making it a 53-week period. Prior to the merger (the Wright/Tornier merger or the merger) with Tornier N.V. (legacy Tornier) in October 2015, ourThe fiscal year ended December 31, each year.2017 was a 53-week period.
The condensed consolidated financial statements and accompanying notes present our consolidated results for each of the three and nine months ended September 24, 2017April 1, 2018 and September 25, 2016.March 26, 2017. The three and nine months ended September 24,April 1, 2018 and March 26, 2017 and September 25, 2016 each consisted of thirteen and thirty-nine weeks, respectively.weeks.
All amounts are presented in U.S. dollars ($), except where expressly stated as being in other currencies, e.g., Euros (€).
References in these notes to the condensed consolidated financial statements to "we," "our" and "us" refer to Wright Medical Group N.V. and its subsidiaries after the Wright/merger with Tornier mergerN.V. (legacy Tornier) (Wright/Tornier merger) and Wright Medical Group, Inc. (WMG or legacy Wright) and its subsidiaries before the Wright/Tornier merger.

2. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation. The unaudited condensed consolidated interim financial statements of Wright Medical Group N.V. have been prepared in accordance with U.S. generally accepted accounting principles in the United States (US GAAP) for interim financial statements and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to these rules and regulations. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 25, 2016,31, 2017, as filed with the U.S. Securities and Exchange Commission (SEC) on February 23, 2017.27, 2018.
In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments necessary for a fair presentation of our interim financial results. All such adjustments are of a normal and recurring nature. The results of operations for any interim period are not indicative of results for the full fiscal year. The accompanying unaudited condensed consolidated interim financial statements include our accounts and those of our domestic and international subsidiaries, all of which are wholly-ownedcontrolled subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the dates of the financial statements and the amounts of revenues and expenses during the reporting periods. Actual amounts realized or paid could differ from those estimates.
Revenue recognition. Our revenues are primarily generated through two types of customers, hospitals and surgery centers and stocking distributors, with the majority of our revenue derived from sales to hospitals and surgery centers. Our products are sold through a network of employee and independent sales representatives in the United States and by a combination of employee sales representatives, independent sales representatives, and stocking distributors outside the United States. We record revenues from sales to hospitals and surgery centers upon transfer of control of promised products in an amount that reflects the consideration we expect to receive in exchange for those products, which is generally when the product is surgically implanted in a patient.
We record revenues from sales to our stocking distributors at a point in time upon transfer of control of promised products to the distributor. Our stocking distributors, who sell the products to their customers, take control of the products and assume all risks

9
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

of ownership upon transfer. Our stocking distributors are obligated to pay us within specified terms regardless of when, if ever, they sell the products. In general, our stocking distributors do not have any rights of return or exchange; however, in limited situations, we have repurchase agreements with certain stocking distributors. Those certain agreements require us to repurchase a specified percentage of the inventory purchased by the distributor within a specified period of time prior to the expiration of the contract. During those specified periods, we defer the applicable percentage of the sales. An insignificant amount of sales related to these types of agreements were deferred and not yet recognized as revenue as of April 1, 2018 and December 31, 2017.
We must make estimates of potential future product returns related to current period product sales. We base our estimate for sales returns on historical sales and product return information, including historical experience and trend information. Our reserve for sales returns has historically been immaterial. We incur shipping and handling costs associated with the shipment of goods to customers, independent distributors, and our subsidiaries. Amounts billed to customers for shipping and handling of products are included in net sales. Costs incurred related to shipping and handling of products to customers are included in selling, general and administrative expenses. We also record depreciation on instruments within selling, general and administrative expense as these costs are considered to be similar to shipping and handling costs, necessary to deliver the implant products to the end customer.
Discontinued Operations. On October 21, 2016, pursuant to a binding offer letter dated as of July 8, 2016, Tornier France SAS (Tornier France) and certain other entities related to us and Corin Orthopaedics Holdings Limited (Corin) entered into a business sale agreement and simultaneously completed and closed the sale of our business operations operating under the large joints operating segment.former Large Joints business. Pursuant to the terms of the agreement, Tornier Francewe sold substantially all of theour assets related to our hip and knee, or large joints, business (the Large Joints business)business to Corin for approximately €29.7 million in cash, less approximately

9
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

€11.1 €11.1 million for net working capital adjustments and subject to certain other closing adjustments. Upon closing, the parties also executed a transitional services agreement and supply agreement, among other ancillary agreements required to implement the transaction. These agreements were on arm’s length terms and were not material to our consolidated financial statements.
On January 9, 2014, legacy Wrightpursuant to an Asset Purchase Agreement, dated as of June 18, 2013 (the MicroPort Agreement), by and among us and MicroPort Scientific Corporation (MicroPort), we completed the divestituredivesture and sale of its hip and knee (OrthoRecon)our business operations operating under our prior OrthoRecon operating segment (the OrthoRecon Business) to MicroPort Scientific Corporation (MicroPort). Certain liabilities associated with the OrthoRecon business, including product liability claims associated with hip and knee products sold prior to the closing, were not assumed by MicroPort. Charges associated with these product liability claims, including legal defense, settlements and judgments, income associated with product liability insurance recoveries, and changes to any contingent liabilities associated with the OrthoRecon business have been reflected within results of discontinued operations.
All current and historical operating results for the Large Joints and OrthoRecon businesses are reflected within discontinued operations in the condensed consolidated financial statements.
See Note 4 for further discussion of discontinued operations. Other than the discontinued operations discussed in Note 34, unless otherwise stated, all discussion of assets and liabilities in these notesNotes to the condensed consolidated financial statements reflects the assets and liabilities held and used in our continuing operations, and all discussion of revenues and expenses reflects those associated with our continuing operations.
Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, and has subsequently issued several supplemental and/or clarifying ASUs (collectively ASC 606). Accounting Standards Codification (ASC) 606 prescribes a single common revenue standard that replaces most existing U.S.US GAAP revenue recognition guidance. ASC 606 outlines a five-step model, under which we will recognize revenue as performance obligations within a customer contract are satisfied. ASC 606 is intended to provide more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. Adoption ofWe adopted ASC 606 is required for annual reporting periods beginning after December 15, 2017 (fiscal year 2018 for Wright), including interim periods withinduring the reporting period. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or using the cumulative effect transition method with the cumulative effect of initial adoption recognized at the date of initial application. We are currently assessing the impact that the future adoption of ASC 606 may have on our consolidated financial statements by analyzing our current portfolio of customer contracts, including a review of historical accounting policies and practices to identify potential differences in applying the guidance of ASC 606. Based on our review of our customer contracts, we expect that revenue on the majority of our customer contracts will continue to bequarter ended April 1, 2018. Revenue is recognized at a point in time, generally upon surgical implantation or shipment of products to distributors, consistent with our current revenue recognition model. We expect to adoptdistributors. Therefore, adoption of ASC 606 usingdid not have a material effect on our consolidated financial statements except for the modified retrospective method, which recognizes the cumulative effect at the date of initial application.additional disclosures included within Note 14.
On February 25, 2016, the FASB issued ASU 2016-02, Leases, which introduces a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in FASB ASC 606, the FASB’s new revenue recognition standard (e.g., those related to evaluating when profit can be recognized). Furthermore, the ASU addresses other concerns related to the current leases model. The ASU will be effective for us beginning in fiscal year 2019. We are in the initial phases of our adoption plans; and accordingly, we are unable to estimate any effect this may have on our consolidated financial statements.
On March 30, 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which is to simplify accounting for income taxes, forfeitures, and withholding taxes associated with share-based payment arrangements, and reduce ambiguity in cash flow reporting. We adopted this ASU during the quarter ended March 26, 2017 and noted no impact on our condensed consolidated financial statements.
On August 26, 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments, which amends the guidance in ASC 230 on the classification of certain cash receipts and payments in the statement of cash flows. The primary purpose of the ASU is to reduce the diversity in practice that has resulted from the lack of consistent principles on this topic. The ASU’s amendments add or clarify guidance on eight cash flow issues, including debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, and proceeds from the settlement of insurance claims. We elected to early adopt this guidance for the year ended December 25, 2016. The application of this guidance did not impact the historical presentation of our consolidated statement of cash flows.
In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash, which amends ASC 230 to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. The amendments require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period

10
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

total amounts shown on the statement of cash flows. We elected to early adopt the methodology for presenting restricted cash resulting from the Escrow Agreement described in Note 13 for the year ended December 25, 2016.
On January 26, 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, which removes the requirement to compare the implied fair value of goodwill with its carrying amount as part of step 2 of the goodwill impairment test. Under the new guidance, if a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The guidance in the ASU is effective for our interim and annual goodwill impairment tests beginning in 2020 with early adoption permitted for annual and interim goodwill impairment testing dates after January 1, 2017.permitted. We are in the initial phases of our adoption plans; and, accordingly, we are unable to estimate any effect this may have on our consolidated financial statements.

10
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

3. Acquisitions
IMASCAP
On December 14, 2017, we completed the acquisition of IMASCAP SAS (IMASCAP), a leader in the development of software-based solutions for preoperative planning of shoulder replacement surgery. The intent of this transaction is to ensure exclusive access to breakthrough software enabling technology and patents to further differentiate our product portfolio and to further accelerate growth opportunities in our global extremities business. Under the terms of the agreement with IMASCAP, we acquired 100% of IMASCAP’s outstanding equity on a fully diluted basis for an initial payment of €52.9 million, or approximately $62.3 million, consisting of approximately €39.7 million, or approximately $46.7 million, in cash and approximately €13.2 million, or approximately $15.6 million, representing 661,753 Wright ordinary shares, payable at closing. Additionally the purchase price includes an estimated €15.1 million, or approximately $17.8 million, of contingent consideration related to the achievement of certain technical milestones and sales earnouts. The technical milestones involve the development and approval of a patient specific implant system and new software modules. The sales earnouts relate to patient specific guides and the future patient specific implant system.
Purchase Consideration and Net Assets Acquired
The following presents the preliminary allocation of the purchase consideration to the assets acquired and liabilities assumed on December 14, 2017 (in thousands):
Cash and cash equivalents$2,569
Accounts receivable522
Other current assets181
Property, plant and equipment15
Intangible assets10,865
Total assets acquired14,152
Current liabilities(2,065)
Long-term debt(902)
Deferred income taxes(3,033)
Total liabilities assumed(6,000)
Net assets acquired$8,152
  
Goodwill71,981
  
Total preliminary purchase consideration$80,133
The purchase consideration was allocated to the net assets acquired based on their estimated fair values at the acquisition date. The fair values were based on management’s analysis, including work performed by third-party valuation specialists.
Operating assets and liabilities were valued at their existing carrying values as they represented the fair value of those items at the acquisition date, based on management’s judgments and estimates.
In determining the fair value of intangibles, we used an income method which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants and include the amount and timing of future cash flows (including expected growth rates and profitability), technology life cycles, and the discount rate applied to the cash flows.
Of the $10.9 million of acquired intangible assets, $5.6 million was assigned to developed technology (6 year life) and $5.3 million was assigned to in-process research and development.
The excess of the cost of the acquisition over the fair value of the net assets acquired is recorded as goodwill. The goodwill is primarily attributable to strategic opportunities that arose from the acquisition of IMASCAP. The goodwill is not expected to be deductible for tax purposes.
During the quarter ended April 1, 2018, there were no changes to the opening balance sheet.

11
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

4. Discontinued Operations
For the three months ended September 24,April 1, 2018 and March 26, 2017, and September 25, 2016, our loss from discontinued operations, net of tax, totaled $97.7$5.6 million and $57.4 million, respectively. For the nine months ended September 24, 2017 and September 25, 2016, our loss from discontinued operations, net of tax, totaled $139.9 million and $252.6$22.0 million, respectively. Our loss from discontinued operations was attributable primarily to expenses associated with legacy Wright's former OrthoRecon business and, to a lesser degree, the former Large Joints business. 
Large Joints Business
On October 21, 2016, pursuant to a binding offer letter dated as of July 8, 2016, Tornier France, Corin, and certain other entities related to us and Corin entered into a business sale agreement and simultaneously completed and closed the sale of our Large Joints business. Pursuant to the terms of the agreement, we sold substantially all of the assets related to our Large Joints business to Corin for approximately €29.7 million in cash, less approximately €11.1 million for net working capital adjustments. Upon closing, the parties also executed a transitional services agreement and supply agreement, among other ancillary agreements required to implement the transaction. These agreements are on arm’s length terms and are not expected to be material to our condensed consolidated financial statements.
All historical operating results for the Large Joints business as well as continued involvement in accordance with the transitional service agreement and supply agreement are reflected within discontinued operations in the condensed consolidated statements of operations.
For the three and nine months ended September 24,April 1, 2018 and March 26, 2017, our loss from discontinued operations for the Large Joints business, net of tax, totaled $0.9$0.2 million and $2.4$1.0 million, respectively, and wasare primarily attributable to professional fees and internal costs to support transition activities, costs associated with transition services and working capital adjustments.services. The basic and diluted weighted-average number of ordinary shares outstanding was 104.8105.9 million and 104.3103.7 million for the three and nine months ended September 24,April 1, 2018 and March 26, 2017, respectively. The basic and diluted net loss from discontinued operations per share for the Large Joints business was $0.01$0.00 and $0.02$0.01 for the three and nine months ended September 24,April 1, 2018 and March 26, 2017, respectively.


11
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

The following table summarizes the results of discontinued operations for the Large Joints business for the three and nine months ended September 25, 2016 (in thousands, except per share data):
 Three months endedNine months ended
 September 25, 2016September 25, 2016
Net sales$7,320
$29,220
Cost of sales4,348
15,708
Selling, general and administrative4,897
15,069
Other396
1,630
Loss from discontinued operations before income taxes(2,321)(3,187)
Impairment loss on assets held for sale, before income taxes—
(21,876)
Total loss from discontinued operations before income taxes(2,321)(25,063)
Income tax benefit759
5,529
Total loss from discontinued operations, net of tax$(1,562)$(19,534)
   
Net loss from discontinued operations per share-basic and diluted (Note 11)
$(0.02)$(0.19)
   
Weighted-average number of ordinary shares outstanding-basic and diluted (Note 11)
103,072
102,854
Cash used in operating activities from the Large Joints business totaled $3.5$0.5 million and $1.1 million for the ninethree months ended September 24, 2017. Cash provided by operating activities from the Large Joints business totaled $3.0 million for theApril 1, 2018 and nineMarch 26, 2017 months ended September 25, 2016., respectively.
OrthoRecon Business
On January 9, 2014, legacy Wright completed the divestiture and sale of its OrthoRecon business to MicroPort Scientific Corporation. Pursuant to the terms of the agreement, the purchase price (as defined in the agreement) was approximately $283 million (including a working capital adjustment), which MicroPort paid in cash. As a result of the transaction, we recognized approximately $24.3 million as the gain on disposal of the OrthoRecon business, before the effect of income taxes.
Certain liabilities associated with the OrthoRecon business, including product liability claims associated with hip and knee products sold by legacy Wright prior to the closing, were not assumed by MicroPort. Charges associated with these product liability claims, including legal defense, settlements and judgments, income associated with product liability insurance recoveries, and changes to any contingent liabilities associated with the OrthoRecon business have been reflected within results of discontinued operations, and we will continue to reflect these within results of discontinued operations in future periods.

12
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

All current and historical operating results for the OrthoRecon business are reflected within discontinued operations in the condensed consolidated financial statements. The following table summarizes the results of discontinued operations for the OrthoRecon business (in thousands, except per share data):
 Three months ended Nine months ended
 September 24, 2017 September 25, 2016 September 24, 2017 September 25, 2016
Net sales$—
 $—
 $—
 $—
Selling, general and administrative96,917
 55,874
 137,578
 233,037
Loss from discontinued operations before income taxes(96,917) (55,874) (137,578) (233,037)
Benefit for income taxes—
 —
 —
 —
Total loss from discontinued operations, net of tax$(96,917) $(55,874) $(137,578) $(233,037)
        
Net loss from discontinued operations per share-basic and diluted (Note 11)
$(0.92) $(0.54) $(1.32) $(2.27)
        
Weighted-average number of ordinary shares outstanding-basic and diluted (Note 11)
104,836
 103,072
 104,292
 102,854
The above selling, general and administrative expenses during the three and nine months ended September 24, 2017 included charges of $86.9 million and $103.3 million, respectively, related to the retained metal-on-metal product liability claims associated with the OrthoRecon business. The three and nine months ended September 25, 2016 included charges of $38.7 million and $188.7 million, respectively, related to the retained metal-on-metal product liability claims associated with the OrthoRecon business. See Note 12 to the condensed consolidated financial statements for further discussion regarding the metal-on-metal product liability claims.
 Three months ended
 April 1, 2018 March 26, 2017
Net sales$—
 $—
Selling, general and administrative5,437
 21,013
Loss from discontinued operations before income taxes(5,437) (21,013)
Provision for income taxes—
 —
Total loss from discontinued operations, net of tax$(5,437) $(21,013)
    
Net loss from discontinued operations per share-basic and diluted (Note 12)
$(0.05) $(0.20)
    
Weighted-average number of ordinary shares outstanding-basic and diluted (Note 12)
105,904
 103,663
We will incur continuing cash outflows associated with legal defense costs and the ultimate resolution of these contingent liabilities, net of insurance proceeds, until these liabilities are resolved. Cash used in operating activities by the OrthoRecon business totaled $142.7$24.0 million and $29.7$10.5 million for the ninethree months ended September 24, 2017April 1, 2018 and September 25, 2016,March 26, 2017, respectively.

12
4.
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

5. Inventories
Inventories consist of the following (in thousands):
September 24, 2017 December 25, 2016April 1, 2018 December 31, 2017
Raw materials$10,695
 $15,319
$8,114
 $10,816
Work-in-process29,714
 22,422
29,128
 28,581
Finished goods131,902
 113,108
137,139
 128,747
$172,311
 $150,849
$174,381
 $168,144
5.6. Fair Value of Financial Instruments and Derivatives
We account for derivatives in accordance with FASB ASC 815, which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivatives' fair value shall be recognized currently in earnings unless specific hedge accounting criteria are met.
FASB ASC Section 820, Fair Value Measurements and DisclosuresMeasurement requires fair value measurements be classified and disclosed in one of the following three categories:
Level 1:Financial instruments with unadjusted, quoted prices listed on active market exchanges.

13
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

Level 2:Financial instruments determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.
Level 3:Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.
2021 Notes Conversion Derivative and Notes Hedges
On May 20, 2016, we issued $395 million aggregate principal amount of 2.25% cash convertible senior notes due 2021 (2021 Notes). See Note 89 of the condensed consolidated financial statements for additional information regarding the 2021 Notes. The 2021 Notes have a conversion derivative feature (2021 Notes Conversion Derivative) that requires bifurcation from the 2021 Notes in accordance with ASC Topic 815, and is accounted for as a derivative liability. The fair value of the 2021 Notes Conversion Derivative at the time of issuance of the 2021 Notes was $117.2 million.
In connection with the issuance of the 2021 Notes, we entered into hedges (2021 Notes Hedges) with two option counterparties. The 2021 Notes Hedges, which are cash-settled, are generally intended to reduce our exposure to potential cash payments that we are required to make upon conversion of the 2021 Notes in excess of the principal amount of converted notes if our ordinary share price exceeds the conversion price. The aggregate cost of the 2021 Notes Hedges was $99.8 million and is accounted for as a derivative asset in accordance with ASC Topic 815. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to the 2021 Note Hedges, which may reduce the effectiveness of the 2021 Note Hedges.
The following table summarizes the fair value and the presentation in our condensed consolidated balance sheets (in thousands) of the 2021 Notes Hedges and 2021 Notes Conversion Derivative:
Location on condensed consolidated balance sheetSeptember 24, 2017December 25, 2016Location on condensed consolidated balance sheetApril 1, 2018December 31, 2017
2021 Notes HedgesOther assets$177,818
$159,095
Other assets$115,369
$127,063
2021 Notes Conversion DerivativeOther liabilities$177,870
$161,601
Other liabilities$115,427
$126,148
In the first quarter of 2017, the closing price of our ordinary shares was greater than 130% of the 2021 Notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end; and, therefore, the holders of the 2021 Notes had the ability to convert the notes during the succeeding quarterly period. Due to the ability of the holders of the 2021 Notes to convert the notes during this period, the carrying value of the 2021 Notes and the fair value of the 2021 Notes Conversion Derivative were classified as current liabilities, and the fair value of the 2021 Notes Hedges were classified as current assets as of March 26, 2017. There were no conversions during the second quarter of 2017. The closing price of our ordinary shares was less than 130% of the 2021 Notes conversion price for more than 20 of the 30 consecutive trading days preceding the calendar quarters ended June

13
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

30, 2017, and September 30, 2017, December 31, 2017 and April 1, 2018, which resulted in the 2021 Notes no longer being convertible. As such, the 2021 Notes, 2021 Notes Conversion Derivative and 2021 Notes Hedges were classified as long-term as of September 24,April 1, 2018 and December 31, 2017.
The 2021 Notes Hedges and the 2021 Notes Conversion Derivative are measured at fair value using Level 3 inputs. These instruments are not actively traded and are valued using an option pricing model that uses observable and unobservable market data for inputs.
Neither the 2021 Notes Conversion Derivative nor the 2021 Notes Hedges qualify for hedge accounting; thus, any change in the fair value of the derivatives is recognized immediately in our condensed consolidated statements of operations. The following table summarizes the net gain (loss) on changes in fair value (in thousands) related to the 2021 Notes Hedges and 2021 Notes Conversion Derivative:
  Three months ended Nine months ended
  September 24, 2017September 25, 2016 September 24, 2017September 25, 2016
 
 2021 Notes Hedges$(9,074)$85,182
 $18,723
$69,671
 2021 Notes Conversion Derivative9,321
(86,275) (16,269)(55,478)
 Net gain (loss) on changes in fair value$247
$(1,093) $2,454
$14,193

14
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

 Three months ended
 April 1, 2018March 26, 2017
2021 Notes Hedges$(11,694)$101,213
2021 Notes Conversion Derivative10,721
(101,834)
Net loss on changes in fair value$(973)$(621)
2020 Notes Conversion Derivative and Notes Hedges
On February 13, 2015, WMG issued $632.5 million aggregate principal amount of 2.00% cash convertible senior notes due 2020 (2020 Notes). See Note 89 of the condensed consolidated financial statements for additional information regarding the 2020 Notes. The 2020 Notes have a conversion derivative feature (2020 Notes Conversion Derivative) that requires bifurcation from the 2020 Notes in accordance with ASC Topic 815, and is accounted for as a derivative liability. The fair value of the 2020 Notes Conversion Derivative at the time of issuance of the 2020 Notes was $149.8 million.
In connection with the issuance of the 2020 Notes, WMG entered into hedges (2020 Notes Hedges) with three option counterparties. The 2020 Notes Hedges, which are cash-settled, are generally intended to reduce WMG's exposure to potential cash payments that WMG is required to make upon conversion of the 2020 Notes in excess of the principal amount of converted notes if our ordinary share price exceeds the conversion price. The aggregate cost of the 2020 Notes Hedges was $144.8 million and is accounted for as a derivative asset in accordance with ASC Topic 815. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to the 2020 Note Hedges, which may reduce the effectiveness of the 2020 Note Hedges.
Concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2020 Notes exchanged approximately $45 million aggregate principal amount of 2020 Notes (including the 2020 Notes Conversion Derivative) for the 2021 Notes. For each $1,000 principal amount of 2020 Notes validly submitted for exchange, we delivered $990.00 principal amount of the 2021 Notes (subject, in each case, to rounding down to the nearest $1,000 principal amount of the 2021 Notes, the difference being referred as the rounded amount) to the investor plus an amount of cash equal to the unpaid interest on the 2020 Notes and the rounded amount at an aggregate cost of approximately $44.6 million. We settled the associated portion of the 2020 Notes Conversion Derivative at a benefit of approximately $0.4 million and satisfied the accrued interest, which was not material.
In addition, during the second quarter of 2016, we settled a portion of the 2020 Notes Hedges (receiving $3.9 million) and repurchased a portion of the warrants associated with the 2020 Notes (paying $3.3 million), generating net proceeds of approximately $0.6 million.
The following table summarizes the fair value and the presentation in our condensed consolidated balance sheets (in thousands) of the 2020 Notes Hedges and 2020 Notes Conversion Derivative:
Location on condensed consolidated balance sheetSeptember 24, 2017December 25, 2016Location on condensed consolidated balance sheetApril 1, 2018December 31, 2017
2020 Notes HedgesOther assets$73,694
$77,232
Other assets$41,933
$45,033
2020 Notes Conversion DerivativeOther liabilities$72,460
$77,758
Other liabilities$41,753
$44,132
The 2020 Notes Hedges and the 2020 Notes Conversion Derivative are measured at fair value using Level 3 inputs. These instruments are not actively traded and are valued using an option pricing model that uses observable and unobservable market data for inputs.

14
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

Neither the 2020 Notes Conversion Derivative nor the 2020 Notes Hedges qualify for hedge accounting; thus, any change in the fair value of the derivatives is recognized immediately in our condensed consolidated statements of operations. The following table summarizes the net (loss) gain on changes in fair value (in thousands) related to the 2020 Notes Hedges and 2020 Notes Conversion Derivative:
  Three months ended Nine months ended
  September 24, 2017September 25, 2016 September 24, 2017September 25, 2016
 
 2020 Notes Hedges$(10,340)$49,887
 $(3,538)$(40,558)
 2020 Notes Conversion Derivative10,292
(45,421) 5,298
44,701
 Net (loss) gain on changes in fair value$(48)$4,466
 $1,760
$4,143
 Three months ended
 April 1, 2018March 26, 2017
2020 Notes Hedges$(3,100)$72,979
2020 Notes Conversion Derivative2,379
(72,312)
Net (loss) gain on changes in fair value$(721)$667
2017 Notes Conversion Derivative and Notes Hedges
On August 31, 2012, WMG issued $300 million aggregate principal amount of 2.00% cash convertible senior notes due 2017 (2017 Notes). The 2017 Notes matured and the remaining $2.0 million principal amount was repaid on August 15, 2017. See Note 89 of the condensed consolidated financial statements for additional information regarding the 2017 Notes. The 2017 Notes had a conversion derivative feature (2017 Notes Conversion Derivative) that required bifurcation from the 2017 Notes in accordance with ASC Topic 815, and was accounted for as a derivative liability. The fair value of the 2017 Notes Conversion Derivative at

15
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

the time of issuance of the 2017 Notes was $48.1 million.
In connection with the issuance of the 2017 Notes, WMG entered into hedges (2017 Notes Hedges) with three option counterparties. The aggregate cost of the 2017 Notes Hedges was $56.2 million and was accounted for as a derivative asset in accordance with ASC Topic 815.
In connection with the issuance of the 2020 Notes, WMG used approximately $292 million of the 2020 Notes' net proceeds to repurchase and extinguish approximately $240 million aggregate principal amount of the 2017 Notes, settle the associated portion of the 2017 Notes Conversion Derivative at a cost of approximately $49 million, and satisfy the accrued interest of $2.4 million. WMG also settled all of the 2017 Notes Hedges (receiving $70 million) and repurchased all of the warrants associated with the 2017 Notes (paying $60 million), generating net proceeds of approximately $10 million.
Concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2017 Notes exchanged approximately $54.4 million aggregate principal amount of 2017 Notes (including the 2017 Notes Conversion Derivative) for the 2021 Notes. For each $1,000 principal amount of 2017 Notes validly submitted for exchange, we delivered $1,035.40 principal amount of the 2021 Notes (subject, in each case, to rounding down to the nearest $1,000 principal amount of the 2021 Notes, the difference being referred as the rounded amount) to the investor plus an amount of cash equal to the unpaid interest on the 2017 Notes and the rounded amount at a cost of approximately $56.3 million. We settled the associated portion of the 2017 Notes Conversion Derivative at a cost of approximately $1.9 million and satisfied the accrued interest, which was not material.
In addition, during the second quarter of 2016, we repurchased and extinguished an additional $3.6 million aggregate principal amount of the 2017 Notes in privately negotiated transactions and settled the associated portion of the 2017 Notes Conversion Derivative at a cost of approximately $0.1 million, and satisfied the accrued interest, which was not material. The remainder of the 2017 Notes Conversion Derivative was settled at a cost of approximately $0.2 million in conjunction with the maturity of the 2017 Notes on August 15, 2017.
The following table summarizes the fair value and the presentation in our condensed consolidated balance sheets (in thousands) of the 2017 Notes Conversion Derivative:
 Location on condensed consolidated balance sheetSeptember 24, 2017December 25, 2016
2017 Notes Conversion DerivativeAccrued expenses and other current liabilities$—
$164
The 2017 Notes Conversion Derivative was measured at fair value using Level 3 inputs. This instrument was not actively traded and was valued using an option pricing model that used observable and unobservable market data for inputs.
Neither the 2017 Notes Conversion Derivative nor the 2017 Notes Hedges qualified for hedge accounting; thus, any change in the fair value of the derivatives was recognized immediately in our condensed consolidated statements of operations. The following table summarizes the net (loss) gainloss on changes in fair value (in thousands) related to the 2017 Notes Conversion Derivative:
  Three months ended Nine months ended
  September 24, 2017September 25, 2016 September 24, 2017September 25, 2016
 
 2017 Notes Conversion Derivative$15
$(186) $(51)$8,124
 Net (loss) gain on changes in fair value$15
$(186) $(51)$8,124
 Three months ended
 April 1, 2018March 26, 2017
2017 Notes Conversion Derivative$—
$(411)
Net loss on changes in fair value$—
$(411)
To determine the fair value of the embedded conversion option in the 2017, 2020 and 2021 Notes Conversion Derivatives, a trinomial lattice model was used. A trinomial stock price lattice generates three possible outcomes of stock price - one up, one down, and

15
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

one stable. This lattice generates a distribution of stock prices at the maturity date and throughout the life of the 2017, 2020 and 2021 Notes. Using this stock price lattice, a convertible note lattice was created where the value of the embedded conversion option was estimated by comparing the value produced in a convertible note lattice with the option to convert against the value without the ability to convert. In each case, the convertible note lattice first calculates the possible convertible note values at the maturity date, using the distribution of stock prices, which equals to the maximum of (x) the remaining bond cash flows and (y) stock price times the conversion price. The values of the 2017, 2020 and 2021 Notes Conversion Derivatives at the valuation date were estimated using the values at the maturity date and moving back in time on the lattices (both for the lattice with the conversion option and without the conversion option). Specifically, at each node, if the 2017, 2020 or 2021 Notes are eligible for early conversion, the value at this node is the maximum of (i) converting to stock, which is the stock price times the conversion price, and (ii) holding onto the 2017, 2020 and 2021 Notes, which is the discounted and probability-weighted value

16
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

from the three possible outcomes at the future nodes plus any accrued but unpaid coupons that are not considered at the future nodes. If the 2017, 2020 or 2021 Notes are not eligible for early conversion, the value of the conversion option at this node equals to (ii). In the lattice, a credit adjustment was applied to the discount for each cash flow in the model as the embedded conversion option, as well as the coupon and notional payments, is settled with cash instead of shares.
To estimate the fair value of the 2020 and 2021 Notes Hedges, we used the Black-Scholes formula combined with credit adjustments, as the option counterparties have credit risk and the call options are cash settled. We assumed that the call options will be exercised at the maturity since our ordinary shares do not pay any dividends and management does not expect to declare dividends in the near term.
The following assumptions were used in the fair market valuations of the 2020 Notes Conversion Derivative, 2020 Notes Hedge, 2021 Notes Conversion Derivative, and 2021 Notes Hedge as of September 24, 2017:April 1, 2018:
2020 Notes Conversion Derivative2020 Notes
Hedge		2021 Notes Conversion Derivative
2021 Notes
Hedge
2020 Notes Conversion Derivative2020 Notes
Hedge		2021 Notes Conversion Derivative
2021 Notes
Hedge
Stock Price Volatility (1)31.07%35.58%42.29%
Credit Spread for Wright (2)2.31%N/A3.42%N/A3.52%N/A4.53%N/A
Credit Spread for Deutsche Bank AG (3)N/A0.43%N/AN/A1.21%N/A
Credit Spread for Wells Fargo Securities, LLC (3)N/A0.19%N/AN/A0.59%N/A
Credit Spread for JPMorgan Chase Bank (3)N/A0.24%N/A0.41%N/A0.52%N/A0.52%
Credit Spread for Bank of America (3)N/A0.42%N/A0.55%
(1)Volatility selected based on historical and implied volatility of ordinary shares of Wright Medical Group N.V.
(2)Credit spread implied from traded price.
(3)Credit spread of each bank is estimated using CDS curves. Source: Bloomberg.
Derivatives not Designated as Hedging Instruments
We employDuring 2017, we employed a derivative program using foreign currency forward contracts to mitigate the risk of currency fluctuations on our intercompany receivable and payable balances that are denominated in foreign currencies. These forward contracts arewere expected to offset the transactional gains and losses on the related intercompany balances. These forward contracts arewere not designated as hedging instruments under FASB ASC Topic 815. Accordingly, the changes in the fair value and the settlement of the contracts arewere recognized in the period incurred in the accompanying condensed consolidated statements of operations. During the quarter ended April 1, 2018, we discontinued our foreign currency forward contracts derivative program. At September 24, 2017April 1, 2018 and December 25, 2016,31, 2017, we had $1 million and $0.4 million inno foreign currency contracts outstanding, respectively.
As part of our acquisition of WG Healthcare on January 7, 2013, we were obligated to pay contingent consideration upon the achievement of certain revenue milestones. As of September 24, 2017, we have made all required contingent consideration payments based on the achievement of these milestones. As of December 25, 2016, we had recorded an estimated fair value of future contingent consideration of $0.4 million.outstanding.
As a result of the acquired sales and distribution business of Surgical Specialties Australia Pty. Ltd in 2015, we have recorded the estimated fair value of future contingent consideration of approximately $1.1$0 million and $1.7$0.9 million as of September 24, 2017April 1, 2018 and December 25, 2016,31, 2017, respectively.
The fair value of the contingent consideration as of September 24, 2017April 1, 2018 and December 25, 201631, 2017 was determined using a discounted cash flow model and probability adjusted estimates of the future earnings and is classified in Level 3. Changes in the fair value of contingent consideration are recorded in “Other (income) expense, (income), net” in our condensed consolidated statements of operations.
On March 1, 2013, as part of our acquisition of BioMimetic Therapeutics, Inc. (BioMimetic), we issued Contingent Value Rights (CVRs) as part of the merger consideration. Each CVR entitles its holder to receive additional cash payments of up to $6.50 per

16
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

share, which are payable upon receipt of FDA approval of AUGMENT® Bone Graft and upon achieving certain revenue milestones. On September 1, 2015, AUGMENT® Bone Graft received FDA approval and the first of the milestone payments associated with the CVRs was paid out at $3.50 per share, which totaled $98.1 million. The fair value of the CVRs outstanding at September 24, 2017April 1, 2018 and December 25, 201631, 2017 was $43.7$38.4 million and $37.0$42.3 million, respectively, and was determined using the closing price of the security in the active market (Level 1). For the three and nine months ended September 24,April 1, 2018 and March 26, 2017, the change in the fair value of the CVRs resulted in income of $3.9 million and expense of $4.5 million and $6.7 million, respectively. For the three and nine months ended September 25, 2016, the change in the fair value of the CVRs resulted in expense of $2.3 million and $9.0$6.2 million, respectively. The income or

17
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

expense related to the change in the value of the CVRs is recorded in “Other (income) expense, (income), net” in our condensed consolidated statements of operations. If, prior to March 1, 2019, sales of AUGMENT® Bone Graft reach $40 million over 12 consecutive months, cash payment would be required at $1.50 per share, or $42 million. Further, if, prior to March 1, 2019, sales of AUGMENT® Bone Graft reach $70 million over 12 consecutive months, an additional cash payment would be required at $1.50 per share, or $42 million. As of September 24, 2017,April 1, 2018, we have reflected the $42$38.4 million balance related to CVR liability within "Accrued expenses and other current liabilities."
The carrying value of cash and cash equivalents, accounts receivable, and accounts payable approximates the fair value of these financial instruments at September 24, 2017April 1, 2018 and December 25, 201631, 2017 due to their short maturities and variable rates.
The following tables summarize the valuation of our financial instruments (in thousands):
Total
Quoted prices
in active
markets
(Level 1)
Prices with
other
observable
inputs
(Level 2)
Prices with
unobservable
inputs
(Level 3)
Total
Quoted prices
in active
markets
(Level 1)
Prices with
other
observable
inputs
(Level 2)
Prices with
unobservable
inputs
(Level 3)
At September 24, 2017 
At April 1, 2018 
Assets  
Cash and cash equivalents$238,867
$238,867
$—
$—
$138,051
$138,051
$—
$—
Restricted cash38,922
38,922
—
—
2020 Notes Hedges73,694
—
—
73,694
41,933
—
—
41,933
2021 Notes Hedges177,818
—
—
177,818
115,369
—
—
115,369
Total$529,301
$277,789
$—
$251,512
$295,353
$138,051
$—
$157,302
  
Liabilities  
2020 Notes Conversion Derivative$72,460
$—
$—
$72,460
$41,753
$—
$—
$41,753
2021 Notes Conversion Derivative177,870
—
—
177,870
115,427
—
—
115,427
Contingent consideration1,306
—
—
1,306
19,189
—
—
19,189
Contingent consideration (CVRs)43,726
43,726
—
—
38,400
38,400
—
—
Total$295,362
$43,726
$—
$251,636
$214,769
$38,400
$—
$176,369
TotalQuoted prices
in active
markets
(Level 1)		Prices with
other
observable
inputs
(Level 2)		Prices with
unobservable
inputs
(Level 3)		TotalQuoted prices
in active
markets
(Level 1)		Prices with
other
observable
inputs
(Level 2)		Prices with
unobservable
inputs
(Level 3)
At December 25, 2016 
At December 31, 2017 
Assets  
Cash and cash equivalents$262,265
$262,265
$—
$—
$167,740
$167,740
$—
$—
Restricted cash150,000
150,000
—
—
2020 Notes Hedges77,232
—
—
77,232
45,033
—
—
45,033
2021 Notes Hedges159,095
—
—
159,095
127,063
—
—
127,063
Total$648,592
$412,265
$—
$236,327
$339,836
$167,740
$—
$172,096
  
Liabilities 
 
 
 
 
 
 
 
2017 Notes Conversion Derivative$164
$—
$—
$164
2020 Notes Conversion Derivative77,758
—
—
77,758
$44,132
$—
$—
$44,132
2021 Notes Conversion Derivative161,601
—
—
161,601
126,148
—
—
126,148
Contingent consideration2,249
—
—
2,249
19,188
—
—
19,188
Contingent consideration (CVRs)36,999
36,999
—
—
42,325
42,325
—
—
Total$278,771
$36,999
$—
$241,772
$231,793
$42,325
$—
$189,468

1817
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

The following is a roll forward of our assets and liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) (in thousands):
 Balance at December 25, 2016AdditionsTransfers into Level 3Gain/(loss) included in earningsSettlementsCurrencyBalance at September 24, 2017 Balance at December 31, 2017AdditionsTransfers into Level 3Gain/(loss) included in earningsSettlementsCurrencyBalance at April 1, 2018
      
2017 Notes Conversion Derivative $(164)$—
$—
$(51)$215
$—
$—
2020 Notes Hedges 77,232
—
—
(3,538)—
—
73,694
 $45,033
—
—
(3,100)—
—
$41,933
2020 Notes Conversion Derivative (77,758)—
—
5,298
—
—
(72,460) $(44,132)—
—
2,379
—
—
$(41,753)
2021 Notes Hedges 159,095
—
—
18,723
—
—
177,818
 $127,063
—
—
(11,694)—
—
$115,369
2021 Notes Conversion Derivative (161,601)—
—
(16,269)—
—
(177,870) $(126,148)—
—
10,721
—
—
$(115,427)
Contingent consideration (2,249)—
—
(305)1,429
(181)(1,306) $(19,188)—
—
(414)919
(506)$(19,189)
6.7. Property, Plant and Equipment
Property, plant and equipment, net consists of the following (in thousands):
September 24, 2017 December 25, 2016April 1, 2018 December 31, 2017
Property, plant and equipment, at cost$428,419
 $368,278
$471,773
 $448,921
Less: Accumulated depreciation(216,634) (166,546)(259,442) (236,542)
$211,785
 $201,732
$212,331
 $212,379
7.8. Goodwill and Intangible Assets
Changes in the carrying amount of goodwill occurring during the ninethree months ended September 24, 2017April 1, 2018 are as follows (in thousands):
 
U.S. Lower Extremities
& Biologics
 U.S. Upper Extremities 
International Extremities
& Biologics
 Total
Goodwill at December 25, 2016$218,525
 $558,669
 $73,848
 $851,042
Foreign currency translation—
 —
 9,818
 9,818
Goodwill at September 24, 2017$218,525
 $558,669
 $83,666
 $860,860
 
U.S. Lower Extremities
& Biologics
 U.S. Upper Extremities 
International Extremities
& Biologics
 Total
Goodwill at December 31, 2017$218,525
 $630,650
 $84,487
 $933,662
Foreign currency translation—
 3,275
 5,642
 8,917
Goodwill at April 1, 2018$218,525
 $633,925
 $90,129
 $942,579
Goodwill is recognized for the excess of the purchase price over the fair value of net assets of businesses acquired. Goodwill is required to be tested for impairment at least annually. Unless circumstances otherwise dictate, the annual impairment test is performed in the fourth quarter annually.
Following the December 2017 IMASCAP acquisition, foreign currency translation will be reported within the U.S. Upper Extremities segment. While the IMASCAP offices are located in France and the majority of their operations have a functional currency of the Euro, the results of the IMASCAP business are managed by U.S. Upper Extremities segment.

1918
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

The components of our identifiable intangible assets, net, are as follows (in thousands):
September 24, 2017 December 25, 2016April 1, 2018 December 31, 2017
Cost 
Accumulated
amortization
 Cost 
Accumulated
amortization
Cost 
Accumulated
amortization
 Cost 
Accumulated
amortization
Indefinite life intangibles:              
In-process research and development (IPRD) technology$1,071
   $938
  $6,597
   $6,422
  
              
Finite life intangibles:              
Distribution channels900
 $575
 900
 $374
900
 $705
 900
 $640
Completed technology145,223
 38,531
 133,966
 26,550
152,205
 45,194
 149,645
 40,810
Licenses4,868
 1,427
 4,868
 1,115
5,122
 1,448
 5,268
 1,530
Customer relationships129,819
 21,434
 122,974
 15,133
131,111
 25,368
 129,693
 23,268
Trademarks14,505
 9,767
 13,950
 6,881
14,482
 11,352
 14,368
 10,487
Non-compete agreements11,020
 9,192
 11,810
 7,833
3,386
 2,325
 3,964
 2,603
Other580
 443
 524
 247
558
 691
 569
 490
Total finite life intangibles306,915
 $81,369
 288,992
 $58,133
307,764
 $87,083
 304,407
 $79,828
              
Total intangibles307,986
   289,930
  314,361
   310,829
  
Less: Accumulated amortization(81,369)   (58,133)  (87,083)   (79,828)  
Intangible assets, net$226,617
   $231,797
  $227,278
   $231,001
  
Based on the total finite life intangible assets held at September 24, 2017,April 1, 2018, we expect amortization expense of approximately $29.3 million in 2017, $24.1$25.3 million in 2018, $22.0$23.3 million in 2019, $21.3$22.6 million in 2020, and $21.1$22.5 million in 2021.

2021, and $22.4 million in 2022.
8.9. Debt and Capital Lease Obligations
Debt and capital lease obligations consist of the following (in thousands):
 September 24, 2017 December 25, 2016
Capital lease obligations$17,268
 $14,892
    
2021 Notes295,065
 280,811
2020 Notes505,106
 482,364
2017 Notes 1 
—

1,971
Asset-based line of credit53,908
 30,000
Mortgages2,626
 2,544
Shareholder debt1,683
 1,773
 875,656
 814,355
Less: Current portion(56,783) (33,948)
 $818,873
 $780,407
1
The 2017 Notes matured on August 15, 2017.

20
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

 April 1, 2018 December 31, 2017
Capital lease obligations$22,077
 $20,401
    
2021 Notes305,160
 300,051
2020 Notes521,095
 513,014
Asset-based line of credit53,012
 53,645
Other debt9,518
 8,003
 910,862
 895,114
Less: Current portion(59,340) (58,906)
 $851,522
 $836,208
2021 Notes
On May 20, 2016, we issued $395 million aggregate principal amount of the 2021 Notes pursuant to an indenture (2021 Notes Indenture), dated as of May 20, 2016, between us and The Bank of New York Mellon Trust Company, N.A., as trustee. The 2021 Notes require interest to be paid at an annual rate of 2.25% semi-annually in arrears on each May 15 and November 15, and will mature on November 15, 2021 unless earlier converted or repurchased. The 2021 Notes are convertible, subject to certain conditions, solely into cash. The initial conversion rate for the 2021 Notes will be 46.8165 ordinary shares (subject to adjustment as provided in the 2021 Notes Indenture) per $1,000 principal amount of the 2021 Notes (subject to, and in accordance with, the settlement provisions of the 2021 Notes Indenture), which is equal to an initial conversion price of approximately $21.36 per ordinary share. We may not redeem the 2021 Notes prior to the maturity date, and no “sinking fund” is available for the 2021 Notes, which means that we are not required to redeem or retire the 2021 Notes periodically.

19
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

The holders of the 2021 Notes may convert their 2021 Notes at any time prior to May 15, 2021 solely into cash, in multiples of $1,000 principal amount, upon satisfaction of one or more of the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2016 (and only during such calendar quarter), if the last reported sale price of our ordinary shares for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of 2021 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our ordinary shares and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events. On or after May 15, 2021 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 2021 Notes solely into cash, regardless of the foregoing circumstances. Upon conversion, a holder will receive an amount in cash, per $1,000 principal amount of the 2021 Notes, equal to the settlement amount as calculated under the 2021 Notes Indenture. If we undergo a fundamental change, as defined in the 2021 Notes Indenture, subject to certain conditions, holders of the 2021 Notes will have the option to require us to repurchase for cash all or a portion of their 2021 Notes at a repurchase price equal to 100% of the principal amount of the 2021 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date, as defined in the 2021 Notes Indenture. In addition, following certain corporate transactions, we, under certain circumstances, will increase the applicable conversion rate for a holder that elects to convert its 2021 Notes in connection with such corporate transaction. The 2021 Notes are senior unsecured obligations that rank: (i) senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2021 Notes; (ii) equal in right of payment to any of our unsecured indebtedness that is not so subordinated; (iii) effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and (iv) structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. As a result of the issuance of the 2021 Notes, we recorded deferred financing charges of approximately $7.3 million, which are being amortized over the term of the 2021 Notes using the effective interest method.
In the first quarter of 2017, the closing price of our ordinary shares was greater than 130% of the 2021 Notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end; and, therefore, the holders of the 2021 Notes had the ability to convert the notes during the succeeding quarterly period. Due to the ability of the holders of the 2021 Notes to convert the notes during this period, the carrying value of the 2021 Notes and the fair value of the 2021 Notes Conversion Derivative were classified as current liabilities, and the fair value of the 2021 Notes Hedges were classified as current assets as of March 26, 2017. There were no conversions during the second quarter of 2017. The closing price of our ordinary shares was less than 130% of the 2021 Notes conversion price for more than 20 of the 30 consecutive trading days preceding the calendar quarters ended June 30, 2017, and September 30, 2017, December 31, 2017 and April 1, 2018, which resulted in the 2021 Notes no longer being convertible. As such, the 2021 Notes, 2021 Notes Conversion Derivative and 2021 Notes Hedges were classified as long-term as of September 24,April 1, 2018 and December 31, 2017.
The 2021 Notes Conversion Derivative requires bifurcation from the 2021 Notes in accordance with ASC Topic 815, Derivatives and Hedging, and is accounted for as a derivative liability. See Note 56 for additional information regarding the 2021 Notes Conversion Derivative. The fair value of the 2021 Notes Conversion Derivative at the time of issuance of the 2021 Notes was $117.2 million and was recorded as original debt discount for purposes of accounting for the debt component of the 2021 Notes. This discount is amortized as interest expense using the effective interest method over the term of the 2021 Notes. For the three and nine months ended September 24,April 1, 2018 and March 26, 2017, we recorded $4.6$4.8 million and $13.4$4.4 million respectively, of interest expense, related to the amortization of the debt discount based upon an effective rate of 9.72%. For the three and nine months ended September 25, 2016, we recorded $4.2 million and $5.6 million, respectively, of interest expense related to the amortization of the debt discount based upon an effective rate of 9.72%.

21
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

The components of the 2021 Notes were as follows (in thousands):
September 24, 2017 December 25, 2016April 1, 2018 December 31, 2017
Principal amount of 2021 Notes$395,000
 $395,000
$395,000
 $395,000
Unamortized debt discount(94,025) (107,441)(84,523) (89,332)
Unamortized debt issuance costs(5,910) (6,748)(5,317) (5,617)
Net carrying amount of 2021 Notes$295,065
 $280,811
$305,160
 $300,051
The estimated fair value of the 2021 Notes was approximately $528.4$448.9 million at September 24, 2017,April 1, 2018, based on a quoted price in an active market (Level 1).
We entered into 2021 Notes Hedges in connection with the issuance of the 2021 Notes with two counterparties. The 2021 Notes Hedges, which are cash-settled, are generally intended to reduce our exposure to potential cash payments that we would be required

20
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

to make if holders elect to convert the 2021 Notes at a time when our ordinary share price exceeds the conversion price. However, in connection with certain events, including, among others, (i) a merger or other make-whole fundamental change (as defined in the 2021 Notes Indenture); (ii) certain hedging disruption events, which may include changes in tax laws, an increase in the cost of borrowing our ordinary shares in the market or other material increases in the cost to the option counterparties of hedging the 2021 Note Hedges; (iii) our failure to perform certain obligations under the 2021 Notes Indenture or under the 2021 Notes Hedges; (iv) certain payment defaults on our existing indebtedness in excess of $25 million; or (v) if we or any of our significant subsidiaries become insolvent or otherwise becomes subject to bankruptcy proceedings, the option counterparties have the discretion to terminate the 2021 Notes Hedges, which may reduce the effectiveness of the 2021 Notes Hedges. In addition, the option counterparties have broad discretion to make certain adjustments to the 2021 Notes Hedges and warrant transactions upon the occurrence of certain other events, including, among others, (i) any adjustment to the conversion rate of the 2021 Notes; or (ii) upon the announcement of certain significant corporate events, including events that may give rise to a termination event as described above, such as the announcement of a third-party tender offer. Any such adjustment may also reduce the effectiveness of the 2021 Note Hedges. The aggregate cost of the 2021 Notes Hedges was $99.8 million and is accounted for as a derivative asset in accordance with ASC Topic 815. See Note 56 of the condensed consolidated financial statements for additional information regarding the 2021 Notes Hedges and the 2021 Notes Conversion Derivative.
We also entered into warrant transactions in which we sold warrants for an aggregate of 18.5 million ordinary shares to the two option counterparties, subject to adjustment, for an aggregate of $54.6 million. The strike price of the warrants is $30.00 per share, which was 69% above the last reported sale price of our ordinary shares on May 12, 2016. The warrants are expected to be net-share settled and exercisable over the 100 trading day period beginning on February 15, 2022. The warrant transactions will have a dilutive effect on our ordinary shares to the extent that the market value per ordinary share during such period exceeds the applicable strike price of the warrants. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to warrant transactions, which may increase our obligations under the warrant transactions.
Aside from the initial payment of the $99.8 million premium in the aggregate to the two option counterparties and subject to the right of the option counterparties to terminate the 2021 Notes Hedges in certain circumstances, we do not expect to be required to make any cash payments to the option counterparties under the 2021 Notes Hedges and expect to be entitled to receive from the option counterparties cash, generally equal to the amount by which the market price per ordinary share exceeds the strike price of the convertible note hedging transactions during the relevant valuation period. The strike price under the 2021 Notes Hedges is initially equal to the conversion price of the 2021 Notes. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to the 2021 Note Hedges, which may reduce the effectiveness of the 2021 Note Hedges. Additionally, if the market value per ordinary share exceeds the strike price on any settlement date under the warrant transaction, we will generally be obligated to issue to the option counterparties in the aggregate a number of shares equal in value to one percent of the amount by which the then-current market value of one ordinary share exceeds the then-effective strike price of each warrant, multiplied by the number of ordinary shares into which the 2021 Notes are initially convertible. We will not receive any additional proceeds if warrants are exercised.
As described in more detail below, concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2017 Notes and the 2020 Notes exchanged their 2017 Notes or 2020 Notes for the 2021 Notes.
2020 Notes
On February 13, 2015, WMG issued $632.5 million aggregate principal amount of the 2020 Notes pursuant to an indenture (2020 Notes Indenture), dated as of February 13, 2015 between WMG and The Bank of New York Mellon Trust Company, N.A., as

22
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

trustee. The 2020 Notes require interest to be paid semi-annually on each February 15 and August 15 at an annual rate of 2.00%, and mature on February 15, 2020 unless earlier converted or repurchased. The 2020 Notes were initially issued whereby they were convertible at the option of the holder, during certain periods and subject to certain conditions described below, solely into cash at an initial conversion rate of 32.3939 shares of WMG common stock per $1,000 principal amount of the 2020 Notes, subject to adjustment upon the occurrence of certain events, which represented an initial conversion price of approximately $30.87 per share of WMG common stock. On November 24, 2015, Wright Medical Group N.V. executed a supplemental indenture, fully and unconditionally guaranteeing, on a senior unsecured basis, WMG’s obligations relating to the 2020 Notes, changing the underlying reference securities from WMG common stock to Wright Medical Group N.V. ordinary shares and making a corresponding adjustment to the conversion price. From and after the effective time of the Wright/Tornier merger, (i) all calculations and other determinations with respect to the 2020 Notes previously based on references to WMG common stock are calculated or determined by reference to our ordinary shares, and (ii) the conversion rate (as defined in the 2020 Notes Indenture) for the 2020 Notes was adjusted to a conversion rate of 33.39487 ordinary shares (subject to adjustment as provided in the 2020 Notes Indenture) per $1,000 principal amount of the 2020 Notes, which represents a conversion price of approximately $29.94 per ordinary share (subject to, and in accordance with, the settlement provisions of the 2020 Notes Indenture). The 2020 Notes may not be redeemed

21
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

by WMG prior to the maturity date, and no “sinking fund” is available for the 2020 Notes, which means that WMG is not required to redeem or retire the 2020 Notes periodically.
The holders of the 2020 Notes may convert their notes at any time prior to August 15, 2019 solely into cash, in multiples of $1,000 principal amount, upon satisfaction of one or more of the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2015 (and only during such calendar quarter), if the last reported sale price of our ordinary shares for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of 2020 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our ordinary shares and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events. The Wright/Tornier merger did not result in a conversion right for holders of the 2020 Notes. On or after August 15, 2019 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 2020 Notes solely into cash, regardless of the foregoing circumstances. Upon conversion, a holder will receive an amount in cash, per $1,000 principal amount of the 2020 Notes, equal to the settlement amount as calculated under the 2020 Notes Indenture. If WMG undergoes a fundamental change, as defined in the 2020 Notes Indenture, subject to certain conditions, holders of the 2020 Notes will have the option to require WMG to repurchase for cash all or a portion of their notes at a purchase price equal to 100% of the principal amount of the 2020 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date, as defined in the 2020 Notes Indenture. In addition, following certain corporate transactions, WMG, under certain circumstances, will increase the applicable conversion rate for a holder that elects to convert its 2020 Notes in connection with such corporate transaction. The 2020 Notes are senior unsecured obligations that rank: (i) senior in right of payment to any of WMG's indebtedness that is expressly subordinated in right of payment to the 2020 Notes; (ii) equal in right of payment to any of WMG's unsecured indebtedness that is not so subordinated; (iii) effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and (iv) structurally junior to all indebtedness and other liabilities (including trade payables) of WMG's subsidiaries. In conjunction with the issuance of the 2020 Notes, we recorded deferred financing charges of approximately $18.1 million, which are being amortized over the term of the 2020 Notes using the effective interest method.
The 2020 Notes Conversion Derivative requires bifurcation from the 2020 Notes in accordance with ASC Topic 815, Derivatives and Hedging, and is accounted for as a derivative liability. See Note 56 of the condensed consolidated financial statements for additional information regarding the 2020 Notes Conversion Derivative. The fair value of the 2020 Notes Conversion Derivative at the time of issuance of the 2020 Notes was $149.8 million and was recorded as original debt discount for purposes of accounting for the debt component of the 2020 Notes. This discount is amortized as interest expense using the effective interest method over the term of the 2020 Notes. For the three and nine months ended September 24,April 1, 2018 and March 26, 2017, we recorded $6.9$7.2 million and $20.3$6.6 million respectively, of interest expense, related to the amortization of the debt discount based upon an effective rate of 8.54%. For the three and nine months ended September 25, 2016, we recorded $6.3 million and $19.4 million, respectively, of interest expense related to the amortization of the debt discount based upon an effective rate of 8.54%.
Concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2020 Notes exchanged approximately $45.0 million aggregate principal amount of their 2020 Notes for the 2021 Notes. For each $1,000 principal amount of 2020 Notes validly submitted for exchange, we delivered $990.00 principal amount of the 2021 Notes (subject to rounding down to the nearest $1,000 principal amount of the 2021 Notes, the difference being referred as the rounded amount) to the investor plus an amount of cash equal to the unpaid interest on the 2020 Notes and the rounded amount. As a result of this note exchange and retirement

23
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

of $45.0 million aggregate principal amount of the 2020 Notes, we recognized approximately $9.3 million for the write-off of related pro-rata unamortized deferred financing fees and debt discount within “Other (income) expense, (income), net” in our condensed consolidated statements of operations during the three months ended June 26, 2016.
The components of the 2020 Notes were as follows (in thousands):
September 24, 2017 December 25, 2016April 1, 2018 December 31, 2017
Principal amount of 2020 Notes$587,500
 $587,500
$587,500
 $587,500
Unamortized debt discount(73,470) (93,749)(59,213) (66,418)
Unamortized debt issuance costs(8,924) (11,387)(7,192) (8,068)
Net carrying amount of 2020 Notes$505,106
 $482,364
$521,095
 $513,014
The estimated fair value of the 2020 Notes was approximately $632.4$587.4 million at September 24, 2017,April 1, 2018, based on a quoted price in an active market (Level 1).

22
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

WMG entered into the 2020 Notes Hedges in connection with the issuance of the 2020 Notes with three option counterparties. See Note 56 of the condensed consolidated financial statements for additional information on the 2020 Notes Hedges. The 2020 Notes Hedges, which are cash-settled, are generally intended to reduce WMG's exposure to potential cash payments that WMG would be required to make if holders elect to convert the 2020 Notes at a time when our ordinary share price exceeds the conversion price. However, in connection with certain events, including, among others, (i) a merger or other make-whole fundamental change (as defined in the 2020 Notes indenture); (ii) certain hedging disruption events, which may include changes in tax laws, an increase in the cost of borrowing our ordinary shares in the market or other material increases in the cost to the option counterparties of hedging the 2020 Note Hedges; (iii) WMG's failure to perform certain obligations under the 2020 Notes Indenture or under the 2020 Notes Hedges; (iv) certain payment defaults on WMG's existing indebtedness in excess of $25 million; or (v) if WMG or any of its significant subsidiaries become insolvent or otherwise becomes subject to bankruptcy proceedings, the option counterparties have the discretion to terminate the 2020 Note Hedges at a value determined by them in a commercially reasonable manner and/or adjust the terms of the 2020 Note Hedges, which may reduce the effectiveness of the 2020 Note Hedges. In addition, the option counterparties have broad discretion to make certain adjustments to the 2020 Notes Hedges upon the occurrence of certain other events, including, among others, (i) any adjustment to the conversion rate of the 2020 Notes; or (ii) upon the announcement of certain significant corporate events, including events that may give rise to a termination event as described above, such as the announcement of a third-party tender offer. Any such adjustment may also reduce the effectiveness of the 2020 Note Hedges. The aggregate cost of the 2020 Notes Hedges was $144.8 million and is accounted for as a derivative asset in accordance with ASC Topic 815. See Note 56 of the condensed consolidated financial statements for additional information regarding the 2020 Notes Hedges and the 2020 Notes Conversion Derivative.
WMG also entered into warrant transactions in which it sold warrants for an aggregate of 20.5 million shares of WMG common stock to the three option counterparties, subject to adjustment. The strike price of the warrants was initially $40 per share of WMG common stock, which was 59% above the last reported sale price of WMG common stock on February 9, 2015. On November 24, 2015, Wright Medical Group N.V. assumed WMG's obligations pursuant to the warrants. Following the assumption, the warrants became exercisable for 21.1 million Wright Medical Group N.V. ordinary shares and the strike price of the warrants was adjusted to $38.8010 per ordinary share. The warrants are expected to be net-share settled and exercisable over the 200 trading day period beginning on May 15, 2020. The warrant transactions will have a dilutive effect on our ordinary shares to the extent that the market value per ordinary share during such period exceeds the applicable strike price of the warrants. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to warrant transactions, which may increase our obligations under the warrant transactions.
In addition, during the second quarter of 2016, we settled a portion of the 2020 Notes Hedges (receiving $3.9 million) and repurchased a portion of the warrants associated with the 2020 Notes (paying $3.3 million), generating net proceeds of approximately $0.6 million. Subsequent to this partial settlement, we had warrants which were exercisable for 19.6 million ordinary shares and the strike price of the warrants remained $38.8010 per ordinary share.
Aside from the initial payment of the $144.8 million premium in the aggregate to the option counterparties, we do not expect to be required to make any cash payments to the option counterparties under the 2020 Notes Hedges and expect to be entitled to receive from the option counterparties cash, generally equal to the amount by which the market price per ordinary share exceeds the strike price of the convertible note hedging transactions during the relevant valuation period. The strike price under the 2020 Notes Hedges is initially equal to the conversion price of the 2020 Notes. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to the 2020 Note Hedges, which may reduce the effectiveness of

24
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

the 2020 Note Hedges. Additionally, if the market value per ordinary share exceeds the strike price on any settlement date under the warrant transaction, we will generally be obligated to issue to the option counterparties in the aggregate a number of ordinary shares equal in value to one half of one percent of the amount by which the then-current market value of one ordinary share exceeds the then-effective strike price of each warrant, multiplied by the number of reference ordinary shares into which the 2020 Notes are initially convertible. We will not receive any additional proceeds if warrants are exercised.
2017 Notes
On August 31, 2012, WMG issued $300 million aggregate principal amount of the 2017 Notes pursuant to an indenture (2017 Notes Indenture), dated as of August 31, 2012 between WMG and The Bank of New York Mellon Trust Company, N.A., as trustee. The 2017 Notes matured on August 15, 2017. Prior to maturity, we paid interest on the 2017 Notes semi-annually on each February 15 and August 15 at an annual rate of 2.00%. WMG could not redeem the 2017 Notes prior to the maturity date, and no “sinking fund” was available for the 2017 Notes, which means that WMG was not required to redeem or retire the 2017 Notes periodically. The 2017 Notes were convertible at the option of the holder, during certain periods and subject to certain conditions as described below, solely into cash at an initial conversion rate of 39.3140 shares per $1,000 principal amount of the 2017 Notes, subject to adjustment upon the occurrence of specified events, which represented an initial conversion price of $25.44 per share. Holders

23
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

could have converted their 2017 Notes at any time prior to February 15, 2017 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending December 31, 2012 (and only during such calendar quarter), if the last reported sale price of our ordinary shares for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter was greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our ordinary shares and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events. On or after February 15, 2017 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders could convert their 2017 Notes solely into cash, regardless of the foregoing circumstances. The 2017 Notes were senior unsecured obligations that ranked: (i) senior in right of payment to any of WMG's indebtedness that is expressly subordinated in right of payment to the 2017 Notes; (ii) equal in right of payment to any of WMG's unsecured indebtedness that is not so subordinated; (iii) effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and (iv) structurally junior to all indebtedness and other liabilities (including trade payables) of WMG's subsidiaries. As a result of the issuance of the 2017 Notes, we recognized deferred financing charges of approximately $8.8 million, which were amortized over the term of the 2017 Notes using the effective interest method.
The 2017 Notes Conversion Derivative required bifurcation from the 2017 Notes in accordance with ASC Topic 815, Derivatives and Hedging, and was accounted for as a derivative liability. See Note 56 of the condensed consolidated financial statements for additional information regarding the 2017 Notes Conversion Derivative. The fair value of the 2017 Notes Conversion Derivative at the time of issuance of the 2017 Notes was $48.1 million and was recorded as original debt discount for purposes of accounting for the debt component of the 2017 Notes. This discount is amortized as interest expense using the effective interest method over the term of the 2017 Notes. For the three and nine months ended September 25, 2016,March 26, 2017, we recorded $18.0 thousand and $0.9$0.5 million respectively, of interest expense related to the amortization of the debt discount based upon an effective rate of 6.47%. The amount of interest expense related to the amortization of debt discount for the three and nine months ended September 24, 2017 was insignificant.
In connection with the issuance of the 2020 Notes on February 13, 2015, WMG repurchased and extinguished $240 million aggregate principal amount of the 2017 Notes and settled all of the 2017 Notes Hedges (receiving $70 million) and repurchased all of the warrants (paying $60 million) associated with the 2017 Notes. As a result of the repurchase, we recognized approximately $25.1 million for the write-off of related pro-rata unamortized deferred financing fees and debt discount within “Other (income) expense, (income), net” in our condensed consolidated statements of operations during the three months ended March 31, 2015.
Concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2017 Notes exchanged approximately $54.4 million aggregate principal amount their 2017 Notes for the 2021 Notes. For each $1,000 principal amount of 2017 Notes validly submitted for exchange, we delivered $1,035.40 principal amount of 2021 Notes (subject to rounding down to the nearest $1,000 principal amount of the 2021 Notes, the difference being referred as the rounded amount) to the investor plus an amount of cash equal to the unpaid interest on the 2017 Notes and the rounded amount. In addition, during the three months ended June 26, 2016, we repurchased and extinguished an additional $3.6 million aggregate principal amount of the 2017 Notes in privately negotiated transactions. As a result of this exchange and these repurchases, we recognized approximately $3.0 million for the write-off of

25
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

related pro-rata unamortized deferred financing fees and debt discount within “Other (income) expense, (income), net” in our condensed consolidated statements of operations during the three months ended June 26, 2016.
The components of the 2017 Notes were as follows (in thousands):
 September 24, 2017 December 25, 2016
Principal amount of 2017 Notes$—
 $2,026
Unamortized debt discount—
 (47)
Unamortized debt issuance costs—
 (8)
Net carrying amount of 2017 Notes$—
 $1,971
ABL Facility
On December 23, 2016, we, together with WMG and certain of our other wholly-owned U.S. subsidiaries (collectively, Borrowers), entered into a Credit, Security and Guaranty Agreement (ABL Credit Agreement) with Midcap Financial Trust, as administrative agent (Agent) and a lender and the additional lenders from time to time party thereto. The ABL Credit Agreement provides for a $150.0 million senior secured asset-based line of credit, subject to the satisfaction of a borrowing base requirement (ABL Facility). The ABL Facility may be increased by up to $100.0 million upon the Borrowers’ request, subject to the consent of the Agent and each of the other lenders providing such increase. All borrowings under the ABL Facility are subject to the satisfaction of customary conditions, including the absence of default, the accuracy of representations and warranties in all material respects and the delivery of an updated borrowing base certificate. As of September 24, 2017April 1, 2018 and December 25, 2016,31, 2017, we had $53.9$53.0 million and $30.0$53.6 million respectively, in borrowings outstanding under the ABL Facility. We have reflected this debt as a current liability on our condensed consolidated balance sheet as of September 24, 2017April 1, 2018 and December 25, 2016,31, 2017, as required by US GAAP due to the weekly lockbox repayment/re-borrowing arrangement underlying the agreement, as well as the ability for the lenders to accelerate the repayment of the debt under certain circumstances as described below. As of September 24, 2017April 1, 2018 and December 25, 2016,31, 2017, we had $2.4$2.1 million and $2.5$2.2 million, respectively, of unamortized debt issuance costs related to the ABL Facility. These amounts are included within "Other

24
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

"Other assets" on our condensed consolidated balance sheets and will be amortized over the five-year term of the ABL Facility as described below.
The interest rate margin applicable to borrowings under the ABL Facility is, at the option of the Borrowers, equal to either (a) 3.25% for base rate loans or (b) 4.25% for LIBOR rate loans, subject to a 0.75% LIBOR floor. In addition to paying interest on the outstanding loans under the ABL Facility, the Borrowers also are required to pay a customary unused line fee equal to 0.50% per annum in respect of unutilized commitments and certain other customary fees related to Agent’s administration of the ABL Facility. Beginning January 1, 2017, the Borrowers are required to maintain a minimum drawn balance on the ABL Facility equal to 20% of the average borrowing base for each month. To the extent the actual drawn balance is less than 20%, the Borrowers must pay a fee equal to the amount the lenders under the ABL Facility would have earned had the Borrowers maintained a minimum drawn balance equal to 20% of the average borrowing base for such month.
The ABL Credit Agreement requires that the Borrowers calculate the borrowing base for the ABL Facility on at least a monthly basis and each time the Borrowers make a draw on the ABL Facility in accordance with the formula set forth in the ABL Credit Agreement. The borrowing base is subject to adjustment and the implementation of reserves by the Agent in its permitted discretion, as further described in the ABL Credit Agreement. If at any time the outstanding drawn balance under the ABL Facility exceeds the borrowing base as in effect at such time, Borrowers will be required to prepay loans under the ABL Facility in an amount equal to such excess. Certain accounts receivables and proceeds of collateral of the Borrowers will be applied to reduce the outstanding principal amount of the ABL Facility on a periodic basis.
There is no scheduled amortization under the ABL Facility and (subject to borrowing base requirements and applicable conditions to borrowing) the available revolving commitment may be borrowed, repaid and reborrowed without restriction. All outstanding loans under the ABL Facility will be due and payable in full on the date that is the earliest to occur of (x) December 23, 2021; (y) the date that is 91 days prior to the maturity date of the 2020 Notes or (z) the date that is 91 days prior to the maturity date of the 2021 Notes; provided that, the springing maturity under clauses (y) and (z) are subject to the Borrowers’ ability to refinance, extend, renew or replace the 2020 Notes and/or the 2021 Notes, as applicable, in full pursuant to the terms of the ABL Credit Agreement. Any voluntary or mandatory permanent reduction or termination of the revolving commitments under the ABL Facility is subject to a prepayment premium applicable to such reduced or terminated amount equal to (i) 3.0% through December 23, 2017, (ii) 2.0% from December 24, 2017 through December 23, 2018 and (iii) 0.75% at any time thereafter.
The ABL Credit Agreement contains certain negative covenants that restrict our ability to take certain actions as specified in the ABL Credit Agreement and an affirmative covenant that we maintain net revenue at or above minimum levels and maintain liquidity

26
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

in the United States at a level specified in the ABL Credit Agreement, subject to certain exceptions. All of the obligations under the ABL Facility are guaranteed jointly and severally by Wright Medical Group N.V. and each of the Borrowers on the terms set forth in the ABL Credit Agreement. Subject to certain exceptions set forth in the ABL Credit Agreement, amounts outstanding under the ABL Facility are secured by a senior first priority security interest in substantially all existing and after-acquired assets of Wright Medical Group N.V. and each Borrower. As
On May 7, 2018, we amended and restated the ABL Credit Agreement to add a $40.0 million term loan facility (Term Loan Facility). The initial $20.0 million term loan tranche was funded at closing. The Company may at any time borrow the second $20.0 million term loan tranche, but will be required to do so no later than May 7, 2019 unless it meets certain adjusted EBITDA targets; in which case, the Company will be permitted to extend the borrowing requirement for up to an additional 2 years. All borrowings under the Term Loan Facility are subject to the satisfaction of September 24, 2017, we werecustomary conditions, including the absence of default and the accuracy of representations and warranties in complianceall material respects.
The interest rate applicable to borrowings under the Term Loan Facility will be equal to one-month LIBOR plus 7.85%, subject to a 1.00% LIBOR floor. Amortization payments under the Term Loan Facility are due in equal monthly installments beginning on May 1, 2019 unless the Company meets certain adjusted EBITDA targets; in which case, the amortization payments would not commence until May 1, 2021. In addition to paying interest on the outstanding loans under the Term Loan Facility, the Borrowers will also be required to pay certain other customary fees related to Agent’s administration of the Term Loan Facility.
The Term Loan Facility requires mandatory prepayments, subject to the right of reinvestment and certain other exceptions, in amounts equal to 100% of the net cash proceeds from certain asset sales and casualty and condemnation events in excess of $10 million in any fiscal year. Any voluntary or mandatory prepayment under the Term Loan Facility, subject to certain exceptions, is subject to a 1.00% prepayment premium. The advances under the Term Loan Facility will be due and payable in full at the same time as the outstanding loans under the ABL Facility.
All of the obligations under the Term Loan Facility and the ABL Facility are guaranteed jointly and severally by the Company and each of the Borrowers and are secured by a senior first priority security interest in substantially all existing and after-acquired

25
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

assets of the Company and each Borrower on the terms set forth in the Credit Agreement.
In addition to financial and liquidity covenants consistent with allthose in the ABL Credit Agreement, while the Term Loan Facility is outstanding, the Company is required to maintain a minimum adjusted EBITDA, as described in the Credit Agreement. The Credit Agreement will not affect the Company’s ability to meet its existing contractual obligations, including payments under the Borrower Representative’s contingent value rights agreement, except in circumstances where an event of default (subject to certain exceptions) has occurred and is continuing.
The Credit Agreement also contains negative covenants, underrepresentations and warranties, affirmative covenants and events of default, in each case subject to grace periods, thresholds and materiality qualifiers consistent with the ABL Credit Agreement.
MortgagesOther Debt
Other debt primarily includes mortgages, shareholder debt and Shareholder Debt
loans acquired as a result of the IMASCAP acquisition. We have mortgages that had an outstanding balance of $2.6$0.9 million and $2.5$1.0 million as of September 24, 2017at April 1, 2018 and December 25, 2016,31, 2017, respectively. The majority of this debt is mortgages that were acquired as a result of the Wright/Tornier merger. These mortgages are secured by an office building in Montbonnot, France and bear fixed annual interest rates of 2.55%-4.9%. As a result of the IMASCAP acquisition, we have two zero interest loans with a state investment company that had an outstanding balance of $1.2 million at April 1, 2018 and December 31, 2017. We also had shareholder debt outstanding of $1.6 million as of April 1, 2018 and December 31, 2017. The remainder of other debt totaled approximately $5.8 million and $4.2 million as of April 1, 2018 and December 31, 2017, respectively.
The shareholder debt was acquired in conjunction with the Wright/Tornier merger. This debt was the result of a 2008 transaction where a 51%-owned and consolidated subsidiary of legacy Tornier borrowed $2.2 million from a then-current member of the legacy Tornier board of directors, who was also a 49% owner of the consolidated subsidiary. This loan was used to partially fund the purchase of real estate in Grenoble, France, to be used as a manufacturing facility. Interest on the debt is variable-based on the three-month Euro Libor rate plus 0.5% and has no stated term. The outstanding balance on this debt was $1.7 million as of September 24, 2017 and $1.8 million as of December 25, 2016.

9.10. Accumulated Other Comprehensive Income (AOCI)
Other comprehensive income (OCI) includes certain gains and losses that under US GAAP are included in comprehensive income but are excluded from net loss as these amounts are initially recorded as an adjustment to shareholders’ equity. Amounts in OCI may be reclassified to net loss upon the occurrence of certain events.
For the ninethree months ended September 24,April 1, 2018 and March 26, 2017, and September 25, 2016, OCI was comprised solely of foreign currency translation adjustments.
Changes in AOCI for the ninethree months ended September 24,April 1, 2018 and March 26, 2017 and September 25, 2016 were as follows (in thousands):
 Nine months ended September 24, 2017
 Currency translation adjustment
Balance at December 25, 2016$(19,461)
Other comprehensive income44,362
Balance at September 24, 2017$24,901
 Three months ended April 1, 2018
 Currency translation adjustment
Balance at December 31, 2017$22,290
Other comprehensive income12,458
Balance at April 1, 2018$34,748
 Nine months ended September 25, 2016
 Currency translation adjustment
Balance at December 27, 2015$(10,484)
Other comprehensive income11,763
Balance at September 25, 2016$1,279

 Three months ended March 26, 2017
 Currency translation adjustment
Balance at December 25, 2016$(19,461)
Other comprehensive income8,445
Balance at March 26, 2017$(11,016)

2726
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

10.11. Changes in Shareholders' Equity
The belowfollowing table provides an analysis of changes in each balance sheet caption of shareholders’ equity for the ninethree months ended September 24,April 1, 2018 and March 26, 2017 and September 25, 2016 (in thousands, except share data):
Three months ended April 1, 2018
Ordinary shares Additional paid-in capital Accumulated deficit Accumulated other comprehensive income (loss) Total shareholders' equity
Number of shares Amount 
Balance at December 31, 2017105,807,424
 $3,896
 $1,971,347
 $(1,408,837) $22,290
 $588,696
2018 Activity:           
Net loss—
 —
 —
 (25,514) —
 (25,514)
Foreign currency translation—
 —
 —
 —
 12,458
 12,458
Issuances of ordinary shares141,566
 5
 2,634
 —
 —
 2,639
Vesting of restricted stock units655
 —
 —
 —
 —
 —
Share-based compensation—
 —
 4,896
 —
 —
 4,896
Balance at April 1, 2018105,949,645
 $3,901
 $1,978,877
 $(1,434,351) $34,748
 $583,175
           
Nine Months Ended September 24, 2017Three months ended March 26, 2017
Ordinary shares Additional paid-in capital Accumulated deficit Accumulated other comprehensive income (loss) Total shareholders' equityOrdinary shares Additional paid-in capital Accumulated deficit Accumulated other comprehensive income (loss) Total shareholders' equity
Number of shares Amount Number of shares Amount 
Balance at December 25, 2016103,400,995
 $3,815
 $1,908,749
 $(1,206,239) $(19,461) $686,864
103,400,995
 $3,815
 $1,908,749
 $(1,206,239) $(19,461) $686,864
2017 Activity:                      
Net loss—
 —
 —
 (231,731) —
 (231,731)—
 —
 —
 (58,699) —
 (58,699)
Foreign currency translation—
 —
 —
 —
 44,362
 44,362
—
 —
 —
 —
 8,445
 8,445
Issuances of ordinary shares1,217,088
 40
 24,788
 —
 —
 24,828
730,984
 23
 14,625
 —
 —
 14,648
Vesting of restricted stock units393,595
 13
 (13) —
 —
 —
1,165
 —
 —
 —
 —
 —
Share-based compensation—
 —
 14,193
 —
 —
 14,193
—
 —
 3,958
 —
 —
 3,958
Balance at September 24, 2017105,011,678
 $3,868
 $1,947,717
 $(1,437,970) $24,901
 $538,516
           
Nine Months Ended September 25, 2016
Ordinary shares Additional paid-in capital Accumulated deficit Accumulated other comprehensive income (loss) Total shareholders' equity
Number of shares Amount 
Balance at December 27, 2015102,672,678
 $3,790
 $1,835,586
 $(773,866) $(10,484) $1,055,026
2016 Activity:           
Net loss—
 —
 —
 (387,503) —
 (387,503)
Foreign currency translation—
 —
 —
 —
 11,763
 11,763
Issuances of ordinary shares287,328
 10
 5,654
 —
 —
 5,664
Vesting of restricted stock units265,378
 9
 (9) —
 —
 —
Share-based compensation—
 —
 9,843
 —
 —
 9,843
Issuance of stock warrants, net of repurchases and equity issuance costs—
 —
 50,312
 —
 —
 50,312
Balance at September 25, 2016103,225,384
 $3,809
 $1,901,386
 $(1,161,369) $1,279
 $745,105
Balance at March 26, 2017104,133,144
 $3,838
 $1,927,332
 $(1,264,938) $(11,016) $655,216
11.12. Capital Stock and Earnings Per Share
We are authorized to issue up to 320 million ordinary shares, each share with a par value of three Euro cents (€0.03). We had 105.0105.9 million and 103.4105.8 million ordinary shares issued and outstanding as of September 24, 2017April 1, 2018 and December 25, 2016,31, 2017, respectively.
FASB ASC Topic 260, Earnings Per Share, requires the presentation of basic and diluted earnings per share. Basic earnings per share is calculated based on the weighted-average number of ordinary shares outstanding during the period. Diluted earnings per share is calculated to include any dilutive effect of our ordinary share equivalents. For the three and nine months ended September 24,April 1, 2018 and March 26, 2017, and September 25, 2016, our ordinary share equivalents consisted of stock options, restricted stock units, performance share units, and warrants. The dilutive effect of the stock options, restricted stock units, performance share units, and warrants is calculated using the treasury-stock method.
We had outstanding options to purchase 10.49.7 million ordinary shares, 1.41.3 million restricted stock units, and 0.1 million performance stock units, assuming target performance, at September 24, 2017April 1, 2018 and outstanding options to purchase 10.79.6 million ordinary shares and 1.41.3 million restricted stock units at September 25, 2016.March 26, 2017. We had outstanding net-share settled warrants on the 2020 Notes of 19.6 million ordinary shares at September 24, 2017April 1, 2018 and September 25, 2016.March 26, 2017. We also had net-share settled warrants on the 2021 Notes of 18.5 million ordinary shares at September 24,April 1, 2018 and March 26, 2017.
None of the options, restricted stock units, performance share units, or warrants were included in diluted earnings per share for the three months ended April 1, 2018 or March 26, 2017 because we recorded a net loss for all periods; and September 25, 2016.therefore, including these instruments would be anti-dilutive.

2827
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

None of the options, restricted stock units, or warrants were included in diluted earnings per share for the three and nine months ended September 24, 2017 or September 25, 2016 because we recorded a net loss for all periods; and therefore, including these instruments would be anti-dilutive.
The weighted-average number of ordinary shares outstanding for basic and diluted earnings per share purposes is as follows (in thousands):
 Three months ended Nine months ended
 September 24, 2017 September 25, 2016 September 24, 2017 September 25, 2016
Weighted-average number of ordinary shares outstanding-basic and diluted104,836
 103,072
 104,292
 102,854

 Three months ended
 April 1, 2018 March 26, 2017
Weighted-average number of ordinary shares outstanding-basic and diluted105,904
 103,663
12.13. Commitments and Contingencies
Legal Contingencies
The legal contingencies described in this footnote relate primarily to Wright Medical Technology, Inc. (WMT),WMT, an indirect subsidiary of Wright Medical Group N.V., and are not necessarily applicable to Wright Medical Group N.V. or other affiliated entities. Maintaining separate legal entities within our corporate structure is intended to ring-fence liabilities.  We believe our ring-fenced structure should preclude corporate veil-piercing efforts against entities whose assets are not associated with particular claims.
As described below, our business is subject to various contingencies, including patent and other litigation, product liability claims, and a government inquiry.  These contingencies could result in losses, including damages, fines, or penalties, any of which could be substantial, as well as criminal charges. Although such matters are inherently unpredictable, and negative outcomes or verdicts can occur, we believe we have significant defenses in all of them, and are vigorously defending all of them. However, we could incur judgments, pay settlements, or revise our expectations regarding the outcome of any matter. Such developments, if any, could have a material adverse effect on our results of operations in the period in which applicable amounts are accrued, or on our cash flows in the period in which amounts are paid, however, unless otherwise indicated, we do not believe any of them will have a material adverse effect on our financial position.
Our legal contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss or the measurement of a loss can be complex. We have accrued for losses that are both probable and reasonably estimable. Unless otherwise indicated, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued.  Our assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate. Unanticipated events and circumstances may occur that could cause us to change our estimates and assumptions.
Governmental Inquiries
On August 3, 2012, we received a subpoena from the United States Attorney's Office for the Western District of Tennessee requesting records and documentation relating to our PROFEMUR® series of hip replacement devices. The subpoena covers the period from January 1, 2000 to August 2, 2012. We will continue to cooperate with the investigation.as required.
Patent Litigation
In June 2013, Anglefix, LLC filed suit in the United States District Court for the Western District of Tennessee, alleging that our ORTHOLOC® products infringe Anglefix’s asserted patent, which was licensed to Anglefix by the University of North Carolina (UNC). On April 14, 2014, we filed a request for Inter Partes Review (IPR) with the U.S. Patent and Trademark Office. On June 30, 2015, the Patent Office Board entered judgment in our favor as to all patent claims at issue in the IPR and twelve patent claims remained at issue in the District Court. In January 2017, UNC was added to the District Court case as a co-plaintiff. On July 13, 2017, the Court denied plaintiffs’ motion for summary judgment of infringement, and granted our motion for summary judgment of noninfringement as to the asserted apparatus claims. The Court denied our motion as to the asserted method claims based on the perceived possible existence of a fact issue. In the wake of the Court’s rulings, on July 28, 2017, plaintiffs Anglefix and UNC stipulated to dismissal of their claims against us with prejudice. On the same date, the Court entered judgment dismissing plaintiffs’ claims against us with prejudice thereby ending the case.
On September 23, 2014, Spineology filed a patent infringement lawsuit, Case No. 0:14-cv-03767, in the U.S. District Court in Minnesota, alleging that our X-REAM® bone reamer infringes U.S. Patent No. RE42,757 entitled “EXPANDABLE REAMER.” In January 2015, on the deadline for service of its complaint, Spineology dismissed its complaint without prejudice and filed a

29
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

new, identical complaint. We filed an answer to the new complaint with the Court on April 27, 2015. The Court conducted a Markman hearing on March 23, 2016. Mediation was held on August 11, 2016, but no agreement could be reached. The Court issued a Markman decision on August 30, 2016, in which it found all asserted product claims invalid as indefinite under applicable patent laws and construed several additional claim terms. The parties completed fact and expert discovery with respect to the remaining asserted method claims. We filed a motion for summary judgment of non-infringement of the remaining asserted patent claims and motions to exclude testimony from Spineology’s technical and damages experts. Spineology filed a motion for summary judgment of infringement. On July 25, 2017, the Court granted our motion for summary judgment of non-infringement; denied Spineology’s motion for summary judgment of infringement; and denied all remaining motions as moot. The Court also entered judgment in our favor and against Spineology on all issues. Spineology has appealed the judgment to the U.S. Court of Appeals for the Federal Circuit.Circuit and we are awaiting oral argument, which is scheduled for June 4, 2018.
On September 13, 2016, we filed a civil action, Case No. 2:16-cv-02737-JPM, against Spineology in the U.S. District Court for the Western District of Tennessee alleging breach of contract, breach of implied warranty against infringement, and seeking a judicial declaration of indemnification from Spineology for patent infringement claims brought against us stemming from our sale and/or use of certain expandable reamers purchased from Spineology. Spineology filed a motion to dismiss on October 17, 2016, but withdrew the motion on November 28, 2016. On December 7, 2016, Spineology filed an answer to our complaint and counterclaims, including counterclaims relating to a 2004 non-disclosure agreement between Spineology and WMT. On December 28, 2016, we filed a motion to dismiss the counterclaims relating to that 2004 agreement. On January 4, 2017, Spineology filed a

28
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

motion for summary judgment on certain claims set forth in our complaint. We opposed that motion. On January 27, 2017, we filed a motion for summary judgment on certain issues pertaining to our indemnification claims. Spineology has opposed that motion. On July 7, 2017, the Court extended the deadlines for completing discovery until after it rulesruled on those pending motions. On August 29, 2017, the Court ruled on the motions to dismiss and for summary judgment. In view of that decision, on September 22, 2017, the parties stipulated to, and the Court entered, a judgment that effectively ended the case in a draw. We have appealed the judgment as to our claims against Spineology to the U.S. Court of Appeals for the Sixth Circuit.Circuit and are awaiting oral argument. Spineology did not appeal the District Court’s dismissal of its contract counterclaim.
In August 2016, we received a letter from KFx Medical Corporation (KFx) alleging that a legacy Tornier product (the Piton Suture Anchor) infringes one of KFx’s patents when used in knotless double row tissue fixation techniques. On April 6, 2017, we filed a declaratory judgment action in the United States District Court for the District of Delaware, Case No. 1:17-cv-00384, seeking declaratory judgment of non-infringement and invalidity of United States Patent Nos. 7,585,311; 8,100,942; and 8,109,969. On April 20, 2017, KFx filed an answer and counterclaim alleging we indirectly infringe, and induce infringement of, these patents. On March 13, 2018, we entered into a settlement agreement pursuant to which we paid KFx a one-time lump sum license fee in an immaterial amount in exchange for a fully paid global license to the relevant KFx patents. As a result of the settlement, the Court dismissed the case (including KFx’s counterclaims of patent infringement) with prejudice on March 23, 2018.
Product Liability
We have received claims for personal injury against us associated with fractures of our PROFEMUR® long titanium modular neck product (PROFEMUR® Claims). As of September 24, 2017April 1, 2018 there were approximately 3020 pending U.S. lawsuits and approximately 60 pending non-U.S. lawsuits alleging such claims. The overall fracture rate for the product is low and the fractures appear, at least in part, to relate to patient demographics. Beginning in 2009, we began offering a cobalt-chrome version of our PROFEMUR® modular neck, which has greater strength characteristics than the alternative titanium version. Historically, we have reflected our liability for these claims as part of our standard product liability accruals on a case-by-case basis. However, during the fiscal quarter ended September 30, 2011, as a result of an increase in the number and monetary amount of these claims, management estimated our liability to patients in the United States and Canada who have previously required a revision following a fracture of a PROFEMUR® long titanium modular neck, or who may require a revision in the future. Management has estimated that this aggregate liability ranges from approximately $22.4is $19.3 million. We have classified $11.8 million of this liability as current in “Accrued expenses and other current liabilities,” as we expect to $25.5 million.pay such claims within the next twelve months, and $7.5 million as non-current in “Other liabilities” on our consolidated balance sheet. We expect to pay the majority of these claims within the next three years. Any claims associated with this product outside of the United States and Canada, or for any other products, will be managed as part of our standard product liability accrual methodology on a case-by-case basis.
Due to the uncertainty within our aggregate range of loss resulting from the estimation of the number of claims and related monetary payments, we have recorded a liability of $22.4 million, which represents the low-end of our estimated aggregate range of loss. We have classified $14.5 million of this liability as current in “Accrued expenses and other current liabilities,” as we expect to pay such claims within the next twelve months, and $7.9 million as non-current in “Other liabilities” on our consolidated balance sheet. We expect to pay the majority of these claims within the next three years.
We are aware that MicroPort has recalled certain sizes of its cobalt chrome modular neck products as a result of alleged fractures. As of September 24, 2017, there were six pending U.S. lawsuits and eight pending non-U.S. lawsuits against us alleging personal injury resulting from the fracture of a cobalt chrome modular neck. These claims will be managed as part of our standard product liability accrual methodology on a case-by-case basis.
We have maintained product liability insurance coverage on a claims-made basis. During the fiscal quarter ended March 31, 2013, we received a customary reservation of rights from our primary product liability insurance carrier asserting that present and future

30
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

claims related to fractures of our PROFEMUR® titanium modular neck hip products and which allege certain types of injury (Titanium Modular Neck Claims) would be covered as a single occurrence under the policy year the first such claim was asserted. The effect of this coverage position would be to place Titanium Modular Neck Claims into a single prior policy year in which applicable claims-made coverage was available, subject to the overall policy limits then in effect. Management agreesagreed with the assertion that the Titanium Modular Neck Claims should be treated as a single occurrence, but notified the carrier that it disputed the carrier's selection of available policy years. During the second quarter of 2013, we received confirmation from the primary carrier confirming their agreement with our policy year determination. Based on our insurer's treatment of Titanium Modular Neck Claims as a single occurrence, we increased our estimate of the total probable insurance recovery related to Titanium Modular Neck Claims by $19.4 million, and recognized such additional recovery as a reduction to our selling, general and administrative expenses for the three monthsfiscal quarter ended March 31, 2013, within results of discontinued operations. In the fiscal quarter ended June 30, 2013, we received payment from the primary insurance carrier of $5 million. In the fiscal quarter ended September 30, 2013, we received payment of $10 million from the next insurance carrier in the tower. We have requested, but did not yet received,receive, payment of the remaining $25 million from the third insurance carrier in the tower for that policy period. The policies with the second and third carrier in this tower are “follow form” policies and management believesbelieved the third carrier should follow the coverage position taken by the primary and secondary carriers. On September 29, 2015, that third carrier asserted that the terms and conditions identified in its reservation of rights willwould preclude coverage for the Titanium Modular Neck Claims. We strongly dispute the carrier's position and, in accordance with the dispute resolution provisions of the policy, have initiated an arbitration proceeding in London, England seeking payment of these funds. Pursuant to applicable accounting standards, we reduced our insurance receivable balance for this claim to $0, and recorded a $25 million charge within "Net“Net loss from discontinued operations"operations” during the fiscal year ended December 27, 2015. We strongly disputed the carrier's position and, in accordance with the dispute resolution provisions of the policy, initiated an arbitration proceeding in London, England seeking payment of these funds. The arbitration proceeding is ongoing.was completed on February 15, 2018 and, on April 11, 2018, the arbitration tribunal issued its ruling. Thereafter, we and the insurance carrier agreed to resolve the entire matter in exchange for a

29
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

single lump sum payment by the carrier to us in the amount of $30.75 million, representing the full policy limits of $25 million plus an additional $5.75 million for costs and interest. We received payment of this sum from the carrier on May 8, 2018. This insurance recovery will be reflected within our results of discontinued operations for the quarter ended July 1, 2018.
We are aware that MicroPort has recalled certain sizes of its cobalt chrome modular neck products as a result of alleged fractures. As of April 1, 2018, there were five pending U.S. lawsuits and seven pending non-U.S. lawsuits against us alleging personal injury resulting from the fracture of a cobalt chrome modular neck. These claims will be managed as part of our standard product liability accrual methodology on a case-by-case basis.
Claims for personal injury have also been made against us associated with our metal-on-metal hip products (primarily our CONSERVE® product line). The pre-trial management of certain of these claims has beenwas consolidated in the federal court system, in the United States District Court for the Northern District of Georgia under multi-district litigation (MDL)the MDL and certain other claims by the Judicial Counsel Coordinated Proceedings (JCCP)JCCP in state court in Los Angeles County, California (collectively the Consolidated Metal-on-Metal Claims).
As of September 24, 2017, there were approximately 1,000 lawsuits pending Pursuant to previously disclosed settlement agreements with the Court-appointed attorneys representing plaintiffs in the MDL and JCCP described below, the MDL and an additional 50JCCP were closed to new cases effective October 18, 2017 and October 31, 2017, respectively.
Excluding claims resolved in the settlement agreements described below, as of April 1, 2018, there were approximately 110 metal-on-metal hip cases pending in various U.S. courts. This number includes cases ineligible for settlement, cases which opted out of settlement, post-settlement cases, and existing state courts.court cases that were not part of the MDL or JCCP.  As of April 1, 2018, we estimate there also was pending approximately 60 non-U.S. metal-on metal cases and 30 modular neck cases alleging claims related to the release of metal ions. We also estimate that date, we have also entered intoas of April 1, 2018 there were approximately 850 so called "tolling agreements" with potential claimants who have not yet filed suit. The number of lawsuits pending550 non-revision claims awaiting dismissal in the MDL and JCCP and tolling agreements disclosed above includes the claims that have been resolved pursuant to the Master Settlement Agreement and Second Settlement Agreements discussed below. Based onterms of the settlement agreements. Although there is a limited time period during which dismissed non-revision claims may be refiled, it is presently available information, we believe approximately 350 of these matters allege claims involving bilateral implants. As of September 24, 2017, there were also approximately 50 non-U.S. lawsuits pending.unclear how many non-revision claimants will elect to do so. We believe we have data that supports the efficacy and safety of our metal-on-metal hip products.
Every hip implant case, including metal-on-metal hip casecases, involves fundamental issues of law, science and medicine that often are uncertain, that continue to evolve, and which present contested facts and issues that can differ significantly from case to case. Such contested facts and issues include medical causation, individual patient characteristics, surgery specific factors, statutes of limitation, and the existence of actual, provable injury.
The first bellwether trial in the MDL commenced on November 9, 2015 in Atlanta, Georgia. On November 24, 2015, the jury returned a verdict in favor of the plaintiff and awarded the plaintiff $1 million in compensatory damages and $10 million in punitive damages. We believe there were significant trial irregularities and vigorously contested the trial result. On December 28, 2015, we filed a post-trial motion for judgment as a matter of law or, in the alternative, for a new trial or a reduction of damages awarded. On April 5, 2016, the trial judge issued an order reducing the punitive damage award from $10 million to $1.1 million, but otherwise denied our motion. On May 4, 2016, we filed a notice of appeal with the United States Court of Appeals for the Eleventh Circuit. The United States Court of Appeals for the Eleventh Circuit heard oral arguments on January 26, 2017 and on March 20, 2017, the Eleventh Circuit Court of Appeals upheld the lower court’s verdict. On April 10, 2017, we filed a petition for rehearing en banc or for panel rehearing, which was denied. In light of this denial, we elected to forego a further appeal and paid the judgment in July 2017.
The first bellwether trial in the JCCP, which was scheduled to commence on October 31, 2016, and subsequently rescheduled to January 9, 2017, was settled for an immaterial amount.
The first state court metal-on-metal hip trial not part of the MDL or JCCP commenced on October 24, 2016, in St. Louis, Missouri. On November 3, 2016, the jury returned a verdict in our favor. The plaintiff has appealed.
On November 1, 2016, WMT entered into a Master Settlement Agreement (MSA)the MSA with Court-appointed attorneys representing plaintiffs in the MDL and JCCP. Under the terms of the MSA, the parties agreed to settle 1,292 specifically identified claims

31
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

associated with CONSERVE®, DYNASTY® and LINEAGE® products that meet the eligibility requirements of the MSA and are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a settlement amount of $240 million.
The $240 million settlement amount is a maximum settlement based on the pool of 1,292 specific, existing claims comprised of an identified mix of CONSERVE®, DYNASTY® and LINEAGE® products (Initial Settlement Pool), with a value assigned to each product type, resulting in a total settlement of $240 million for the 1,292 claims in the Initial Settlement Pool.
Actual settlements paid to individual claimants will beare determined under the claims administration procedures contained in the MSA and may be more or less than the amounts used to calculate the $240 million settlement for the 1,292 claims in the Initial Settlement Pool. However in no event will variations in actual settlement amounts payable to individual claimants affect WMT’s maximum settlement obligation of $240 million or the manner in which it may be reduced due to opt outs, final product mix, or elimination of ineligible claims.
If it is determined a claim in the Initial Settlement Pool is ineligible due to failure to meet the eligibility criteria of the MSA, such claim will be removed and, where possible, replaced with a new eligible claim involving the same product, with the goal of having the number and mix of claims in the final settlement pool (before opt-outs) (Final Settlement Pool) equal, as nearly as possible, the number and mix of claims in the Initial Settlement Pool. Additionally, if any DYNASTY® or LINEAGE® claims in the Final Settlement Pool are determined to have been misidentified as CONSERVE® claims, or vice versa, the total settlement amount will be adjusted based on the value for each product type (not to exceed $240 million).
The MSA contains specific eligibility requirements and establishes procedures for proof and administration of claims, negotiation and execution of individual settlement agreements, determination of the final total settlement amount, and funding of individual settlement amounts by WMT. Eligibility requirements include, without limitation, that the claimant has a claim pending or tolled in the MDL or JCCP, that the claimant has undergone a revision surgery within eight years of the original implantation surgery, and that the claim has not been identified by WMT as having possible statute of limitation issues. Claimants who have had bilateral revision surgeries will be counted as two claims but only to the extent both claims separately satisfy all eligibility criteria.

30
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

The MSA includes a 95% opt-in requirement, meaning the MSA could have been terminated by WMT prior to any settlement disbursement if claimants holding greater than 5% of eligible claims in the Final Settlement Pool elected to “opt-out” of the settlement. WMT has confirmed that of the 1,292 eligible claims, 1,279 opted to participate in the settlement and 13 opted out, resulting in a final opt-in percentage of approximately 99%, well in excess of the required 95% threshold. On March 2, 2017, WMT agreed to replace the 13 opt-out claims with 13 additional claims that would have been eligible to participate in the MSA but for the 1,292 claim limit, bringing the total MSA settlement to the maximum limit of $240 million to settle 1,292 claims. Due to apparent demand from additional claimants excluded from settlement because of the 1,292 claims ceiling, but otherwise eligible for participation, on May 15, 2017 WMT agreed to settle an additional 53 such claims, on terms substantially identical to the MSA settlement terms, for a maximum additional settlement amount of $9.4 million.
During 2016, WMT escrowed $150 million of which $38.9 million was remaining as of September 24, 2017, to secure its obligations under the MSA.MSA, all of which had been disbursed as of December 31, 2017. As additional security, Wright Medical Group N.V., the indirect parent company of WMT, agreed to guarantee WMT’s obligations under the MSA.
On October 3, 2017, WMT entered into two additional settlement agreements (collectively, the Second Settlement Agreements)Agreements with the Court-appointed attorneys representing plaintiffs in the MDL and JCCP. Under the terms of the Second Settlement Agreements, the parties agreed to settle 629 specifically identified CONSERVE®, DYNASTY® and LINEAGE® claims that meet the eligibility requirements of the Second Settlement Agreements and are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a maximum settlement amount of $89.75 million. The comprehensive settlement amount iswas contingent on WMT’s recovery of new insurance paymentsproceeds totaling at least $35 million from applicable insurance carriers by December 31, 2017. On December 29, 2017, WMT entered into a First Amendment to the Third Settlement Agreement pursuant to which the deadline for the recovery of new insurance proceeds totaling at least $35 million from applicable insurance carriers was extended through February 28, 2018 and, on February 23, 2018, WMT entered into a Second Amendment to the Third Settlement Agreement pursuant to which the deadline was extended through March 30, 2018. On March 29, 2018, WMT entered into a Third Amendment to the Third Settlement Agreement which eliminates the contingency and gives WMT the option, by September 30, 2018, to either pay or make available for payment the then outstanding deficit on the insurance contingency or transfer to eligible claimants WMT’s claims against the insurance carriers with whom WMT has not settled, and pay or make available for payment such insurance deficit in March 2019, subject to the right to recover these funds from any plaintiff recoveries from carriers plus ten percent interest, plus an additional $5 million in costs, in each case after recovery by plaintiffs’ counsel of costs and fees. In connection with such transfer agreement, WMT would also enter into a stipulated judgment in the amount of $541 million, which judgment would not be recoverable against WMT or its affiliates. To date, certain of the insurance carriers have contributed $21.9 million of funds applicable against the $35 million contingency, leaving a $13.1 million deficit as of April 30, 2018.
The $89.75 million settlement amount is a maximum settlement based on the pool of 629 specific, existing claims comprised of an identified mix of CONSERVE®, DYNASTY® and LINEAGE® products (Second Settlement Initial Settlement Pool), with a value assigned to each product type. The actual settlement may be less, but not more, depending on several factors including the mix of products and claimants in the final settlement pool (Second Settlement Final Settlement Pool) and the number of claimants electing to “opt-out” of the settlement.
The total maximum settlement amount of $89.75 million is allocated among the following three tranches: (1) Tranche 1: $7.9 million to settle 49 additional claims that would have been eligible to participate in the MSA but for the claim limit contained therein, which amount will be funded as such claims are settled; (2) Tranche 2: $5.1 million to settle 39 eligible claims of the oldest claimants (by age), which amount will be funded as such claims are settled; and (3) Tranche 3: $76.75 million to settle 511

32
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

eligible claims pending or tolled in the MDL and JCCP existing as of June 30, 2017, and 30 new eligible claims which were presented between July 1, 2017 and October 1, 2017, which amount2017. Settlement funds for Tranche 3 will be fundedpaid or made available for payment as follows: $45 million by(less the remaining insurance deficit, which is presently $13.1 million) on June 30, 2018, the remaining insurance deficit (presently $13.1 million) by either September 30, 2018 or March 7, 2019, depending on whether WMT elects to assign its remaining insurance claims to plaintiffs, and $31.75 millionthe balance by September 30, 2019. The Tranche 3 settlement is contingent upon WMT receiving at least $35 millionActual funding may extend beyond these dates pending completion of new insurance payments from applicable carriers by December 31, 2017. There is no contingency with respect to Tranches 1 and 2.claims administration processes.
Actual settlements paid to individual claimants will be determined under the claims administration procedures contained in the Second Settlement Agreements and may be more or less than the amounts used to calculate the $89.75 million settlement for the 629 claims in the Second Settlement Initial Settlement Pool. However in no event will variations in actual settlement amounts payable to individual claimants affect WMT’s maximum settlement obligation of $89.75 million or the manner in which it may be reduced due to opt outs, final product mix, or elimination of ineligible claims.

31
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

If it is determined that a claim in the Second Settlement Initial Settlement Pool is ineligible due to failure to meet the eligibility criteria of the Second Settlement Agreements, such claim will be removed and, where possible, replaced with a new eligible claim involving the same products as the removed claim.
The Second Settlement Agreements contain specific eligibility requirements and establish procedures for proof and administration of claims, negotiation and execution of individual settlement agreements, determination of the final total settlement amount, and funding of individual settlement amounts by WMT. Eligibility requirements include, without limitation, that the claimant has a claim pending or tolled in the MDL or JCCP and that, with limited exceptions, the claimant has undergone a revision surgery. Claimants who have had bilateral revision surgeries will be counted as two claims but only to the extent both claims separately satisfy all eligibility criteria.
Each of the Second Settlement Agreements includes a 95% opt-in requirement, meaning WMT may terminate either Settlement Agreement prior to any settlement disbursement if claimants holding greater than 5% of eligible claims in Tranches 1 and 2, collectively, or claimants holding greater than 5% of eligible claims in Tranche 3, in the Second Settlement Final Settlement Pool, elect to “opt-out” of the settlement. On January 2, 2018, WMT received notification that 100% of the claimants in Tranches 1 and 2 opted-in. WMT reviewed proof of claim documentation for these claimants and confirmed a final opt-in percentage of 100%. On or about May 1, 2018, WMT received notice from plaintiffs that the 95% opt-in threshold has also been met for Tranche 3. WMT has until May 30, 2018 to confirm this.
While the Second Settlement Agreements did not require WMT to escrow any amount to secure its obligations thereunder, as additional security, Wright Medical Group N.V., the indirect parent company of WMT, agreed to guarantee WMT’s obligations under the Second Settlement Agreements.
The MSA (which reference includes the supplemental settlements described above) and the Second Settlement Agreements were entered into solely as a compromise of the disputed claims being settled and are not evidence that any claim has merit nor are they an admission of wrongdoing or liability by WMT. WMT will continue to vigorously defend metal-on-metal hip claims not settled pursuant to the above agreements. The Second Settlement Agreements are contingent upon the dismissal without prejudice of pending and tolled claims in the MDL and JCCP that do not meet the inclusion criteria of the MDL or JCCP. Additionally, the Second Settlement Agreements are contingent upon the dismissal without prejudice of all remaining non-revision claims in the MDL and JCCP (presently estimated to number approximately 550), pursuant to a tolling agreement that tolls applicable statutes of limitation and repose for three months from a revision of the products or determination that a revision of the products is necessary. The parties are in the process of jointly coordinating the closures of the MDL and JCCP courts have both entered orders closing these proceedings to new claims.
As of September 24, 2017, we estimate there were approximately 15 outstanding metal-on-metal hip revision claims that were not included in the MSA or Second Settlement Agreements, approximately 50 claims pending in U.S courts other than the MDL and JCCP, and approximately 50 claims pending in non-U.S. courts. We also estimate that there were approximately 650 outstanding metal-on-metal hip non-revision claims as of September 24, 2017. These non-revision cases were excluded from the MSA and Second Settlement Agreements. As a result of entering into the Second Settlement Agreements during the third quarter of 2017, we recorded an additional accrual of $82.7 million for the 629 matters included within the settlement and for matters that have the same eligibility criteria.
As of September 24, 2017,April 1, 2018, our accrual for metal-on-metal claims totaled $244.2$149.3 million, of which $199.3$100.7 million is included in our condensed consolidated balance sheet within “Accrued expenses and other current liabilities” and $44.9$48.6 million is included within “Other liabilities.” Our accrual is based on (i) case by case accruals for specific cases where facts and circumstances warrant, and (ii) the implied settlement values for eligible claims under the MSA or Second Settlement Agreements. We are unable to reasonably estimate the high-end of a possible range of loss for claims which elected or will elect to opt-out of the MSA or Second Settlement Agreements. Claims we can confirm would meet MSA or Second Settlement Agreements eligibility criteria but are excluded from the settlements due to the maximum settlement cap, or because they are state cases not part of the MDL or JCCP, have been accrued as of the respective settlement rates. Due to the general uncertainties surrounding all metal-on metal claims as noted above, as well as insufficient information about individual claims, we are presently unable to reasonably estimate a range of loss for future claims; hence we have not accrued for these claims at the present time.

33
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

We are unable to predict whether we will be successful in recovering the necessary insurance proceeds required to complete the comprehensive settlement pursuant to the Second Settlement Agreements within the requisite timeframe. We continue to believe the high-end of a possible range of loss for existing revision claims that do not meet eligibility criteria of the MSA or Second Settlement Agreements will not, on an average per case basis, exceed the average per case accrual we take for revision claims we can confirm do meet eligibility criteria of the MSA or Second Settlement Agreements, as applicable. Future claims will be evaluated for accrual on a case by case basis using the accrual methodologies described above (which could change if future facts and circumstances warrant).
The first state court metal-on-metal hip trial not part of the MDL or JCCP commenced on October 24, 2016, in St. Louis, Missouri. On November 3, 2016, the jury returned a verdict in our favor. The plaintiff appealed and the appellate court heard oral argument on November 8, 2017. On February 20, 2018, the Missouri Court of Appeals, Eastern District, denied the plaintiff’s appeal and upheld the verdict of the trial court. The plaintiff’s time for seeking any further relief from the verdict has lapsed and this matter is closed.

32
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

We have maintained product liability insurance coverage on a claims-made basis. During the fiscal quarter ended September 30, 2012, we received a customary reservation of rights from our primary product liability insurance carrier asserting that certain present and future claims which allege certain types of injury related to our CONSERVE® metal-on-metal hip products (CONSERVE® Claims) would be covered as a single occurrence under the policy year the first such claim was asserted. The effect of this coverage position would be to place CONSERVE® Claims into a single prior policy year in which applicable claims-made coverage was available, subject to the overall policy limits then in effect. Management agrees that there is insurance coverage for the CONSERVE® Claims, but has notified the carrier that it disputes the carrier's characterization of the CONSERVE® Claims as a single occurrence.
In June 2014, St. Paul Surplus Lines Insurance Company (Travelers),Travelers, which was an excess carrier in our coverage towers across multiple policy years, filed a declaratory judgment action in Tennessee state court naming us and certain of our other insurance carriers as defendants and asking the court to rule on the rights and responsibilities of the parties with regard to the CONSERVE® Claims. Among other things, Travelers appeared to dispute our contention that the CONSERVE® Claims arise out of more than a single occurrence thereby triggering multiple policy periods of coverage.  Travelers further sought a determination as to the applicable policy period triggered by the alleged single occurrence.  We filed a separate lawsuit in state court in California for declaratory judgment against certain carriers and breach of contract against the primary carrier, and moved to dismiss or stay the Tennessee action on a number of grounds, including that California is the most appropriate jurisdiction. During the third quarter of 2014, the California Court granted Travelers' motion to stay our California action. On April 29, 2016, we filed a dispositive motion seeking partial judgment in our favor in the Tennessee action, which motion is pending and has been referred to a Special Master to consider the parties’ arguments and report to the Court by December 8, 2017. Oral argument on the motion is scheduled for February 23, 2018.arguments. On June 10, 2016, Travelers withdrew its motion for summary judgment in the Tennessee action. One of the other insurance companies in the Tennessee action has stated that it will re-file a similar motion in the future.
In March 2017, Lexington, Insurance Company (“Lexington”), which had been dismissed from the Tennessee action, requested arbitration under five Lexington insurance policies in connection with the CONSERVE® Claims. We subsequently engaged in discussions and correspondence with Lexington about the scope of the requested arbitration(s). On or about October 27, 2017, Lexington filed an Application for Order to Compel Arbitration in the Commonwealth of Massachusetts, Suffolk County Superior Court, naming WMT, Wright Medical Group, Inc., and Wright Medical Group N.V. We are presently considering our responseopposed the Application. On February 28, 2018, the Massachusetts Court ordered the parties to arbitrate the Application.two Lexington insurance policies containing Massachusetts arbitration clauses but did not order arbitration under the remaining three Lexington policies at issue. We have appealed that ruling.
On October 28, 2016, WMT and Wright Medical Group, Inc. (Wright Entities), entered into a Settlement Agreement, Indemnity and Hold Harmless Agreement and Policy Buyback Agreement (Insurance Settlement Agreement) with a subgroup of three insurance carriers, namely Columbia Casualty Company, Travelers and AXIS Surplus Lines Insurance Company (collectively, the Three Settling Insurers), pursuant to which the Three Settling Insurers paid WMT an aggregate of $60 million (in addition to $10 million previously paid by Columbia) in a lump sum. This amount is in full satisfaction of all potential liability of the Three Settling Insurers relating to metal-on-metal hip and similar metal ion release claims, including but not limited to all claims in the MDL and the JCCP, and all claims asserted by WMT against the Three Settling Insurers in the Tennessee action described above.
As part of the settlement with the Three Settling Insurers, the Three Settling Insurers bought back from WMT their policies in the five policy years beginning with the August 15, 2007- August 15, 2008 policy year (Repurchased Policy Years). Consequently, the Wright Entities have no further coverage from the Three Settling Insurers for any present or future claims falling in the Repurchased Policy Years, or any other period in which a released claim is asserted. Additionally, the Insurance Settlement Agreement contains a so-called most favored nation provision which could require us to refund a pro rata portion of the settlement amount if we voluntarily enter into a settlement with the remaining carriers in the Repurchased Policy Years on certain terms more favorable than analogous terms in the Insurance Settlement Agreement. The Tennessee action will continue as to the remaining defendant insurers other than the Three Settling Insurers. The amount due to the Wright Entities under the Insurance Settlement Agreement was paid in the fourth quarter of 2016 and the Three Settling Insurers have been dismissed from the Tennessee action.
On December 13, 2016, we filed a motion in the Tennessee action described above to include allegations of bad faith against the primary insurance carrier.  The motion was subsequently amended on February 8, 2017 to add similar bad faith claims against the remaining excess carriers.  On April 13, 2017, the Court denied our motion, without prejudice to our right to re-assert the motion at a later time. On August 29, 2017, we refiled the motion to add a bad faith claim against the primary and excess insurance carriers. The Court granted our motion on October 19, 2017 and, on October 23, 2017, we filed amended cross-claims alleging bad faith against all of the insurance carriers.
As part of On November 9, 2017, our primary insurance carrier brought a motion to dismiss and strike our bad faith claim. The remaining excess carriers either joined the settlement,primary insurer’s motion or brought their own separate motions. On December 22, 2017 and December 29, 2017, we opposed the Three Settling Insurers bought back from WMT their policies in the five policy years beginning with the August 15, 2007- August 15, 2008 policy year (Repurchased Policy Years). Consequently, the Wright Entities have no further coverage from the Three Settling Insurersinsurers’ motions to dismiss and strike our claim for any present or future claims falling in the Repurchased Policy Years, or any other period in which a released claim is asserted. Additionally, the Insurance Settlement Agreement contains a so-called most favored nation provision which could require us to refund a pro rata portion of the settlement amount if we voluntarily enter into a settlementbad faith. The motions remain pending.

3433
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

withOn February 22, 2018, we and certain of our subsidiaries entered into the remaining carriers in the Repurchased Policy Years on certain terms more favorable than analogous terms in the Insurance Settlement Agreement. The Tennessee action will continue as to the remaining defendant insurers other than the Three Settling Insurers. The amount due to the Wright Entities under theSecond Insurance Settlement Agreement waswith Federal, pursuant to which Federal has paid us a single lump sum payment of $15 million (in addition to $5 million previously paid by Federal). This amount is in full satisfaction of all potential liability of Federal relating to designated metal-on-metal hip claims, including but not limited to all claims asserted by our subsidiary WMT against Federal in the fourth quarterpreviously disclosed insurance coverage litigation. We recorded a $15 million receivable as a result of 2016 and the Three Settling Insurers have beenthis agreement within “Other current assets” as of December 31, 2017. On March 20, 2018, Federal was dismissed from the Tennessee action.and California actions described above.
ManagementOn April 19, 2018, we and certain of our subsidiaries entered into a Settlement and Release Agreement (Third Insurance Settlement Agreement) with Catlin Underwriting Agencies Limited for and on behalf of Syndicate 2003 at Lloyd’s of London (Lloyd’s Syndicate 2003) pursuant to which Lloyd’s Syndicate 2003 has recorded anpaid us a single lump sum payment of $1.9 million (in addition to $5 million previously paid by Lloyd’s Syndicate 2003). This amount is in full satisfaction of all potential liability of Lloyd’s Syndicate 2003 relating to designated metal-on-metal hip claims, including but not limited to all claims asserted by our subsidiary WMT against Lloyd’s Syndicate 2003 in the previously disclosed insurance receivable of $5.0 million for the probable recovery of spendingcoverage litigation. On May 1, 2018, Lloyd’s Syndicate 2003 was dismissed from the remaining carriers (other thanTennessee action described above. The dismissal of Lloyd’s Syndicate 2003 from the Three Settling Carriers)California action is in excess of our retention for a single occurrence. process.
As of September 24, 2017, we have received $73.3 million of insurance proceeds, including the above amount from the Three Settling Insurers, andMay 1, 2018, our insurance carriers have paid a totalan aggregate of $101.9 million of insurance proceeds related to the metal-on-metal claims, including amounts received under the three above referenced settlement agreements, of which $95.2 million has been paid directly to us and $6.7 million has been paid directly to claimantsclaimants. Except as provided in connection with various settlements, which represents amounts undisputed by the carriers. OurInsurance Settlement Agreement, the Second Insurance Settlement Agreement and the Third Insurance Settlement Agreement, our acceptance of thesethe insurance proceeds was not a waiver of any other claim we may have against the insurance carriers.carriers unrelated to metal-on-metal coverage and our disputes with carriers relating thereto. However, the amount we ultimately receive will depend on the outcome of our dispute with the remaining carriers (other than the Three Settling Carriers)(Lexington and Catlin, with remaining policy limits totaling $30 million and $5 million, respectively) concerning the number of policy years available. We believe our contracts with the insurance carriers are enforceable for these claims; and, therefore, we believe it is probable we will receive additional recoveries from the remaining carriers. Settlement discussions with the remaining insurance carriers continue.
Given the substantial or indeterminate amounts sought in these matters, and the inherent unpredictability of such matters, an adverse outcome in these matters in excess of the amounts included in our accrual for contingencies could have a material adverse effect on our financial condition, results of operations and cash flow. Future revisions to our estimates of these provisions could materially impact our results of operations and financial position. We use the best information available to determine the level of accrued product liabilities, and believe our accruals are adequate.
In June 2015, a jury returned a $4.4 million verdict against us in a case involving a fractured hip implant stem sold prior to the MicroPort closing.  This was a one-of-a-kind case unrelated to the modular neck fracture cases we have been reporting. There are no other cases pending related to this component, nor are we aware of other instances where this component has fractured. In September 2015, the trial judge reduced the jury verdict to $1.025 million and indicated that if the plaintiff did not accept the reduced award he would schedule a new trial solely on the issue of damages. The plaintiff elected not to accept the reduced damage award, and both parties have appealed. The Court has not setOn November 14, 2017, our primary insurance carrier agreed to defend and indemnify us in connection with this lawsuit under a date for a new trialreservation of rights. On January 9, 2018, the California appellate court heard oral argument on the issueparties’ cross-appeals. On March 6, 2018, the appellate court rejected our appeal and granted plaintiff’s, reinstating the original jury award of damages and we do not expect it will do so until the appeals are adjudicated. We will maintain our current $4.4 million, accrual as a probable liability untilplus interest. Our primary insurance carrier has directly paid this amount in full and the matter is resolved.case will be dismissed with prejudice. The $4.4$5.8 million probable liability associated with this matter is reflected within “Accrued expenses and other current liabilities,” and a $4$5.8 million receivable associated with the probable recovery from product liability insurance is reflected within “Other current assets.”
Other
In addition to those noted above, we are subject to various other legal proceedings, product liability claims, corporate governance, and other matters which arise in the ordinary course of business.

13. Restricted Cash
During the fourth quarter of 2016, WMT deposited $150.0 million into a restricted escrow account to secure its obligations under the MSA that WMT entered into in connection with the metal-on-metal hip litigation, as described in Note 12 to the condensed consolidated financial statements. All individual settlements under the MSA will be funded first from the escrow account and then, once all funds held in the escrow account have been exhausted, directly by WMT. Within 30 days of each funding request, unless WMT in good faith objects to the accuracy of any payment request, WMT will instruct the escrow agent to transfer funds from the restricted escrow account to a master account designated by plaintiffs’ counsel, who will then arrange for disbursements of individual settlement amounts. During the quarter ended September 24, 2017, WMT made $111.1 million in settlement payments from the escrow account. As of September 24, 2017, $38.9 million remained in the restricted escrow account, and therefore, considered restricted cash under US GAAP. WMT expects to utilize the remaining funds held in the escrow account during the fourth quarter of 2017. See Note 12 to the condensed consolidated financial statements for further discussion regarding the MSA and the metal-on-metal hip litigation. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within our condensed consolidated balance sheets that sum to the totals of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands):

35
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

 September 24, 2017 December 25, 2016
Cash and cash equivalents$238,867
 $262,265
Restricted cash38,922
 150,000
Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows$277,789
 $412,265

14. Segment Information
Our management, including our Chief Executive Officer, who is our chief operating decision maker, manages our operations as three operating business segments: U.S. Lower Extremities & Biologics, U.S. Upper Extremities, and International Extremities & Biologics. We determined that each of these operating segments represented a reportable segment. Our Chief Executive Officer reviews financial information at the operating segment level to allocate resources and to assess the operating results and performance of each segment.  

34
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

Our U.S. Lower Extremities & Biologics segment consists of our operations focused on the sale in the United States of our lower extremities products, such as joint implants and bone fixation devices for the foot and ankle, and our biologics products used to support treatment of damaged or diseased bone, tendons, and soft tissues or to stimulate bone growth. Our U.S. Upper Extremities segment consists of our operations focused on the sale in the United States of our upper extremities products, such as joint implants and bone fixation devices for the shoulder, elbow, wrist, and hand, and products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries and other ancillary products. As the IMASCAP operations will be managed by the U.S. Upper Extremities management team, results of operations and assets related to IMASCAP will be included within the U.S. Upper Extremities segment. Our International Extremities and Biologics segment consists of our operations focused on the sale outside the United States of all lower and upper extremities products, including associated biologics products.
Management measures segment profitability using an internal operating performance measure that excludes the impact of inventory step-up amortization and transaction and transition costs associated with acquisitions, as such items are not considered representative of segment results. We have determined that each reportable segment represents a reporting unit and, in accordance with ASC 350, requires an allocation of goodwill to each reporting unit.
Selected financial information related to our segments is presented below for the three months ended September 24,April 1, 2018 and March 26, 2017 and September 25, 2016 (in thousands):
 Three months ended September 24, 2017
 U.S. Lower Extremities & BiologicsU.S. Upper ExtremitiesInternational Extremities & Biologics
Corporate 1
Total
Net sales from external customers$70,946
$55,918
$43,639
$—
$170,503
Depreciation expense3,871
2,372
3,298
5,459
15,000
Amortization expense—
—
—
7,178
7,178
Segment operating income (loss)$13,506
$16,575
$(1,563)$(43,716)$(15,198)
Other:     
Transaction and transition expenses    3,311
Operating loss    (18,509)
Interest expense, net    18,978
Other expense, net    5,457
Loss before income taxes    $(42,944)

36
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

 Three months ended April 1, 2018
 U.S. Lower Extremities & BiologicsU.S. Upper ExtremitiesInternational Extremities & Biologics
Corporate 1
Total
Net sales from external customers$75,897
$68,896
$53,744
$—
$198,537
Depreciation expense3,031
2,926
2,808
5,734
14,499
Amortization expense—
—
—
7,141
7,141
Segment operating income (loss)$19,458
$24,154
$258
$(43,850)$20
Other:     
Transaction and transition expenses    910
Operating loss    (890)
Interest expense, net    19,812
Other income, net    (1,000)
Loss before income taxes    $(19,702)
Three months ended September 25, 2016Three months ended March 26, 2017
U.S. Lower Extremities & BiologicsU.S. Upper ExtremitiesInternational Extremities & Biologics
Corporate 1
TotalU.S. Lower Extremities & BiologicsU.S. Upper ExtremitiesInternational Extremities & Biologics
Corporate 1
Total
Net sales from external customers$70,654
$47,411
$39,267
$—
$157,332
$74,993
$57,161
$45,037
$—
$177,191
Depreciation expense3,494
3,181
3,086
5,124
14,885
3,195
2,415
2,531
5,305
13,446
Amortization expense—
—
—
7,466
7,466
—
—
—
7,397
7,397
Segment operating income (loss)$17,980
$12,594
$(2,945)$(47,822)$(20,193)$20,825
$17,486
$2,319
$(47,256)$(6,626)
Other:  
Inventory step-up amortization 10,306
Transaction and transition expenses 8,105
 2,972
Operating loss (38,604) (9,598)
Interest expense, net 16,795
 18,195
Other income, net (365)
Other expense, net 7,975
Loss before income taxes $(55,034) $(35,768)
Selected financial information related to our segments is presented below for the nine months ended September 24, 2017 and September 25, 2016 (in thousands):
 Nine months ended September 24, 2017
 U.S. Lower Extremities & BiologicsU.S. Upper ExtremitiesInternational Extremities & Biologics
Corporate 1
Total
Net sales from external customers$220,259
$171,695
$135,433
$—
$527,387
Depreciation expense10,080
7,321
8,539
16,184
42,124
Amortization expense—
—
—
21,574
21,574
Segment operating income (loss)$51,988
$52,942
$1,641
$(133,987)$(27,416)
Other:     
Transaction and transition expenses    9,484
Operating loss    (36,900)
Interest expense, net    55,512
Other expense, net    6,875
Loss before income taxes    $(99,287)

37
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

 Nine months ended September 25, 2016
 U.S. Lower Extremities & BiologicsU.S. Upper ExtremitiesInternational Extremities & Biologics
Corporate 1
Total
Net sales from external customers$214,559
$149,923
$132,857
$—
$497,339
Depreciation expense9,183
8,400
8,541
14,881
41,005
Amortization expense—
—
—
21,407
21,407
Segment operating income (loss)$57,813
$46,729
$840
$(146,792)$(41,410)
Other:     
Inventory step-up amortization    30,922
Transaction and transition expenses    27,952
Legal settlement    1,800
Management changes    1,348
Costs associated with new convertible debt    234
Operating loss    (103,666)
Interest expense, net    41,673
Other income, net    (3,494)
Loss before income taxes    $(141,845)
            
1 
The Corporate category primarily reflects general and administrative expenses not specifically associated with the U.S. Lower Extremities & Biologics, U.S. Upper Extremities, and International Extremities & Biologics segments. These non-allocated corporate expenses relate to global administrative expenses that support all segments, including salaries and benefits of certain executive officers and expenses such as: information technology administration and support; corporate headquarters; legal, compliance, and corporate finance functions; insurance; and all share-based compensation.

35
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

benefits of certain executive officers and expenses such as: information technology administration and support; corporate headquarters; legal, compliance, and corporate finance functions; insurance; and all share-based compensation.
Our principal geographic regions consist of the United States, EMEAEMEAC (which includes Europe, the Middle East, Africa, and Africa)Canada), and Other (which principally represents Asia, Australia, Canada, and Latin America). Net sales attributed to each geographic region are based on the location in which the products were sold.
Net sales by geographic region by product line are as follows (in thousands):
 Three months ended
Net sales by geographic region:September 24, 2017 September 25, 2016
United States$126,864
 $118,065
EMEA25,371
 23,693
Other18,268
 15,574
Total$170,503
 $157,332
 Nine months ended
Net sales by geographic region:September 24, 2017 September 25, 2016
United States$391,954
 $364,482
EMEA85,181
 87,040
Other50,252
 45,817
Total$527,387
 $497,339
 Three months ended
 April 1, 2018 March 26, 2017
United States   
Lower extremities$56,823
 $55,461
Upper extremities67,658
 55,958
Biologics18,165
 18,634
Sports med & other2,147
 2,101
Total United States$144,793
 $132,154
    
EMEAC   
Lower extremities$12,159
 $10,550
Upper extremities23,454
 17,655
Biologics2,205
 2,523
Sports med & other3,299
 3,511
Total EMEAC$41,117
 $34,239
    
Other   
Lower extremities$3,168
 $3,092
Upper extremities6,140
 4,767
Biologics3,052
 2,648
Sports med & other267
 291
Total other$12,627
 $10,798
    
Total net sales$198,537
 $177,191
Assets in the U.S. Upper Extremities, U.S. Lower Extremities & Biologics, and International Extremities & Biologics segments are those assets used exclusively in the operations of each business segment or allocated when used jointly. Assets in the Corporate category are principally cash and cash equivalents, derivative assets, property, plant and equipment associated with our corporate headquarters, assets associated with discontinued operations, product liability insurance receivables, and assets associated with income taxes. Total assets by business segment as of September 24, 2017April 1, 2018 and December 25, 201631, 2017 are as follows (in thousands):

38
Table of Contents
WRIGHT MEDICAL GROUP N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

 April 1, 2018
 U.S. Lower Extremities & BiologicsU.S. Upper ExtremitiesInternational Extremities & BiologicsCorporateTotal
Total assets$470,308
$929,683
$332,879
$343,671
$2,076,541
 September 24, 2017
 U.S. Lower Extremities & BiologicsU.S. Upper ExtremitiesInternational Extremities & BiologicsCorporateTotal
Total assets$472,925
$842,029
$306,258
$579,471
$2,200,683
 December 25, 2016
 U.S. Lower Extremities & BiologicsU.S. Upper ExtremitiesInternational Extremities & BiologicsCorporateTotal
Total assets$491,531
$845,102
$264,680
$689,273
$2,290,586
 December 31, 2017
 U.S. Lower Extremities & BiologicsU.S. Upper ExtremitiesInternational Extremities & BiologicsCorporateTotal
Total assets$490,528
$929,930
$301,985
$406,281
$2,128,724



ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
The following management’s discussion and analysis of financial condition and results of operations describes the principal factors affecting the results of our operations, financial condition, and changes in financial condition for the three and nine months ended September 24, 2017.April 1, 2018. This discussion should be read in conjunction with the accompanying unaudited condensed consolidated financial statements, our Annual Report on Form 10-K for the year ended December 25, 2016,31, 2017, which includes additional information about our critical accounting policies and practices and risk factors, and "Special Note Regarding Forward-Looking Statements."
Background
On October 1, 2015, we became Wright Medical Group N.V. following the merger of Wright Medical Group, Inc. with Tornier N.V. Because of the structure of the merger and the governance of the combined company immediately post-merger, the merger was accounted for as a "reverse acquisition" under US GAAP, and as such, legacy Wright was considered the acquiring entity for accounting purposes.
On October 21, 2016, pursuant to a binding offer letter dated as of July 8, 2016, we, Corin Orthopaedics Holdings Limited (Corin), and certain other entities related to us entered into a business sale agreement and simultaneously completed and closed the sale of our former Large Joints business. The financial results of our Large Joints business, including costs associated with corporate employees and infrastructure transferred as a part of the sale and services we are providing Corin under a transitional services agreement and supply agreement, are reflected within discontinued operations for all periods presented, unless otherwise noted. Further, all assets and associated liabilities transferred to Corin were classified as assets and liabilities held for sale in our consolidated balance sheets for the periods prior to the divestiture.
On January 9, 2014, legacy Wright completed the sale of its former hip and knee (OrthoRecon) business to MicroPort Scientific Corporation (MicroPort). The financial results of the OrthoRecon business are reflected within discontinued operations for all periods presented, unless otherwise noted.
All current and historical operating results for the Large Joints and OrthoRecon businesses are reflected within discontinued operations in the condensed consolidated financial statements.
Other than the discontinued operations discussed above, unless otherwise stated, all discussion of assets and liabilities in the notes to the condensed consolidated financial statements and in this section reflects the assets and liabilities held and used in our continuing operations, and all discussion of revenues and expenses reflects those associated with our continuing operations.
References in this section to "we," "our" and "us" refer to Wright Medical Group N.V. and its subsidiaries after the Wright/Tornier merger and Wright Medical Group, Inc. and its subsidiaries before the merger. Our fiscal yearyear-end is generally determined on a 52-week basis and runs from the first Monday afternearest to the last Sunday31st of December of a year, and ends on the last Sunday nearest to the 31st of December of the following year. Every few years, it is necessary to add an extra week to the year making it a 53-week period. The fiscal year ended December 31, 2017 was a 53-week period. The three and nine months ended September 24,April 1, 2018 and March 26, 2017 and September 25, 2016 each consisted of thirteen and thirty-nine weeks, respectively.weeks.
Executive Overview
Company Description. We are a global medical device company focused on extremities and biologics products. We are committed to delivering innovative, value-added solutions improving quality of life for patients worldwide and are a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics. Our product portfolio consists of the following product categories:
Upper extremities, which include joint implants and bone fixation devices for the shoulder, elbow, wrist, and hand;
Lower extremities, which include joint implants and bone fixation devices for the foot and ankle;
Biologics, which include products used to support treatment of damaged or diseased bone, tendons, and soft tissues or to stimulate bone growth; and
Sports medicine and other, which include products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries and other ancillary products
Our global corporate headquarters are located in Amsterdam, the Netherlands. We also have significant operations located in Memphis, Tennessee (U.S. headquarters, research and development, sales and marketing administration, and administrative activities); Bloomington, Minnesota (upper extremities sales and marketing and warehousing operations); Arlington, Tennessee (manufacturing and warehousing operations); Franklin, Tennessee (manufacturing and warehousing operations); Montbonnot, France (manufacturing and warehousing operations); Plouzané, France (research and development); and Macroom, Ireland (manufacturing). In addition, we have local sales and distribution offices in Canada, Australia, Asia, Latin America, and throughout Europe.

We promote our products in overapproximately 50 countries with principal markets in the United States, Europe, Asia, Canada, Australia, and Latin America. Our products are sold primarily through a network of employee and independent sales representatives in the United States and by a combination of employee sales representatives, independent sales representatives, and stocking distributors outside the United States.
Principal Products. We have focused our efforts into growing our position in the high-growth extremities and biologics markets. We believe a more active and aging patient population with higher expectations regarding “quality of life,” an increasing global awareness of extremities and biologics solutions, improved clinical outcomes as a result of the use of such products, and technological advances resulting in specific designs for such products that simplify procedures and address unmet needs for early interventions, and the growing need for revisions and revision relatedrevision-related solutions will drive the market for extremities and biologics products.
Our principal upper extremities products include the AEQUALIS ASCEND®and SIMPLICITI®total shoulder replacement systems, the AEQUALIS® REVERSED II™ reversed shoulder system, and the AEQUALIS ASCEND® FLEX™ convertible shoulder system. SIMPLICITI®is the first minimally invasive, ultra-short stem total shoulder available in the United States. We believe SIMPLICITI® allows us to expand the market to include younger patients that historically have deferred these procedures.  In December 2016, we received FDA 510(k) clearance of our AEQUALIS® PERFORM™ REVERSED Glenoid System, our first reverse augmented glenoid, and we commercially launched it during the first quarter of 2017. We continue to release new options for our BluePrintOur BLUEPRINT™ 3D Planning software , whichSoftware can be used with our AEQUALIS® PERFORM™ REVERSED Glenoid System to assist surgeons in accurately positioning the glenoid implant and replicating the pre-operationpre-operative surgical plan. Other principal upper extremities products include the EVOLVE® radial head prosthesis for elbow fractures, the EVOLVE® Elbow Plating System, RAYHACK® osteotomy system, and the MICRONAIL® intramedullary wrist fracture repair system.
Our principal lower extremities products include the INBONE® and INFINITY®Total Ankle Replacement Systems. In July 2017, we commercially launchedSystems, both of which can be used with our PROPHECY® Preoperative Navigation Guides, which combine computer imaging with a patient’s CT scan, and are designed to provide alignment accuracy while reducing surgical steps. Our lower extremities products also include the CLAW® II Polyaxial Compression Plating System, the ORTHOLOC® 3Di Reconstruction Plating System, the PhaLinx® System used for hammertoe indications, PRO-TOE® VO Hammertoe System, the DARCO® family of locked plating systems, the VALOR® ankle fusion nail system, and the Swanson line of toe joint replacement products. Physician testing of our most recent total ankle replacement product, the INVISION™INVISIONTM Total Ankle Revision System, the ORTHOLOC 3Di Ankle Fracture Low Profile Systembegan in 2016 and the MICATM Minimally-Invasive Foot and Ankle System. We also launched line extensions for our SALVATION Limb Salvage Systemreached full commercial launch in the third quarter of 2017. The MICA™ Minimally-Invasive Foot and Ankle system was launched to limited users in the third quarter of 2017. Full commercial launch of MICA™ is planned for the second half of 2018. We also launched and plan to continue to launch during 2018 a number of line extensions to the SALVATION™ limb salvage portfolio. We expect demand for these new products during 2018.
Our biologic products includeuse both biological tissue-based and synthetic materials to allow the body to regenerate damaged or diseased bone and to repair damaged or diseased soft tissue. The newest addition to our biologics product portfolio is AUGMENT® Bone Graft, which is based on recombinant human platelet-derived growth factor (rhPDGF-BB), a synthetic copy of one of the body’s principal healing agents.  FDA approval of AUGMENT® Bone Graft in the United States for ankle and/or hindfoot fusion indications occurred during the third quarter of 2015, and we continue2015.  Prior to roll outFDA approval, this product was available for sale in Canada for foot and work through Value Analysis Committee approvals.ankle fusion indications and in Australia and New Zealand for hindfoot and ankle fusion indications.  The AUGMENT® Bone Graft product line was acquired from BioMimetic in March 2013. We are currently pursuing FDA approval of AUGMENT®Injectable Bone Graft with a Pre-Market Application (PMA)PMA Panel Track Supplement. This does not necessarily result in a panel meeting, but it affordsSupplement as described within the FDA additional time to reviewIn-process research and development section below. Our other principal biologics products include the submission beyond 180 days.GRAFTJACKET® line of soft tissue repair and containment membranes, the ALLOMATRIX® line of injectable tissue-based bone graft substitutes, the PRO-DENSE® Injectable Graft, the OSTEOSET® synthetic bone graft substitute, and the PRO-STIM® Injectable Inductive Graft.
Significant Quarterly Business Developments. During
In September 2015, the first half of 2017, we selectively expanded our U.S. sales force by adding additional direct quota-carrying representatives, primarily weighted towards the lower extremities business. Of these new direct quota-carrying representatives, most of them were current associate sales representatives that moved up to be quota-carrying representatives. Third quarter growththird insurance carrier in the core U.S. lower extremitiespolicy year applicable to titanium modular neck fracture claims denied coverage under its $25 million excess liability policy despite full payout by the other carriers in that policy year. We strongly disputed the carrier's position and, core biologics portfolioin accordance with the dispute resolution provisions of the policy, initiated an arbitration proceeding in London, England seeking payment of these funds. The arbitration proceeding was significantly lower than our more technologically advanced products duecompleted on February 15, 2018 and, on April 11, 2018, the arbitration tribunal issued its ruling. Thereafter, we and the insurance carrier agreed to slower than anticipated benefit fromresolve the sales representative additions that we made earlierentire matter in exchange for a single lump sum payment by the year.
During the third quarter of 2017, we completed a key initiative by transferring our U.S. upper extremities inventory into a hub network, similarcarrier to how we operate our U.S. lower extremities inventory. We believe this will enable us to have more control and visibility over the performance of our field inventory and instrument sets, resulting in an increase in our set turns and a reduction in our field inventory days on hand and improve sales representative productivity. We also made progress during the third quarter of 2017 on our key initiative to reduce the amount of inventory delivered$30.75 million, representing the full policy limits of $25 million plus an additional $5.75 million for surgery.costs and interest. We received payment of this sum from the carrier on May 8, 2018. This insurance recovery will be reflected within our results of discontinued operations for the quarter ended July 1, 2018.
Financial Highlights. Net sales increased 8.4%12.0% totaling $170.5$198.5 million in the thirdfirst quarter of 2018, compared to $177.2 million in the first quarter of 2017, compared to $157.3 million in the third quarter of 2016, driven primarily by 7.5%9.6% growth in our U.S. net sales.

Our U.S. net sales increased $8.8$12.6 million, or 7.5%9.6%, in the thirdfirst quarter of 20172018 as compared to the thirdfirst quarter of 2016,2017, driven primarily by salescontinued success of our AEQUALIS® PERFORM™ REVERSED Glenoid System, that was launched in 2017, as well as the continued success of our SIMPLICITI® shoulder system, our AUGMENT® Bone Graft product, and our INFINITY® total ankle replacement system.system, and our AUGMENT® Bone Graft product. 
Our international net sales increased $4.4$8.7 million, or 11.1%19.3%, in the thirdfirst quarter of 20172018 as compared to the thirdfirst quarter of 2016,2017, driven by 11.1%6.6% growth in our direct markets and a $1.2$5.1 million favorable impact from foreign currency exchange rates.
In the thirdfirst quarter of 2017,2018, our net loss from continuing operations totaled $34.1$19.9 million, compared to a net loss from continuing operations of $52.7$36.7 million for the thirdfirst quarter of 2016.2017. This decrease in net loss from continuing operations was primarily driven by the following:
$8.0 million, netimproved profitability due to an increase in sales and leverage of tax,fixed corporate spending;
$9.0 million decrease in non-cash amortization of inventory step-upother (income) expense, net, primarily driven by changes in fair value adjustmentadjustments associated with the Wright/Tornier merger;CVRs issued in the BioMimetic acquisition; and
$4.82.1 million decrease in transaction and transition expenses;

$8.9 million tax benefit related to a change in the realizability of certain U.S. net operating losses following the completion of a tax project; and
improved profitability due to manufacturing efficiencies and leverage of fixed corporate spending.expenses.
The favorable changes in net loss from continuing operations were partially offset by:
$5.8 million increase in other expense (income), net, primarily driven by changes in fair value adjustments associated with derivative assets and liabilities and the CVRs issued in the BioMimetic acquisition; and
$2.21.6 million of incremental interest expense, primarily due to cashnon-cash interest expense associated with the 2021 Notes and 2020 Notes and additional borrowings under our asset-based line of credit facility (ABL Facility) established inthat took place during the fourth quarter of 2016.ended September 24, 2017.
Opportunities and Challenges. We intend to continue to leverage the global strengths of both our legacy Wright and legacy Tornier product brands as a pure-play extremities and biologics business. We believe our leadership has been and will continue to be further enhanced by the FDA approval of AUGMENT® Bone Graft, a biologic solution that adds additional depth to one of the most comprehensive extremities product portfolios in the industry, as well as provides a platform technology for future new product development. WeAdditionally, we believe the highly complementary nature of legacy Wright’s and legacy Tornier’sour businesses gives us significant diversity and scale across a range of geographies and product categories. We believe we are differentiatedour recent acquisition of IMASCAP, a leader in the marketplace bydevelopment of software-based solutions for preoperative planning of shoulder replacement surgery, ensures exclusive access to breakthrough software enabling technology and patents, including BLUEPRINT™, to further differentiate our strategic focus onproduct portfolio and to further accelerate growth opportunities in our global extremities and biologics, our full portfolio of upper and lower extremities and biologics products, and our specialized and focused sales organization.
business. We are highly focused on ensuring that no business momentum is lostalso currently pursuing FDA approval of AUGMENT® Injectable Bone Graft with a PMA Panel Track Supplement as we continue to integrate legacy Wrightdescribed within the In-process research and legacy Tornier. development section below.
Since the Wright/Tornier merger and through the end of the quarter ended April 1, 2018, we have completed the integration of our global sales force, co-located and consolidated into one enterprise resource planning (ERP)ERP system in three of our top five international markets, transferred our U.S. upper extremities inventory into a hub network, and completed a substantial number of other integration activities, while incurring more cost synergies earlier and less sales dis-synergies than we originally anticipated. Although we recognize that we will continue to have revenue dis-synergies during the remaining integration period, weWe believe we have an excellent opportunityopportunities to improve efficiency and leverage our fixed costs in our business going forward and capture cost synergies. We also believe we have significant opportunity with the recent and anticipated launch of new products and through driving BLUEPRINT™ adoption, strategic service at the same timeambulatory surgery centers, and excellent and efficient service to advance certain balance sheet initiatives, such as improving our inventory, instrument set utilization, and days sales outstanding (DSO).customers.
While our ultimate financial goal is to achieve sustained profitability, we anticipate continuing operating losses until we are able to grow our sales to a sufficient level to support our cost structure, including the inherent infrastructure costs of our industry. In the short term, we remain keenly focused on our revenue and cash initiatives.
Significant Industry Factors. Our industry is affected by numerous competitive, regulatory, and other significant factors. The growth of our business relies on our ability to continue to develop new products and innovative technologies, obtain regulatory clearance and maintain compliance for our products, protect the proprietary technology of our products and our manufacturing processes, manufacture our products cost-effectively, respond to competitive pressures specific to each of our geographic markets, including our ability to enforce non-compete agreements, and successfully market and distribute our products in a profitable manner. We, and the entire industry, are subject to extensive governmental regulation, primarily by the FDA. Failure to comply with regulatory requirements could have a material adverse effect on our business, operating results, and financial condition. We, as well as other participants in our industry, are subject to product liability claims, which could have a material adverse effect on our business, operating results, and financial condition.

Results of Operations
Comparison of the three months ended September 24, 2017April 1, 2018 to the three months ended September 25, 2016March 26, 2017
The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts (in thousands) and as percentages of net sales:
Three months endedThree months ended
September 24, 2017 September 25, 2016April 1, 2018 March 26, 2017
Amount% of net sales Amount% of net salesAmount% of net sales Amount% of net sales
Net sales$170,503
100.0 % $157,332
100.0 %$198,537
100.0 % $177,191
100.0 %
Cost of sales 1,2
38,421
22.5 % 46,149
29.3 %
Cost of sales 1
41,139
20.7 % 37,126
21.0 %
Gross profit132,082
77.5 % 111,183
70.7 %157,398
79.3 % 140,065
79.0 %
Operating expenses:  
   
  
   
Selling, general and administrative 1
131,421
77.1 % 129,840
82.5 %137,248
69.1 % 129,834
73.3 %
Research and development 1
11,992
7.0 % 12,481
7.9 %13,899
7.0 % 12,432
7.0 %
Amortization of intangible assets7,178
4.2 % 7,466
4.7 %7,141
3.6 % 7,397
4.2 %
Total operating expenses150,591
88.3 % 149,787
95.2 %158,288
79.7 % 149,663
84.5 %
Operating loss(18,509)(10.9)% (38,604)(24.5)%(890)(0.4)% (9,598)(5.4)%
Interest expense, net18,978
11.1 % 16,795
10.7 %19,812
10.0 % 18,195
10.3 %
Other expense (income), net5,457
3.2 % (365)(0.2)%
Other (income) expense, net(1,000)(0.5)% 7,975
4.5 %
Loss from continuing operations before income taxes(42,944)(25.2)% (55,034)(35.0)%(19,702)(9.9)% (35,768)(20.2)%
Benefit for income taxes(8,822)(5.2)% (2,325)(1.5)%
Provision for income taxes205
0.1 % 939
0.5 %
Net loss from continuing operations$(34,122)(20.0)% $(52,709)(33.5)%$(19,907)(10.0)% $(36,707)(20.7)%
Loss from discontinued operations, net of tax(97,748)  (57,436) (5,607)  (21,992) 
Net loss$(131,870)  $(110,145) $(25,514)  $(58,699) 
__________________________
1 
These line items include the following amounts of non-cash, share-based compensation expense for the periods indicated:
Three months endedThree months ended
September 24, 2017% of net sales September 25, 2016% of net salesApril 1, 2018% of net sales March 26, 2017% of net sales
Cost of sales$152
0.1% $146
0.1%$165
0.1% $119
0.1%
Selling, general and administrative4,960
2.9% 3,168
2.0%4,522
2.3% 3,656
2.1%
Research and development333
0.2% 214
0.1%331
0.2% 179
0.1%
2

Cost of sales includes amortization of inventory step-up adjustment of $10.3 million for the three months ended September 25, 2016.

The following tables set forth our net sales by product line for the U.S. and International for the periods indicated (in thousands) and the percentage of year-over-year change:
Three months endedThree months ended
September 24, 2017 September 25, 2016 % changeApril 1, 2018 March 26, 2017 % change
U.S.          
Lower extremities$51,417
 $51,586
 (0.3)%$56,823
 $55,461
 2.5 %
Upper extremities54,788
 46,207
 18.6 %67,658
 55,958
 20.9 %
Biologics18,640
 18,247
 2.2 %18,165
 18,634
 (2.5)%
Sports med & other2,019
 2,025
 (0.3)%2,147
 2,101
 2.2 %
Total U.S.$126,864
 $118,065
 7.5 %$144,793
 $132,154
 9.6 %
          
International          
Lower extremities$13,963
 $14,201
 (1.7)%$15,327
 $13,642
 12.4 %
Upper extremities21,197
 17,326
 22.3 %29,594
 22,422
 32.0 %
Biologics5,193
 4,739
 9.6 %5,257
 5,171
 1.7 %
Sports med & other3,286
 3,001
 9.5 %3,566
 3,802
 (6.2)%
Total International$43,639
 $39,267
 11.1 %$53,744
 $45,037
 19.3 %
          
Total net sales$170,503
 $157,332
 8.4 %$198,537
 $177,191
 12.0 %
Net sales
U.S. Sales. U.S. net sales totaled $126.9$144.8 million in the thirdfirst quarter of 2017,2018, a 7.5%9.6% increase from $118.1$132.2 million in the thirdfirst quarter of 2016,2017, primarily due to continued growth in our U.S. upper extremities business, which was partially offset by a negative impact from the hurricanes that hit the U.S. in the third quarter.business. U.S. sales represented approximately 74.4%72.9% of total net sales in the thirdfirst quarter of 2017,2018, compared to 75.0%74.6% of total net sales in the thirdfirst quarter of 2016.2017.
Our U.S. lower extremities net sales were flat at $51.4increased to $56.8 million in the thirdfirst quarter of 2018 compared to $55.5 million in the first quarter of 2017, compared to $51.6 million in the third quarterrepresenting growth of 2016. During the third quarter of 2017, we had2.5%. This growth was driven by a 13.7% net sales growth of 14.3% in our total ankle replacement products. This net sales growth wasproducts, offset by continued distraction caused by the addition of new direct quota-carrying representativesdeclines in the first quarter of 2017.our core foot and ankle plating systems.
Our U.S. upper extremities net sales increased to $54.8$67.7 million in the thirdfirst quarter of 2018 from $56.0 million in the first quarter of 2017, from $46.2 million in the third quarter of 2016, representing growth of 18.6%20.9%. This growth was driven by demand for our innovative shoulder product portfolio, including the recent launch ofcontinued success from our PERFORM™ Reversed Glenoid System and continued success of theour SIMPLICITI® shoulder system.
Our U.S. biologics net sales totaled $18.6$18.2 million in the thirdfirst quarter of 2017,2018, representing a 2.2% increase2.5% decrease over the thirdfirst quarter of 2016,2017. This decrease was driven primarily by declines in sales of our core biologics products. These reduced sales were mostly offset by continued sales volume growth of AUGMENT® Bone Graft mostly offset by declines in our other biologic products.of 6.5%.
International Sales. Net sales in our international regions totaled $43.6$53.7 million in the thirdfirst quarter of 2017,2018, compared to $39.3$45.0 million in the thirdfirst quarter of 2016.2017. This 11.1%19.3% increase was due to 11.1%6.6% growth in our direct markets and a $1.2$5.1 million favorable impact from foreign currency exchange rates (a 311 percentage point favorable impact to international sales growth rate).
Our international lower extremities net sales decreased 1.7%increased 12.4% to $14.0$15.3 million in the thirdfirst quarter of 20172018 from $14.2$13.6 million in the thirdfirst quarter of 2016.2017. Sales decreasedincreased primarily due to lower sales volumes to stocking distributors and timing of stocking orders. These decreases were partially offset by a 8.6% increase in sales in our direct markets, primarily in Australia, as well as a $0.3$1.4 million favorable impact from foreign currency exchange rates (a 210 percentage point favorable impact to international lower extremities sales growth rate).
Our international upper extremities net sales increased 22.3%32.0% to $21.2$29.6 million in the thirdfirst quarter of 2018 from $22.4 million in the first quarter of 2017, which included a $3.1 million favorable impact from $17.3foreign currency exchange rates (a 14 percentage point favorable impact to international upper extremities sales growth rate). Sales increased by 11.9% in our direct markets in Europe and a combined 32.2% increase in our Canada, Australia and Japan direct markets.
Our international biologics net sales increased 1.7% to $5.3 million in the thirdfirst quarter of 2016, which included2018 from $5.2 million in the first quarter of 2017. This increase was attributable to a $0.7$0.2 million favorable impact from foreign currency exchange rates (a 4 percentage point favorable impact to international upper extremities sales growth rate). Sales increased by 14.9% in our direct markets in Europe and a combined 22.5% increase in our Canada, Australia and Japan direct markets.

Our international biologics net sales increased 9.6% to $5.2 million in the third quarter of 2017 from $4.7 million in the third quarter of 2016. This increase was primarily attributable to increased volumes to our stocking distributors and a $0.1 million favorable impact from foreign currency exchange rates (a 2 percentage point favorable impact to international biologics sales growth rate).

Cost of sales
Our cost of sales totaled $38.4$41.1 million, or 22.5%20.7% of net sales, in the thirdfirst quarter of 2017,2018, compared to $46.1$37.1 million, or 29.3%21.0% of net sales, in the thirdfirst quarter of 2016, representing2017, reflecting a decrease of 6.80.3 percentage points as a percentage of net sales. This decrease was primarily driven by $10.3 million (6.6% of net sales) of inventory step-up amortization in the third quarter of 2016 associated with inventory acquired from the Wright/Tornier merger. The remaining decrease in cost of sales as a percentage of net sales was driven byfavorable manufacturing efficiencies as compared to the prior year period.expenses.
Selling, general and administrative
Our selling, general and administrative expenses totaled $131.4$137.2 million, or 77.1%69.1% of net sales, in the thirdfirst quarter of 2017,2018, compared to $129.8 million, or 82.5%73.3% of net sales, in the thirdfirst quarter of 2016.2017. This increase in total expenses was primarily the result of increased variable expenses from increased sales. Selling, general and administrative expenses as a percentage of net sales decreased primarily4.2 percentage points due to a decrease in spending on transition and transaction costs which totaled $1.9of $2.3 million, (1.1% of net sales) and $6.4 million (4.1% of net sales) for the third quarter of 2017 and 2016, respectively. The remaining decrease as a percentageor 1.2% of net sales, was primarily drivenfrom the first quarter 2017 and by leverage ofleveraging relatively flat general and administrative expenses over increased net sales and lower levels of cash incentive compensation expense.sales.
Research and development
Our research and development expense totaled $12.0$13.9 million in the thirdfirst quarter of 20172018 compared to $12.5$12.4 million in the thirdfirst quarter of 2016.2017. Research and development costs remained constant at approximately 7%7.0% of net sales. Our research and development expenses are estimated to range from 7% to 8% as a percentage of net sales in 2017.2018.
Amortization of intangible assets
Charges associated with amortization of intangible assets totaled $7.2$7.1 million in the thirdfirst quarter of 2017,2018, compared to $7.5$7.4 million in the thirdfirst quarter of 2016.2017. Based on intangible assets held at September 24, 2017,April 1, 2018, we expect amortization expense to be approximately $29.3$25.3 million for the full year of 2017, $24.1 million in 2018, $22.0$23.3 million in 2019, $21.3$22.6 million in 2020, and $21.1$22.5 million in 2021.2021, and $22.4 million in 2022.
Interest expense, net
Interest expense, net, totaled $19.0$19.8 million in the thirdfirst quarter of 20172018 and $16.8$18.2 million in the thirdfirst quarter of 2016. Increased interest expense was driven by the increase in debt outstanding following borrowings under our ABL Facility established in the fourth quarter of 2016.2017. Our interest expense in the thirdfirst quarter of 2018 related primarily to non-cash interest expense associated with the amortization of the discount on the 2021 Notes and 2020 Notes of $4.8 million and $7.2 million, respectively; amortization of deferred financing charges on the 2021 Notes, 2020 Notes, and our ABL Facility totaling $1.3 million; and cash interest expense primarily associated with the coupon on the 2021 Notes, 2020 Notes, and our ABL Facility totaling $6.2 million. Our interest expense in the first quarter of 2017 related primarily to non-cash interest expense associated with the amortization of the discount on the 2021 Notes and 2020 Notes of $4.6$4.4 million and $6.9$6.6 million, respectively;respectively, amortization of deferred financing charges on the 2021 Notes, 2020 Notes, 2017 Notes, and our ABL Facility totaling $1.2 million; and cash interest expense primarily associated with the coupon on the 2021 Notes, 2020 Notes, and 2017 Notes, and our ABL Facility totaling $6.0 million. Our interest expense in the third quarter of 2016 related primarily to non-cash interest expense associated with the amortization of the discount on the 2021 Notes and 2020 Notes of $4.2 million and $6.3 million, respectively, non-cash interest expense associated with the amortization of deferred financing charges on the 2021 Notes, 2020 Notes, and 2017 Notes totaling $0.9 million; and cash interest expense primarily associated with the coupon on the 2021 Notes, 2020 Notes, and 2017 Notes totaling $5.1$5.8 million.
Other (income) expense, (income), net
Other expense,income, net totaled $5.5$1.0 million in the thirdfirst quarter of 2017,2018, compared to $0.4$8.0 million of other income,expense, net in the thirdfirst quarter of 2016.2017.
In the thirdfirst quarter of 2017,2018, other expense,income, net, primarily consisted of:
an unrealized lossgain of $4.5$3.9 million for the mark-to-market adjustment on CVRs issued in connection with the BioMimetic acquisition; partially offset by
an unrealized gainloss of $0.2$1.7 million for the net mark-to-market adjustments on our derivative assets and liabilities.liabilities;
an unrealized loss of $0.8 million from foreign currency translation; and
an unrealized loss of $0.4 million for fair value adjustments from contingent considerations.
In the thirdfirst quarter of 2016,2017, other income,expense, net primarily consisted of:
an unrealized gainloss of $3.2$6.2 million for the mark-to-market adjustment on CVRs issued in connection with the acquisition of BioMimetic;
an unrealized loss of $0.4 million for the net mark-to-market adjustments on and settlements of our derivative assets and liabilities; partially offset byand

$0.4 million of unused line fees and other customary fees related to our ABL Facility.
an unrealized loss of $2.2 million for the mark-to-market adjustment on CVRs issued in connection with the acquisition of BioMimetic.
BenefitProvision for income taxes
We recorded a tax benefitprovision of $8.8$0.2 million in the thirdfirst quarter of 2017,2018, compared to a tax benefitprovision of $2.3$0.9 million in the thirdfirst quarter of 2016.2017. Our income tax benefitprovision during the thirdfirst quarter of 20172018 includes a $8.9 million benefit recorded due to a change in our valuation allowance with respect to certain deferredthe impact of the lower statutory tax assets that we had previously determined were not more likely than not to be realized.  The remainder of any difference results from the mix of earningsrate in the various jurisdictions.  We record incomeU.S. of 21% and the ability to carryforward net operating losses indefinitely as enacted by the Tax Cuts and Jobs Act ("2017

Tax Act") in December 2017, tax expense or benefit onfor foreign currency losses and the result of net earnings in jurisdictions for which we do not have a valuation allowance, butallowance. We are unable to recognize a tax benefit in jurisdictions where we are incurring losses (primarily the U.S.) due to the remaining valuation allowance on our net deferred tax assets.  Other provisions under the 2017 Tax Act include U.S. taxation on certain foreign earnings referred to as Global Intangible Low-Taxed Income and the Base Erosion Anti-Abuse Tax both of which did not have an effect on our financial results due to the losses and valuation allowance in the U.S. During the thirdfirst quarter of 2016,2017, the tax benefitsprovision primarily related to losses, including amortization of inventory fair value step-up and intangibles assets,the net earnings mix in jurisdictions wherefor which we do not have a valuation allowance.
Further, we recognized the income tax effects of the 2017 Tax Act in our 2017 financial statements in accordance with Staff Accounting Bulletin No. 118 (SAB 118), which provides SEC staff guidance for the application of ASC Topic 740, Income Taxes, in the reporting period in which the 2017 Tax Act was signed into law. We included the provisional amount pertaining to the one-time deemed repatriation charge in our 2017 financial statements and still conclude this is a reasonable estimate based on current guidance and interpretations. We did not identify any items for which the income tax effects of the 2017 Tax Act could not be reasonably estimated as of April 1, 2018.
Loss from discontinued operations, net of tax
Loss from discontinued operations, net of tax, consists primarily of the costs associated with legal defense, income/loss associated with product liability insurance recoveries/denials, and changes to any contingent liabilities associated with the OrthoRecon business that was sold to MicroPort and, to a lesser degree, costs associated with the Large Joints business that was sold to Corin. During
As described within Note 13, in September 2015, the third quarter of 2017insurance carrier in the policy year applicable to titanium modular neck fracture claims denied coverage under its $25 million excess liability policy despite full payout by the other carriers in that policy year. We strongly disputed the carrier's position and, 2016, we recognized a charge of $86.9 million and $38.7 million, respectively, for certain retained metal-on-metal product liability claims associatedin accordance with the OrthoRecon business. dispute resolution provisions of the policy, initiated an arbitration proceeding in London, England seeking payment of these funds. The arbitration proceeding was completed on February 15, 2018 and, on April 11, 2018, the arbitration tribunal issued its ruling. Thereafter, we and the insurance carrier agreed to resolve the entire matter in exchange for a single lump sum payment by the carrier to us in the amount of $30.75 million, representing the full policy limits of $25 million plus an additional $5.75 million for costs and interest. We received payment of this sum from the carrier on May 8, 2018. This insurance recovery will be reflected within our results of discontinued operations for the quarter ended July 1, 2018.
See Note 34 and Note 1213 to our condensed consolidated financial statements for further discussion regarding our discontinued operations and our retained contingent liabilities associated with the OrthoRecon business.
Comparison of the nine months ended September 24, 2017 to the nine months ended September 25, 2016
The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts (in thousands) and as percentages of net sales:
 Nine months ended
 September 24, 2017 September 25, 2016
 Amount% of net sales Amount% of net sales
Net sales$527,387
100.0 % $497,339
100.0 %
Cost of sales 1,2
113,669
21.6 % 141,824
28.5 %
Gross profit413,718
78.4 % 355,515
71.5 %
Operating expenses:  
   
Selling, general and administrative 1
392,073
74.3 % 401,069
80.6 %
Research and development 1
36,971
7.0 % 36,705
7.4 %
Amortization of intangible assets21,574
4.1 % 21,407
4.3 %
Total operating expenses450,618
85.4 % 459,181
92.3 %
Operating loss(36,900)(7.0)% (103,666)(20.8)%
Interest expense, net55,512
10.5 % 41,673
8.4 %
Other expense (income), net6,875
1.3 % (3,494)(0.7)%
Loss from continuing operations before income taxes(99,287)(18.8)% (141,845)(28.5)%
Benefit for income taxes(7,498)(1.4)% (6,913)(1.4)%
Net loss from continuing operations$(91,789)(17.4)% $(134,932)(27.1)%
Loss from discontinued operations, net of tax(139,942)  (252,571) 
Net loss$(231,731)  $(387,503) 
__________________________
1
These line items include the following amounts of non-cash, share-based compensation expense for the periods indicated:

 Nine months ended
 September 24, 2017% of net sales September 25, 2016% of net sales
Cost of sales$403
0.1% $321
0.1%
Selling, general and administrative12,939
2.5% 9,070
1.8%
Research and development789
0.1% 510
0.1%
2
Cost of sales includes amortization of inventory step-up adjustment of $30.9 million for the nine months ended September 25, 2016.
The following tables set forth our net sales by product line for the U.S. and International for the periods indicated (in thousands) and the percentage of year-over-year change:
 Nine months ended
 September 24, 2017 September 25, 2016 % change
U.S.     
Lower extremities$161,228
 $158,872
 1.5 %
Upper extremities168,280
 146,117
 15.2 %
Biologics56,547
 53,167
 6.4 %
Sports med & other5,899
 6,326
 (6.7)%
Total U.S.$391,954
 $364,482
 7.5 %
      
International     
Lower extremities$42,372
 $45,984
 (7.9)%
Upper extremities66,606
 62,241
 7.0 %
Biologics15,492
 13,804
 12.2 %
Sports med & other10,963
 10,828
 1.2 %
Total International$135,433
 $132,857
 1.9 %
      
Total net sales$527,387
 $497,339
 6.0 %
Net sales
U.S. Sales. U.S. net sales totaled $392.0 million in the first nine months of 2017, a 7.5% increase from $364.5 million in the first nine months of 2016, primarily due to continued growth in our U.S. upper extremities business. U.S. sales represented approximately 74.3% of total net sales in the first nine months of 2017, compared to 73.3% of total net sales in the first nine months of 2016.
International Sales. International net sales totaled $135.4 million in the first nine months of 2017 compared to $132.9 million in the first nine months of 2016. This 1.9% increase was primarily driven by a 5.8% increase in our direct markets in Europe. This increase was partially offset by a $2.1 million unfavorable impact from foreign currency exchange rates (a 2 percentage point unfavorable impact to sales growth rate).
Cost of sales
Our cost of sales as a percentage of net sales decreased to 21.6% in the first nine months of 2017, as compared to 28.5% in the first nine months of 2016. This decrease was primarily driven by $30.9 million (6.2% of net sales) of inventory step-up amortization in the first nine months of 2016 associated with inventory acquired from the Wright/Tornier merger, as well as manufacturing efficiencies as compared to the prior year period.
Operating expenses
As a percentage of net sales, operating expenses decreased to 85.4% in the first nine months of 2017, compared to 92.3% in the first nine months of 2016. This decrease was driven primarily by the decrease in spending on transition and transaction costs, as well as leverage of relatively flat general and administrative expenses over increased net sales.

Benefit for income taxes
We recorded an income tax benefit of $7.5 million in the first nine months of 2017, compared to a tax benefit of $6.9 million in the first nine months of 2016. The tax benefit for the current year period includes a $8.9 million benefit recorded due to a change in our valuation allowance with respect to certain deferred tax assets that we had previously determined were not more likely than not to be realized.  The remaining is the result of net earnings in jurisdictions for which we do not have a valuation allowance. The tax benefit for the prior year period includes a $2.3 million tax benefit related to the resolution of an IRS tax audit as well as the recognition of net losses, including amortization of inventory fair value step-up and intangible assets, in jurisdictions we do not have a valuation allowance. 
Loss from discontinued operations, net of tax
Loss from discontinued operations, net of tax, consists primarily of the costs associated with legal defense, income/loss associated with product liability insurance recoveries/denials, and changes to any contingent liabilities associated with the OrthoRecon business that was sold to MicroPort and, to a lesser degree, costs associated with the Large Joints business that was sold to Corin. During the nine months ended September 24, 2017 and September 25, 2016, we recognized $103.3 million and $188.7 million, respectively, for certain retained metal-on-metal product liability claims associated with the OrthoRecon business. See Note 3 and Note 12 to our condensed consolidated financial statements for further discussion regarding our discontinued operations and our retained contingent liabilities associated with the OrthoRecon business.
Reportable segments
The following tables set forth, for the periods indicated, net sales and operating income of our reportable segments expressed as dollar amounts (in thousands) and as a percentage of net sales:
Three months ended September 24, 2017Three months ended April 1, 2018
U.S. Lower Extremities
& Biologics
 U.S. Upper Extremities 
International Extremities
& Biologics
U.S. Lower Extremities
& Biologics
 U.S. Upper Extremities 
International Extremities
& Biologics
Net sales$70,946
 $55,918
 $43,639
$75,897
 $68,896
 $53,744
Operating income$13,506
 $16,575
 $(1,563)$19,458
 $24,154
 $258
Operating income as a percent of net sales19.0% 29.6% (3.6)%25.6% 35.1% 0.5%
 Three months ended September 25, 2016
 U.S. Lower Extremities
& Biologics		 U.S. Upper Extremities International Extremities
& Biologics
Net sales$70,654
 $47,411
 $39,267
Operating income$17,980
 $12,594
 $(2,945)
Operating income as a percent of net sales25.4% 26.6% (7.5)%
 Nine Months Ended September 24, 2017
 
U.S. Lower Extremities
& Biologics
 U.S. Upper Extremities 
International Extremities
& Biologics
Net sales$220,259
 $171,695
 $135,433
Operating income$51,988
 $52,942
 $1,641
Operating income as a percent of net sales23.6% 30.8% 1.2%
Nine Months Ended September 25, 2016Three months ended March 26, 2017
U.S. Lower Extremities
& Biologics		 U.S. Upper Extremities International Extremities
& Biologics		U.S. Lower Extremities
& Biologics		 U.S. Upper Extremities International Extremities
& Biologics
Net sales$214,559
 $149,923
 $132,857
$74,993
 $57,161
 $45,037
Operating income$57,813
 $46,729
 $840
$20,825
 $17,486
 $2,319
Operating income as a percent of net sales26.9% 31.2% 0.6%27.8% 30.6% 5.1%
Net sales of our U.S. lower extremities and biologics segment increased $0.3 million and $5.7$0.9 million in the three and nine months ended September 24, 2017, respectively,April 1, 2018, as compared to the three and nine months ended September 25, 2016. These increases wereMarch 26, 2017. This increase was driven by net sales growth from the recent launch of our SALVATION® limb salvage system for treating Charcot foottotal ankle replacement products and

limb salvage cases and sales of AUGMENT® Bone Graft, which was commercially launched in the fourth quarter of 2015.Graft. Operating income of our U.S. lower extremities and biologics segment decreased for the three and nine months ended September 24, 2017,April 1, 2018, compared to the three and nine months ended September 25, 2016March 26, 2017, primarily due to investments in research and development for product development and clinical studies, as well as higher levels of selling, general and administrative expenses to support certain growth initiatives.sales mix which drove lower gross profit.

Net sales of our U.S. upper extremities segment increased $8.5 million and $21.8$11.7 million in the three and nine months ended September 24, 2017, respectively,April 1, 2018, as compared to the three and nine months ended September 25, 2016.March 26, 2017. Operating income of our U.S. upper extremities segment increased $4.0 million and $6.2$6.7 million in the three and nine months ended September 24, 2017, respectively,April 1, 2018, as compared to the three and nine months ended September 25, 2016.March 26, 2017. These increases to both net sales and operating income were primarily driven by sales ofgrowth within our innovative shoulder product portfolio, including the recent launchcontinued success of our PERFORM™ Reversed Glenoid System and continued success of the SIMPLICITI® shoulder system.system, as we were able to leverage operating expenses by growing sales at a significantly higher rate than expenses.
Net sales of our International extremities and biologics segment increased $4.4 million and $2.6$8.7 million in the three and nine months ended September 24, 2017, respectively,April 1, 2018, as compared to the three and nine months ended September 25, 2016,March 26, 2017, primarily due to increased sales in our total direct markets, with continued6.6% growth in our international upper extremities business.direct markets and a $5.1 million favorable impact from foreign currency exchange rates. Operating income of our International extremities and biologics segment increased $1.4 million and $0.8decreased $2.1 million in the three and nine months ended September 24, 2017, respectively,April 1, 2018, as compared to the three and nine months ended September 25, 2016,March 26, 2017, primarily driven by a $1.0 million unfavorable impact from foreign currency exchange rates, as well as increased investments in sales, in our total direct markets.marketing, and distribution employees during the latter portion of 2017.
Liquidity and Capital Resources
The following table sets forth, for the periods indicated, certain liquidity measures (in thousands):
September 24, 2017 December 25, 2016April 1, 2018 December 31, 2017
Cash and cash equivalents$238,867
 $262,265
$138,051
 $167,740
Restricted cash38,922
 150,000
Working capital153,294
 285,107
154,701
 151,599
Operating Activities. Cash used in operating activities totaled $129.3$18.8 million and $25.4$14.5 million in the first ninethree months of 20172018 and 2016,2017, respectively. The increase in cash used in operating activities in the first ninethree months of 20172018 was driven primarily by cash payments of previously agreed upon product liability settlements (see Note 1213 to our condensed consolidated financial statements for further discussion of these liabilities) related to the former OrthoRecon business, partially offset by a decrease in net lossincreased cash profitability and working capital changes.
Investing Activities. Our capital expenditures totaled $49.5$11.9 million and $37.8$12.1 million in the first ninethree months of 20172018 and 2016,2017, respectively. Historically, our capital expenditures have consisted principally of surgical instrumentation, purchased manufacturing equipment, research and testing equipment, and computer systems. We expect to incur capital expenditures of more thanapproximately $50 million in 2017.2018.
Financing Activities. During the first ninethree months of 2018 and 2017, cash provided by financing activities totaled $42.8$1.1 million, compared to $241.5$0.4 million in the first ninethree months of 2016.2017. Cash provided by financing activities in the first ninethree months of 20172018 was primarily attributable to $24.8$2.6 million in cash received from the issuance of ordinary shares in connection with option exercises $32.0and $2.0 million of other debt proceeds from additional borrowings from the ABL Facility,as described in Note 9. These proceeds were partially offset by $8.7$1.4 million of payments on capital leases and $1.3 million of net payments due to timing of the weekly lockbox repayment/re-borrowing arrangement underlying the ABL Facility and a $2.0 million payment of the 2017 Notes. DuringFacility. Cash provided by financing activities in the first ninethree months of 2016, cash provided by financing2017 was primarily attributable to the proceeds$14.6 million cash received from the issuance of the 2021 cash convertible notes,ordinary shares in connection with option exercises, partially offset by $12.8 million of net payments due to timing of the partial settlement of previously outstanding convertible notes. weekly lockbox repayment/re-borrowing arrangement underlying the ABL Facility.
Repatriation.We provide for tax liabilities in our condensed consolidated financial statements with respect to amounts that we expect to repatriate from subsidiaries (to the extent the repatriation would be subject to tax); however, no tax liabilities are recorded for amounts that we consider to be permanently reinvested.reinvested Our current plans do not foresee a need to repatriate funds that are designated as permanently reinvested in order to fund our operations or meet currently anticipated liquidity and capital investment needs.
Discontinued Operations. Cash flows from discontinued operations are combined with cash flows from continuing operations in the condensed consolidated statements of cash flows. Cash flows from discontinued operations include those related to both theour former Large Joints and OrthoRecon businesses.
During the first ninethree months of 20172018 and 2016,2017, cash used in the former OrthoRecon business was approximately $142.724.0 million and $29.710.5 million, respectively, for settlements of product liability claims and legal defense costs. Cash used in operating activities

from the Large Joints business totaled $3.5$0.5 million and $1.1 million for the ninethree months ended September 24, 2017. Cash provided by operating activities from the Large Joints business totaled $3.0 million for theApril 1, 2018 and nineMarch 26, 2017 months ended September 25, 2016., respectively.
We expect significant cash outflows resulting from product liabilities during the remainder of 2017,2018 and each year through 2019, associated with the metal-on-metal settlements described in Note 1213. We do not expect that the future cash outflows from discontinued operations, including the payment of these retained liabilities of the OrthoRecon business, will have an impact on our ability to meet contractual cash obligations and fund our working capital requirements, operations, and anticipated capital expenditures.

Contractual Cash Obligations. As of September 24, 2017,April 1, 2018, there were no material changes to our contractual cash obligations and commercial commitments as disclosed in in "Part II. Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations-Liquidity and Capital Resources-Contractual Cash Obligations " of our Annual Report on Form 10-K for the year ended December 25, 2016. As previously disclosed, subsequent to the end of the third quarter, we agreed on a comprehensive settlement intended to resolve substantially all remaining metal-on-metal hip revision claims pending or tolled in the metal-on-metal hip replacement product liability litigation described below that were not settled in the previously disclosed Master Settlement Agreement dated November 2, 2016. The comprehensive settlement is contingent on recovery of new insurance payments totaling at least $35 million from applicable insurance carriers by December 31, 2017. Assuming the receipt of such insurance payments, total obligations under the new settlement agreements are in the aggregate $89.75 million. See Note 12to our condensed consolidated financial statements for additional discussion regarding this recent settlement.
Other Liquidity Information. We have historically funded our cash needs through various equity and debt issuances, more recently borrowings under our ABL Facility, and through cash flow from operations.
On December 23, 2016, we, together with WMG and certain of our other wholly-owned U.S. subsidiaries, entered into a Credit, Security and Guaranty Agreement (ABL Credit Agreement) with Midcap Financial Trust, as administrative agent (Agent) and a lender and the additional lenders from time to time party thereto. The ABL Credit Agreement provides for a $150 million senior secured asset-based line of credit, subject to the satisfaction of a borrowing base requirement.requirement (ABL Facility). The ABL Facility may be increased by up to $100 million upon our request, subject to the consent of the Agent and each of the other lenders providing such increase and the satisfaction of customary conditions. We are required to maintain net revenue at or above specified minimum levels, to maintain liquidity in the United States above a specified level and to comply with other covenants under the ABL Credit Agreement. We are in compliance with all covenants as of September 24, 2017.April 1, 2018. As of September 24, 2017,April 1, 2018, we had $53.9$53.0 million in borrowings outstanding under the ABL Facility and $96.1$97.0 million in unused availability under the ABL Facility. As of December 25, 2016,31, 2017, we had $30.0$53.6 million in borrowings outstanding under the ABL Facility and $120.0$96.4 million in unused availability under the ABL Facility.
On October 3, 2017, WMT entered into two settlement agreements (collectively,May 7, 2018, we amended and restated the Second Settlement Agreements) with the Court-appointed attorneys representing plaintiffs in the MDL and JCCP. Under the terms of the Second Settlement Agreements, the parties agreedABL Credit Agreement to settle 629 specifically identified CONSERVE®, DYNASTY® and LINEAGE® claims that meet the eligibility requirements of the Second Settlement Agreements and are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, foradd a maximum settlement amount of $89.75 million. The comprehensive settlement amount is contingent on WMT’s recovery of new insurance payments totaling at least $35$40.0 million from applicable insurance carriers by December 31, 2017.term loan facility. See additional information within Note 9.
On November 1, 2016, Wright Medical Technology, Inc. (WMT) entered into a Master Settlement Agreement (MSA) with Court-appointed attorneys representing plaintiffs in the metal-on-metal hip replacement product liability litigation pending before the United States District Court for the Northern District of Georgia (the MDL) and the California State Judicial Counsel Coordinated Proceedings (the JCCP). Under the terms of the MSA, the parties agreed to settle 1,292 specifically identified claims associated with CONSERVE®, DYNASTY® and LINEAGE® products that meet the eligibility requirements of the MSA and are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a settlement amount of $240 million.
On October 3, 2017, WMT entered into two settlement agreements (collectively, the Second Settlement Agreements) with the Court-appointed attorneys representing plaintiffs in the MDL and JCCP. Under the terms of the Second Settlement Agreements, the parties agreed to settle 629 specifically identified CONSERVE®, DYNASTY® and LINEAGE® claims that meet the eligibility requirements of the Second Settlement Agreements and are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a maximum settlement amount of $89.75 million. The comprehensive settlement amount is contingent on WMT’s recovery of new insurance payments totaling at least $35 million from applicable insurance carriers by December 31, 2017. On March 29, 2018, WMT entered into a Third Amendment to the Third Settlement Agreement which eliminates the contingency and gives WMT the option, by September 30, 2018, to either pay or make available for payment the then outstanding deficit on the insurance contingency or transfer to eligible claimants WMT’s claims against the insurance carriers with whom WMT has not settled, and pay or make available for payment such insurance deficit in March 2019, subject to the right to recover these funds from any plaintiff recoveries from carriers plus ten percent interest, plus an additional $5 million in costs, in each case after recovery by plaintiffs’ counsel of costs and fees. In connection with such transfer agreement, WMT would also enter into a stipulated judgment in the amount of $541 million, which judgment would not be recoverable against WMT or its affiliates. To date, certain of the insurance carriers have contributed $21.9 million of funds applicable against the $35 million contingency, leaving a $13.1 million deficit as of April 30, 2018.
As of September 24, 2017,April 1, 2018, our accrual for metal-on-metal claims totaled $244.2$149.3 million, of which $199.3$100.7 million is included in our condensed consolidated balance sheet within “Accrued expenses and other current liabilities” and $44.9$48.6 million is included within “Other liabilities.”  As of December 25, 2016,31, 2017, our accrual for metal-on-metal claims totaled $256.7$177.5 million, of which $242.8$127.4 million is included in our condensed consolidated balance sheet within “Accrued expenses and other current liabilities” and $13.9$50.1 million is included within “Other liabilities.” See Note 1213 to our condensed consolidated financial statements for additional discussion regarding the MSA and Second Settlement Agreements and our accrual methodologies for the metal-on-metal hip replacement product liability claims.
DuringIn September 2015, the fourth quarterthird insurance carrier in the policy year applicable to titanium modular neck fracture claims denied coverage under its $25 million excess liability policy despite full payout by the other carriers in that policy year. The company disputed the carrier's position and, in accordance with the dispute resolution provisions of 2016, WMT deposited $150the policy, initiated an arbitration proceeding in London. The arbitration proceeding was completed on February 15, 2018 and, on April 11, 2018, the arbitration tribunal issued its ruling. Thereafter, we and the insurance carrier agreed to resolve the entire matter in exchange for a single lump sum payment by the carrier to us in the amount of $30.75 million, into a restricted escrow account to secure its obligations underrepresenting the MSA. All individual settlements underfull policy limits of $25 million plus an additional $5.75 million for costs and interest. We received payment of this sum from the MSAcarrier on May 8, 2018. This insurance recovery will be funded first from the escrow account and then, once all funds held in the escrow account have been exhausted, directly by WMT. Duringreflected within our results of discontinued operations for the quarter ended September 24, 2017, WMT made $111.1 million in settlement payments from the escrow account. As of September 24, 2017, $38.9 million remained in the restrictedJuly 1, 2018.

escrow account, and therefore, considered restricted cash under US GAAP. See Note 12 and Note 13 to our condensed consolidated financial statements for further discussion regarding the MSA, the metal-on-metal hip litigation and the funding for such claims.
In May 2016, we issued $395 million aggregate principal amount of the 2021 Notes, which, after consideration of the exchange of approximately $54 million principal amount of the 2017 Notes and $45 million principal amount of the 2020 Notes, generated net proceeds of approximately $237.5 million. In connection with the offering of the 2021 Notes, we entered into convertible note hedging transactions with two counterparties. We also entered into warrant transactions in which we sold stock warrants for an aggregate of 18.5 million ordinary shares to these two counterparties. We used approximately $45 million of the net proceeds from the offering to pay the cost of the convertible note hedging transactions (after such cost was partially offset by the proceeds we received from the sale of the warrants).
Although it is difficult for us to predict our future liquidity requirements, we believe that our cash and cash equivalents and restricted cash balance of approximately $277.8$138.1 million, together with $96.1the U.K. arbitration settlement, the $97.0 million in availability under the ABL Facility and the additional $40 million of term loan capacity, as of September 24, 2017April 1, 2018, will be sufficient for at least the next 12 months to fund our working capital requirements and operations, permit anticipated capital expenditures during the remainder of 2017,2018, pay retained metal-on-metal product and other liabilities of the OrthoRecon business, including without limitation amounts under the MSA and Second Settlement Agreements, fund contingent considerations including without limitation the up to $42 million CVR milestone payment, and meet our anticipated contractual cash obligations in 20172018.
In-process research and 2018. We may face liquidity challenges during the next few years in light of anticipated significant contingent liabilities and financial obligations and commitments, including among others, acquisition-related contingent consideration payments, payments related to our outstanding indebtedness, and costs and payments related to pending litigation.
In the event that we would require additional working capital to fund future operations, we could seek to acquire that through borrowings under the additional $100.0 million that may be available under the ABL Facility or additional equity or debt financing arrangements which may or may not be available on favorable terms at such time. If we raise additional funds by issuing equity securities, our shareholders may experience dilution. Additional debt financing, if available, may involve additional covenants restricting our operations or our ability to incur additional debt, in addition to those under our existing indentures and the ABL Credit Agreement. Any additional debt financing or additional equity that we raise may contain terms that are not favorable to us or our shareholders. If we do not have, or are not able to obtain, sufficient funds, we may not be able to develop or enhance our products, execute our business plan, take advantage of future opportunities, or respond to competitive pressures or unanticipated customer requirements or we may have to delay development or commercialization of our products or scale back our operations.
In-Process Research and Development.development. In connection with the BioMimetic acquisition, we acquired in-process research and development (IPRD) technology related to projects that had not yet reached technological feasibility as of the acquisition date, which included AUGMENT® Injectable Bone Graft. The acquisition-date fair value of the IPRD technology was $27.1 million for AUGMENT® Injectable Bone Graft. The fair value of the IPRD technology was reduced to $0 as of December 31, 2014, which reflectedreflects the impairment charges recognized in 2013 after receipt of the not approvable letter from the FDA in response to a pre-market approval (PMA) application for AUGMENT® Bone Graft for use as an alternative to autograft in hindfoot and ankle fusion procedures.
In connection with the Wright/Tornier merger, we acquired IPRD technology related to three projects that had not yet reached technological feasibility as of the merger date. These projects included PerFORM Rev/Rev+, AEQUALIS® Adjustable Reversed Ext (AARE) (re-branded in 2016 to AEQUALIS® Flex Revive), and PerFORM+ that were assigned fair values of $14.5 million, $2.1 million, and $0.4 million, respectively, on the acquisition date. During 2016, we received FDA clearance of PerFORM Rev/Rev+ and PerFORM+.
In connection with the IMASCAP acquisition, we acquired IPRD technology related to a patient specific implant system that had not yet reached technological feasibility as of the acquisition date. This project was assigned a fair value of $5.3 million on the acquisition date.
The current IPRD projects we acquired in our IMASCAP acquisition, BioMimetic acquisition, and the Wright/Tornier merger are as follows:
The patient specific implant is a reverse shoulder replacement implant having glenoid or glenoid and humeral implant components. We have an anticipated first clinical use in 2020 and launch in the first half of 2021. Project cost to complete is estimated to be less than $2 million. However, the risks and uncertainties associated with completion are dependent upon testing validations and FDA and CE mark clearance.
•
AUGMENT® Injectable Bone Graft (Augment Injectable) combines rhPDGF-BB with an injectable osteoconductive matrix. Augment Injectable can be injected into a fusion site during a surgical procedure, delivering rhPDGF-BB to promote fusion as a bone graft substitute. Our initial clinical development program for Augment Injectable has focused on securing regulatory approval for ankle and hindfoot fusion indications in the United States. Augment Injectable is already approved in several markets outside the United States. We currently estimate it could take one to three years to complete this project. We have incurred expenses of approximately $5.7$6.1 million for Augment Injectable since the date of acquisition and $0.3$0.2 million in the three months ended September 24, 2017.April 1, 2018. We are currently pursuing FDA approval with a PMA Panel Track Supplement. This does not necessarily result in a panel meeting, but it affords the FDA additional time to review the submission beyond 180 days.
•
AEQUALIS® Adjustable Reversed Ext (AARE) (re-branded in 2016 to AEQUALIS® Flex Revive) will ultimately be our second-generation revision product, with an improved implant that is convertible and addresses more indications, and a more comprehensive instrument set that includes universal extraction instrumentation to address the entire revision procedure, not just the final implant. The instruments and implants for the new revision system are currently in design phase. We have an anticipated first clinical use in 2018 and launch in the first half of 2019. Project cost to complete is estimated to be less than $1 million. However, the risks and uncertainties associated with completion are dependent upon testing validations and FDA clearance.

Project cost to complete is estimated to be less than $1 million. However, the risks and uncertainties associated with completion are dependent upon testing validations and FDA clearance.
Critical Accounting Policies and Estimates
Information on judgments related to our most critical accounting policies and estimates is discussed in "Part II. Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Estimates" of our

Annual Report on Form 10-K for the year ended December 25, 201631, 2017 filed with the SEC on February 23, 2017.27, 2018. Certain of our more critical accounting estimates require the application of significant judgment by management in selecting the appropriate assumptions in determining the estimate. By their nature, these judgments are subject to an inherent degree of uncertainty. We develop these judgments based on our historical experience, terms of existing contracts, our observance of trends in the industry, information provided by our customers, and information available from other outside sources, as appropriate. Actual results may differ from these judgments under different assumptions or conditions. Different, reasonable estimates could have been used for the current period. Additionally, changes in accounting estimates are reasonably likely to occur from period to period. Both of these factors could have a material impact on the presentation of our financial condition, changes in financial condition or results of operations.
There have been no material changes to our critical accounting policies and estimates discussed in "Part II. Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Estimates" of our Annual Report on Form 10-K for the year ended December 25, 2016.31, 2017.
Recent Accounting Pronouncements
Information regarding recent accounting pronouncements is included in Note 2 to our condensed consolidated financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
Interest Rate Risk
Our exposure to interest rate risk arises principally from variable interest rates applicable to borrowings under our ABL Facility and the interest rates associated with our invested cash balances.
Borrowings under our ABL Facility bear interest at variable rates. The interest rate margin applicable to borrowings under the ABL Facility is, at the option of the Borrowers, equal to either (a) 3.25% for base rate loans or (b) 4.25% for LIBOR rate loans, subject to a 0.75% LIBOR floor. As of September 24, 2017,April 1, 2018, we had $53.9$53.0 million of borrowings under our ABL Facility. Based upon this debt level, and the LIBOR floor on our interest rate, a 100 basis point increase in the annual interest rate on such borrowings would have an immaterial impact on our interest expense on an annual basis.
On September 24, 2017,April 1, 2018, we had invested cash and cash equivalents and restricted cash of approximately $277.8$138.1 million. We believe that a 10 basis point change in interest rates is reasonably possible in the near term. Based on our current level of investment, an increase or decrease of 10 basis points in interest rates would have an annual impact of approximately $0.3$0.1 million to our interest income.
As of September 24, 2017,April 1, 2018, we had outstanding $587.5 million and $395$395.0 million principal amount of our 2020 Notes and 2021 Notes, respectively. We carry these instruments at face value less unamortized discount and unamortized debt issuance costs on our condensed consolidated balance sheets. Since these instruments bear interest at a fixed rate, we have no financial statement risk associated with changes in interest rates. However, the fair value of these instruments fluctuates when interest rates change, and when the market price of our ordinary shares fluctuates. We do not carry the 2020 Notes and 2021 Notes at fair value, but present the fair value of the principal amount of our 2020 Notes and 2021 Notes for disclosure purposes.
Equity Price Risk
On February 13, 2015, WMG issued $632.5 million of the 2020 Notes, which generated net proceeds of approximately $613 million. The holders of the 2020 Notes may convert their 2020 Notes into cash upon the satisfaction of certain circumstances as described in Note 89. The conversion and settlement provisions of the 2020 Notes are based on the price of our ordinary shares at conversion or at maturity of the notes. In addition, the hedges and warrants associated with these convertible notes also include settlement provisions that are based on the price of our ordinary shares. The amount of cash we may be required to pay, or the number of shares we may be required to provide to note holders at conversion or maturity of these notes, is determined by the price of our ordinary shares. The amount of cash that we may receive from hedge counterparties in connection with the related hedges and the number of shares that we may be required to provide warrant counterparties in connection with the related warrants are also determined by the price of our ordinary shares.

Upon the expiration of our warrants issued in connection with the 2020 Notes, we will issue ordinary shares to the purchasers of the warrants to the extent the price of our ordinary shares exceeds the warrant strike price at that time. On November 24, 2015, Wright Medical Group N.V. assumed WMG's obligations pursuant to the warrants, and the strike price of the warrants was adjusted from $40.00 to $38.8010 per ordinary share. The following table shows the number of shares that we would issue to warrant counterparties at expiration of the warrants assuming various closing prices of our ordinary shares on the date of warrant expiration:
Share price Shares (in thousands)
$42.68(10% greater than strike price)1,784
$46.56(20% greater than strike price)3,270
$50.44(30% greater than strike price)4,528
$54.32(40% greater than strike price)5,606
$58.20(50% greater than strike price)6,540
The fair value of the 2020 Notes Conversion Derivative and the 2020 Notes Hedge is directly impacted by the price of our ordinary shares. We entered into the 2020 Notes Hedges in connection with the issuance of the 2020 Notes with the option counterparties. The 2020 Notes Hedges, which are cash-settled, are intended to reduce our exposure to potential cash payments that we are required to make upon conversion of the 2020 Notes in excess of the principal amount of converted notes if our ordinary share price exceeds the conversion price. The following table presents the fair values of the 2020 Notes Conversion Derivative and 2020 Notes Hedge as a result of a hypothetical 10% increase and decrease in the price of our ordinary shares. We believe that a 10% change in our share price is reasonably possible in the near term:

(in thousands)  
Fair value of security given a 10% decrease in share priceFair value of security as of September 24, 2017Fair value of security given a 10% increase in share priceFair value of security given a 10% decrease in share priceFair value of security as of April 1, 2018Fair value of security given a 10% increase in share price
2020 Notes Hedges (Asset)$50,688$73,694$100,837$29,115$41,933$57,237
2020 Notes Conversion Derivative (Liability)$48,473$72,460$101,092$28,415$41,753$57,850
On May 20, 2016, we issued $395$395.0 million aggregate principal amount of the 2021 Notes. The holders of the 2021 Notes may convert their 2021 Notes into cash upon the satisfaction of certain circumstances as described in Note 89. The conversion and settlement provisions of the 2021 Notes are based on the price of our ordinary shares at conversion or at maturity of the notes. In addition, the hedges and warrants associated with these convertible notes also include settlement provisions that are based on the price of our ordinary shares. The amount of cash we may be required to pay, or the number of shares we may be required to provide to note holders at conversion or maturity of these notes, is determined by the price of our ordinary shares. The amount of cash that we may receive from hedge counterparties in connection with the related hedges and the number of shares that we may be required to provide warrant counterparties in connection with the related warrants are also determined by the price of our ordinary shares.
Upon the expiration of our warrants issued in connection with the 2021 Notes, we will issue ordinary shares to the purchasers of the warrants to the extent the price of our ordinary shares exceeds the warrant strike price of $30.00 at that time. The following table shows the number of shares that we would issue to warrant counterparties at expiration of the warrants assuming various closing prices of our ordinary shares on the date of warrant expiration:
Share price Shares (in thousands)
$33.00(10% greater than strike price)1,681
$36.00(20% greater than strike price)3,082
$39.00(30% greater than strike price)4,268
$42.00(40% greater than strike price)5,284
$45.00(50% greater than strike price)6,164

The fair value of the 2021 Notes Conversion Derivative and the 2021 Notes Hedge is directly impacted by the price of our ordinary shares. We entered into the 2021 Notes Hedges in connection with the issuance of the 2021 Notes with the option counterparties. The 2021 Notes Hedges, which are cash-settled, are intended to reduce our exposure to potential cash payments that we are required to make upon conversion of the 2021 Notes in excess of the principal amount of converted notes if our ordinary share price exceeds the conversion price. The following table presents the fair values of the 2021 Notes Conversion Derivative and 2021 Notes Hedge as a result of a hypothetical 10% increase and decrease in the price of our ordinary shares. We believe that a 10% change in our share price is reasonably possible in the near term:
(in thousands)  
Fair value of security given a 10% decrease in share priceFair value of security as of September 24, 2017Fair value of security given a 10% increase in share priceFair value of security given a 10% decrease in share priceFair value of security as of April 1, 2018Fair value of security given a 10% increase in share price
2021 Notes Hedges (Asset)$143,147$177,818$214,475$92,239$115,369$140,126
2021 Notes Conversion Derivative (Liability)$138,848$177,870$219,133$89,985$115,427$142,824
Foreign Currency Exchange Rate Fluctuations
Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies could adversely affect our financial results. Approximately 25.6% and 25.0%25% of our net sales from continuing operations were from international sales fordenominated in foreign currencies during the three months ended September 24, 2017April 1, 2018, and September 25, 2016, respectively. Approximately 25.7% and 26.7% of our net sales were from international sales for the nine months ended September 24, 2017 and September 25, 2016, respectively. Wewe expect that foreign salescurrencies will continue to represent a similarly significant percentage of our net sales in the future. The cost of sales related to these sales is primarily denominated in U.S. dollars; however, operating costs related to these sales are largely denominated in the same respective currencies, thereby partially limiting our transaction risk exposure. For sales not denominated in U.S. dollars, an increase in the rate at which a foreign currency is exchanged for U.S. dollars will require more of the foreign currency to equal a specified amount of U.S. dollars than before the rate increase. In such cases, if we price our products in the foreign currency, we will receive less in U.S. dollars than we did before the rate increase went into effect. If we price our products in U.S. dollars and our competitors price their products in local currency, an increase in the relative strength of the U.S. dollar could result in our prices not being competitive in a market where business is transacted in the local currency.

In the first quarter of 2018, approximately 90% of our net sales denominated in foreign currencies were derived from European Union countries, which are denominated in the Euro; from the United Kingdom, which are denominated in the British pound; from Australia which are denominated in Australian dollar; and from Canada, which are denominated in the Canadian dollar. Additionally, we have significant intercompany receivables, payables, and debt from our foreign subsidiaries that are denominated in foreign currencies, principally the Euro, the Japanese yen, the British pound, the Australian dollar, and the Canadian dollar. Our principal exchange rate risk, therefore, exists between the U.S. dollar and the Euro, British pound, Australian dollar, and the Canadian dollar. Fluctuations from the beginning to the end of any given reporting period result in the revaluation of our foreign currency-denominated intercompany receivables, payables, and debt generating currency translation gains or losses that impact our non-operating income and expense levels in the respective period.
As discussed in Note 56 to the condensed consolidated financial statements, during 2017, we enterentered into certain short-term derivative financial instruments in the form of foreign currency forward contracts. These forward contracts arewere designed to mitigate our exposure to currency fluctuations in our intercompany balances denominated currently in Euros, British pounds, and Canadian dollars. Any change in the fair value of these forward contracts as a result of a fluctuation in a currency exchange rate iswas expected to be offset by a change in the value of the intercompany balance. These contracts are effectively closed at the end of each reporting period. We discontinued our foreign currency forward contracts derivative program in 2018.

A uniform 10% strengthening in the value of the U.S. dollar relative to the currencies in which our transactions are denominated would have resulted in an increase in operating income of approximately $2.0 million for the three months ended April 1, 2018. This hypothetical calculation assumes that each exchange rate would change in the same direction relative to the U.S. dollar. This sensitivity analysis of the effects of changes in foreign currency exchange rates does not factor in a potential change in sales levels or local currency prices, which can also be affected by the change in exchange rates.
ITEM 4. CONTROLS AND PROCEDURES.
Disclosure Controls and Procedures
OurWe have established disclosure controls and procedures, (asas such term is defined in RulesRule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended)1934. Our disclosure controls and procedures are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our principal executive officer and principal financial officer by others within our organization. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of April 1, 2018 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange

Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms of the Securitiesforms. Disclosure controls and Exchange Commissionprocedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. The Chief Executive Officer (CEO)Based on this evaluation, our principal executive officer and the Chief Financial Officer (CFO), with assistance from other members of management, have reviewed the design and effectiveness of our disclosure controls and procedures as of September 24, 2017 and, based on their evaluation, haveprincipal financial officer concluded that our disclosure controls and procedures were effective as of such date.
Remediation of Previously Disclosed Material Weakness in Internal Control Over Financial Reporting
Management previously reported in our Annual Report on Form 10-K for the fiscal year ended December 25, 2016 a material weakness in our internal control over financial reporting related to ineffective design and operation of general information technology controls related to user access to certain information technology systems that are relevant to our financial reporting processes and that are intended to ensure that access to financial applications and data is adequately restricted to appropriate personnel and monitored to ensure adherence to Company policies. Our management initiated a plan to remediate the material weakness. With detailed oversight, our management implemented the following corrective actions:
improved the design, operation and monitoring of control activities and procedures associated with user access to our information technology systems;
hired additional information technology expertise to support our controls over and monitoring of our information technology systems; and
educated and re-trained control owners regarding internal control processes to mitigate identified risks and maintain adequate documentation to evidence the effective design and operation of such processes.
During the fiscal quarter ended September 24, 2017, we completed our testing of the operational effectiveness of the actions discussed above. We have concluded that the enhanced control processes have now been operating for a sufficient period of time so as to provide reasonable assurance as to their effectiveness, and, as a result, that the material weakness described above was remediated as of September 24, 2017.April 1, 2018.
Changes in Internal Control Over Financial Reporting
Other thanDuring the remediation steps taken above,three month period ended April 1, 2018, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) during the fiscal quarter ended September 24, 2017, that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.
From time to time, we or our subsidiaries are subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of our business and some of which involve claims for damages that are substantial in amount. These actions and proceedings may relate to, among other things, product liability, intellectual property, distributor, commercial, and other matters. These actions and proceedings could result in losses, including damages, fines, or penalties, any of which could be substantial, as well as criminal charges. Although such matters are inherently unpredictable, and negative outcomes or verdicts can occur, we believe we have significant defenses in all of them, are vigorously defending all of them, and do not believe any of them will have a material adverse effect on our financial position. However, we could incur judgments, pay settlements, or revise our expectations regarding the outcome of any matter. Such developments, if any, could have a material adverse effect on our results of operations in the period in which applicable amounts are accrued, or on our cash flows in the period in which amounts are paid.
The actions and proceedings described in this section relate primarily to Wright Medical Technology, Inc. (WMT),WMT, an indirect subsidiary of Wright Medical Group N.V., and are not necessarily applicable to Wright Medical Group N.V. or other affiliated entities. Maintaining separate legal entities within our corporate structure is intended to ring-fence liabilities.  We believe our ring-fenced structure should preclude corporate veil-piercing efforts against entities whose assets are not associated with particular claims.

Governmental Inquiries
On August 3, 2012, we received a subpoena from the United States Attorney's Office for the Western District of Tennessee requesting records and documentation relating to our PROFEMUR® series of hip replacement devices. The subpoena covers the period from January 1, 2000 to August 2, 2012. We will continue to cooperate with the investigation.as required.
Patent Litigation
In June 2013, Anglefix, LLC filed suit in the United States District Court for the Western District of Tennessee, alleging that our ORTHOLOC® products infringe Anglefix’s asserted patent, which was licensed to Anglefix by the University of North Carolina (UNC). On April 14, 2014, we filed a request for Inter Partes Review (IPR) with the U.S. Patent and Trademark Office. On June 30, 2015, the Patent Office Board entered judgment in our favor as to all patent claims at issue in the IPR and twelve patent claims remained at issue in the District Court. In January 2017, UNC was added to the District Court case as a co-plaintiff. On July 13, 2017, the Court denied plaintiffs’ motion for summary judgment of infringement, and granted our motion for summary judgment of noninfringement as to the asserted apparatus claims. The Court denied our motion as to the asserted method claims based on the perceived possible existence of a fact issue. In the wake of the Court’s rulings, on July 28, 2017, plaintiffs Anglefix and UNC stipulated to dismissal of their claims against us with prejudice. On the same date, the Court entered judgment dismissing plaintiffs’ claims against us with prejudice, thereby ending the case.
On September 23, 2014, Spineology filed a patent infringement lawsuit, Case No. 0:14-cv-03767, in the U.S. District Court in Minnesota, alleging that our X-REAM® bone reamer infringes U.S. Patent No. RE42,757 entitled “EXPANDABLE REAMER.” In January 2015, on the deadline for service of its complaint, Spineology dismissed its complaint without prejudice and filed a new, identical complaint. We filed an answer to the new complaint with the Court on April 27, 2015. The Court conducted a Markman hearing on March 23, 2016. Mediation was held on August 11, 2016, but no agreement could be reached. The Court issued a Markman decision on August 30, 2016, in which it found all asserted product claims invalid as indefinite under applicable patent laws and construed several additional claim terms. The parties completed fact and expert discovery with respect to the remaining asserted method claims. We filed a motion for summary judgment of non-infringement of the remaining asserted patent claims and motions to exclude testimony from Spineology’s technical and damages experts. Spineology filed a motion for summary judgment of infringement. On July 25, 2017, the Court granted our motion for summary judgment of non-infringement; denied Spineology’s motion for summary judgment of infringement; and denied all remaining motions as moot. The Court also entered judgment in our favor and against Spineology on all issues. Spineology has appealed the judgment to the U.S. Court of Appeals for the Federal Circuit.Circuit and we are awaiting oral argument, which is scheduled for June 4, 2018.
On September 13, 2016, we filed a civil action, Case No. 2:16-cv-02737-JPM, against Spineology in the U.S. District Court for the Western District of Tennessee alleging breach of contract, breach of implied warranty against infringement, and seeking a judicial declaration of indemnification from Spineology for patent infringement claims brought against us stemming from our sale and/or use of certain expandable reamers purchased from Spineology. Spineology filed a motion to dismiss on October 17, 2016, but withdrew the motion on November 28, 2016. On December 7, 2016, Spineology filed an answer to our complaint and counterclaims, including counterclaims relating to a 2004 non-disclosure agreement between Spineology and WMT. On December 28, 2016, we filed a motion to dismiss the counterclaims relating to that 2004 agreement. On January 4, 2017, Spineology filed a motion for summary judgment on certain claims set forth in our complaint. We opposed that motion. On January 27, 2017, we filed a motion for summary judgment on certain issues pertaining to our indemnification claims. Spineology opposed that motion.

On July 7, 2017, the Court extended the deadlines for completing discovery until after it rulesruled on those pending motions. On August 29, 2017, the Court ruled on the motions to dismiss and for summary judgment. In view of that decision, on September 22, 2017, the parties stipulated, and the Court entered, a judgment that effectively ended the case in a draw. We have appealed the judgment as to our claims against Spineology to the U.S. Court of Appeals for the Sixth Circuit.Circuit and are awaiting oral argument. Spineology did not appeal the District Court’s dismissal of its contract counterclaim.
In August 2016, we received a letter from KFx Medical Corporation (KFx) alleging that a legacy Tornier product (the Piton Suture Anchor) infringes one of KFx’s patents when used in knotless double row tissue fixation techniques. On April 6, 2017, we filed a declaratory judgment action in the United States District Court for the District of Delaware, Case No. 1:17-cv-00384, seeking declaratory judgment of non-infringement and invalidity of United States Patent Nos. 7,585,311; 8,100,942; and 8,109,969. On April 20, 2017, KFx filed an answer and counterclaim alleging we indirectly infringe, and induce infringement of, these patents. On March 13, 2018, we entered into a settlement agreement pursuant to which we paid KFx a one-time lump sum license fee in an immaterial amount in exchange for a fully paid global license to the relevant KFx patents. As a result of the settlement, the Court dismissed the case (including KFx’s counterclaims of patent infringement) with prejudice on March 23, 2018.
Product Liability
We have been named as a defendant, in some cases with multiple other defendants, in lawsuits in which it is alleged that as yet unspecified defects in the design, manufacture, or labeling of certain metal-on-metal hip replacement products rendered the products defective. The lawsuits generally employ similar allegations that use of the products resulted in excessive metal ions and particulate in the patients into whom the devices were implanted, in most cases resulting in revision surgery (collectively, the CONSERVE® Claims) and generally seek monetary damages. We anticipate that additional lawsuits relating to metal-on-metal hip replacement products may be brought.

Because of the similar nature of the allegations made by several plaintiffs whose cases were pending in federal courts, upon motion of one plaintiff, Danny L. James, Sr., the United States Judicial Panel on Multidistrict Litigation on February 8, 2012 transferred certain actions pending in the federal court system related to metal-on-metal hip replacement products to the United States District Court for the Northern District of Georgia, for consolidated pre-trial management of the cases before a single United States District Court Judge (the MDL). The consolidated matter is known as In re: Wright Medical Technology, Inc. Conserve Hip Implant Products Liability Litigation.
Certain plaintiffs have elected to file their lawsuits in state courts in California. In doing so, most of those plaintiffs have named a surgeon involved in the design of the allegedly defective products as a defendant in the actions, along with his personal corporation. Pursuant to contractual obligations, we have agreed to indemnify and defend the surgeon in those actions. Similar to the MDL proceeding in federal court, because the lawsuits generally employ similar allegations, certain of those pending lawsuits in California were consolidated for pre-trial handling on May 14, 2012 pursuant to procedures of California State Judicial Counsel Coordinated Proceedings (the JCCP). The consolidated matter is known as In re: Wright Hip Systems Cases, Judicial Counsel Coordination Proceeding No. 4710. Pursuant to previously disclosed settlement agreements with the Court-appointed attorneys representing plaintiffs in the MDL and JCCP described below, the MDL and JCCP were closed to new cases effective October 18, 2017 and October 31, 2017, respectively.
Every hip implant case, including metal-on-metal hip casecases, involves fundamental issues of law, science and medicine that often are uncertain, that continue to evolve, and which present contested facts and issues that can differ significantly from case to case. Such contested facts and issues include medical causation, individual patient characteristics, surgery specific factors, statutes of limitation, and the existence of actual, provable injury.
The first bellwether trialExcluding claims resolved in the MDL commenced on November 9, 2015 in Atlanta, Georgia. On November 24, 2015, the jury returned a verdict in favorsettlement agreements described below, as of the plaintiff and awarded the plaintiff $1 million in compensatory damages and $10 million in punitive damages. We believeApril 1, 2018, there were significant trial irregularitiesapproximately 110 metal-on-metal hip cases pending in U.S. courts. This number includes cases ineligible for settlement, cases which opted out of settlement, post-settlement cases, and vigorously contested the trial result. On December 28, 2015, we filed a post-trial motion for judgment as a matter of law or, in the alternative, for a new trial or a reduction of damages awarded. On April 5, 2016, the trial judge issued an order reducing the punitive damage award from $10 million to $1.1 million, but otherwise denied our motion. On May 4, 2016, we filed a notice of appeal with the United States Court of Appeals for the Eleventh Circuit. The United States Court of Appeals for the Eleventh Circuit heard oral arguments on January 26, 2017 and on March 20, 2017, the Eleventh Circuit Court of Appeals upheld the lower court’s verdict. On April 10, 2017, we filed a petition for rehearing en banc or for panel rehearing, which was denied. In light of this denial, we elected to forego a further appeal and paid the judgment in July 2017.
The first bellwether trial in the JCCP, which was scheduled to commence on October 31, 2016, and subsequently rescheduled to January 9, 2017, was settled for an immaterial amount.
The firstexisting state court metal-on-metal hip trialcases that were not part of the MDL or JCCP, Donald Deline v. Wright Medical Technology, Inc., et al, commenced on October 24, 2016 in the Circuit Court of St. Louis County, Missouri. On November 3, 2016, the jury returned a verdict in our favor. The plaintiff has appealed.
JCCP.  As of September 24, 2017,April 1, 2018, we estimate there also was pending approximately 60 non-U.S. metal-on metal cases and 30 modular neck cases alleging claims related to the release of metal ions. We also estimate that as of April 1, 2018 there were approximately 1,000 lawsuits pending550 non-revision claims awaiting dismissal in the MDL and JCCP and an additional 50 cases pending in various U.S. state courts. As of that date, we have also entered into approximately 850 so called "tolling agreements" with potential claimants who have not yet filed suit. The number of lawsuits pending in the MDL and JCCP and tolling agreements disclosed above includes the claims that have been resolved pursuant to the Master Settlement Agreement and Second Settlement Agreements discussed below. Based onterms of the settlement agreements. Although there is a limited time period during which dismissed non-revision claims may be refiled, it is presently available information, we believe approximately 350 of these matters allege claims involving bilateral implants. As of September 24, 2017, there were also approximately 50 non-U.S. lawsuits pending.unclear how many non-revision claimants will elect to do so. We believe we have data that supports the efficacy and safety of our metal-on-metal hip products. While continuing to dispute liability, the parties continue to mediate unresolved claims.
On November 1, 2016, WMT entered into a Master Settlement Agreement (MSA)the MSA with Court-appointed attorneys representing plaintiffs in the MDL and JCCP. Under the terms of the MSA, the parties agreed to settle 1,292 specifically identified CONSERVE®, DYNASTY®and LINEAGE® claims that meet the eligibility requirements of the MSA and are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a settlement amount of $240 million. Due to apparent demand from additional claimants excluded from settlement because of the 1,292 claims ceiling, but otherwise eligible for participation, on May 15, 2017, WMT agreed to settle an additional 53 such claims, on terms substantially identical to the MSA settlement terms, for a maximum additional settlement amount of $9.4 million.

On October 3, 2017, WMT entered into two additional settlement agreements (collectively, the Second Settlement Agreements)Agreements with the Court-appointed attorneys representing plaintiffs in the MDL and JCCP. Under the terms of the Second Settlement Agreements, the parties agreed to settle 629 specifically identified CONSERVE®, DYNASTY® and LINEAGE® claims that meet the eligibility requirements of the Second Settlement Agreements and are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a maximum settlement amount of $89.75 million. The comprehensive settlement amount iswas contingent on WMT’s recovery of new insurance paymentsproceeds totaling at least $35 million from applicable insurance carriers by December 31, 2017. On December 29, 2017, WMT entered into a First Amendment to the Third Settlement Agreement pursuant to which the deadline for the recovery of new insurance proceeds totaling at least $35 million from applicable insurance carriers was extended through February 28, 2018 and, on February 23, 2018, WMT entered into a Second Amendment to the Third Settlement Agreement pursuant to which the deadline was extended through March 30, 2018. On March 29, 2018, WMT entered into a Third Amendment to the Third Settlement Agreement which eliminates the contingency and gives WMT the option, by September 30, 2018, to either pay or make available for payment the then outstanding deficit on the insurance contingency or transfer to eligible claimants WMT’s claims against the insurance carriers with whom WMT has not settled, and pay or make available for payment such insurance deficit in March 2019, subject to the right to recover these funds from any plaintiff recoveries from carriers plus ten percent interest, plus an additional $5 million in costs, in each case after recovery by plaintiffs’ counsel of costs and fees. In connection with such transfer agreement, WMT would also enter into a stipulated judgment in the amount of $541 million, which judgment would not be recoverable against WMT or its affiliates. To date, certain of the insurance carriers have contributed $21.9 million of funds applicable against the $35 million contingency, leaving a $13.1 million deficit as of April 30, 2018.

The first state court metal-on-metal hip trial not part of the MDL or JCCP, Donald Deline v. Wright Medical Technology, Inc., et al, commenced on October 24, 2016 in the Circuit Court of St. Louis County, Missouri. On November 3, 2016, the jury returned a verdict in our favor. The plaintiff appealed and the appellate court heard oral argument on November 8, 2017. On February 20, 2018, the Missouri Court of Appeals, Eastern District, denied the plaintiff’s appeal and upheld the verdict of the trial court. The plaintiff’s time for seeking any further relief from the verdict has lapsed and this matter is closed.
We have received claims for personal injury against us associated with fractures of our PROFEMUR® long titanium modular neck product (Titanium Modular Neck Claims). As of September 24, 2017,April 1, 2018, there were 30approximately 20 pending U.S. lawsuits and approximately 60 pending non-U.S. lawsuits alleging such claims. These lawsuits generally seek monetary damages.
We are aware that MicroPort has recalled certain sizes of its cobalt chrome modular neck products as a result of alleged fractures. As of September 24, 2017,April 1, 2018, there were sixfive pending U.S. lawsuits and eightseven pending non-U.S. lawsuits against us alleging personal injury resulting from the fracture of a cobalt chrome modular neck. These lawsuits generally seek monetary damages.
In June 2015, a jury returned a $4.4 million verdict against us in a case involving a fractured hip implant stem sold prior to the MicroPort closing. This was a one-of-a-kind case unrelated to the modular neck fracture cases we have previously reported. There are no other cases pending related to this component, nor are we aware of other instances where this component has fractured. The case, Alan Warner et al. vs. Wright Medical Technology, Inc. et al., case no. BC 475958, which was filed on December 27, 2011, was tried in the Superior Court of the State of California for the County of Los Angeles, Central District. In September 2015, the trial judge reduced the jury verdict to $1.025 million and indicated that if the plaintiff did not accept the reduced award he would schedule a new trial solely on the issue of damages. The plaintiff elected not to accept the reduced damage award, and both parties have appealed. The Court has not setOn November 14, 2017, our primary insurance carrier agreed to defend and indemnify us in connection with this lawsuit under a date for a new trialreservation of rights. On January 9, 2018, the California appellate court heard oral argument on the issueparties’ cross-appeals. On March 6, 2018, the appellate court rejected our appeal and granted plaintiff’s, reinstating the original jury award of damages$4.4 million, plus interest. Our primary insurance carrier has directly paid this amount in full and we do not expect itthe case will do so until the appeals are adjudicated.be dismissed with prejudice.
Insurance Litigation
On June 10, 2014, St. Paul Surplus Lines Insurance Company (Travelers), which was an excess carrier in our coverage towers across multiple policy years, filed a declaratory judgment action in the Chancery Court of Shelby County, Tennessee naming us and certain of our other insurance carriers as defendants and asking the Court to rule on the rights and responsibilities of the parties with regard to the CONSERVE® Claims. This case is known as St. Paul Surplus Lines Insurance Company v. Wright Medical Group, Inc., et al. Among other things, Travelers appeared to dispute our contention that the CONSERVE® Claims arise out of more than a single occurrence thereby triggering multiple policy periods of coverage.  Travelers further sought a determination as to the applicable policy period triggered by the alleged single occurrence.  On June 17, 2014, we filed a separate lawsuit in the Superior Court of the State of California, County of San Francisco for declaratory judgment against certain carriers and breach of contract against the primary carrier, and moved to dismiss or stay the Tennessee action on a number of grounds, including that California is the most appropriate jurisdiction. This case is known as Wright Medical Group, Inc. et al. v. Federal Insurance Company, et al. On September 9, 2014, the California Court granted Travelers' motion to stay our California action. On April 29, 2016, we filed a dispositive motion seeking partial judgment in our favor in the Tennessee action, which motion is pending and has been referred to a Special Master to consider the parties’ arguments and report to the Court by December 8, 2017. Oral argument on the motion is scheduled for February 23, 2018.arguments. On June 10, 2016, Travelers withdrew its motion

for summary judgment in the Tennessee action. One of the other insurance companies in the Tennessee action has stated that it will re-file a similar motion in the future.
In March 2017, Lexington Insurance Company (“Lexington”)(Lexington), which had been dismissed from the Tennessee action, requested arbitration under five Lexington insurance policies in connection with the CONSERVE® Claims. We subsequently engaged in discussions and correspondence with Lexington about the scope of the requested arbitration(s). On or about October 27, 2017, Lexington filed an Application for Order to Compel Arbitration in the Commonwealth of Massachusetts, Suffolk County Superior Court, naming WMT, Wright Medical Group, Inc., and Wright Medical Group N.V. We are presently considering our responseopposed the Application. On February 28, 2018, the Massachusetts Court ordered the parties to arbitrate the Application.two Lexington insurance policies containing Massachusetts arbitration clauses but did not order arbitration under the remaining three Lexington policies at issue. We have appealed that ruling.
On October 28, 2016, WMT and Wright Medical Group, Inc. (WMG)WMG entered into a Settlement Agreement, Indemnity and Hold Harmless Agreement and Policy Buyback Agreement (Insurance Settlement Agreement) with a subgroup of three insurance carriers, namely Columbia, Casualty Company (Columbia), Travelers and AXIS Surplus Lines Insurance Company (collectively, the Three Settling Insurers), pursuant to which the Three Settling Insurers paid WMT an aggregate of $60 million (in addition to $10 million previously paid by Columbia) in a lump sum. This amount is in full satisfaction of all potential liability of the Three Settling Insurers relating to metal-on-metal hip and similar metal ion release claims, including but not limited to all claims in the MDL and the JCCP, and all claims asserted by WMT against the Three Settling Insurers in the Tennessee action described above. The amount due under the Insurance Settlement Agreement was paid in the fourth quarter of 2016 and the Three Settling Insurers have been dismissed from the Tennessee action.
On December 13, 2016, we filed a motion in the Tennessee action described above to include allegations of bad faith against the primary insurance carrier. The motion was subsequently amended on February 8, 2017 to add similar bad faith claims against the remaining excess carriers. On April 13, 2017, the Court denied our motion, without prejudice to our right to re-assert the motion at a later time. On August 29, 2017, we refiled the motion to add a bad faith claim against the primary and excess insurance carriers. The Court granted our motion on October 19, 2017 and, on October 23, 2017, we filed amended cross-claims alleging bad faith against all of the insurance carriers. On November 9, 2017, our primary insurance carrier brought a motion to dismiss and strike our bad faith claim. The remaining excess carriers either joined the primary insurer’s motion or brought their own separate motions. On December 22, 2017 and December 29, 2017, we opposed the insurers’ motions to dismiss and strike our claim for bad faith. The motions remain pending. Two of the remaining insurers in the Tennessee action take the position that certain prior payments made by them totaling $10 million were purportedly made under reservations of rights and they claim the right to seek recoupment of those prior payments.
On September 29, 2015, Markel InternationalFebruary 22, 2018, we and certain of our subsidiaries entered into a Settlement and Release Agreement (Second Insurance Settlement Agreement) with Federal Insurance Company Ltd., as successor to Max Insurance Europe Ltd. (Max Insurance), which is the third insurance carrier in our coverage towers across multiple policy years, asserted that the terms and conditions

identified in its reservation(a subsidiary of rights will preclude coverage for the Titanium Modular Neck Claims. We strongly dispute the carrier's position, and in accordance with the dispute resolution provisions of the policy, on January 18, 2016, we filed a Notice of Arbitration against Max Insurance in London, EnglandChubb Insurance) (Federal), pursuant to the provisionswhich Federal has paid us a single lump sum payment of the Arbitration Act$15 million (in addition to $5 million previously paid by Federal). This is in full satisfaction of 1996.  We are seeking reimbursement, upall potential liability of Federal relating to the policy limits of $25 million, of costs incurreddesignated metal-on-metal hip claims, including but not limited to all claims asserted by our subsidiary WMT against Federal in the defensepreviously disclosed insurance coverage litigation. On March 20, 2018, Federal was dismissed from the Tennessee and settlementCalifornia actions described above.
On April 19, 2018, we and certain of our subsidiaries entered into a Settlement and Release Agreement (Third Insurance Settlement Agreement) with Catlin Underwriting Agencies Limited for and on behalf of Syndicate 2003 at Lloyd’s of London (Lloyd’s Syndicate 2003) pursuant to which Lloyd’s Syndicate 2003 has paid us a single lump sum payment of $1.9 million (in addition to $5 million previously paid by Lloyd’s Syndicate 2003). This amount is in full satisfaction of all potential liability of Lloyd’s Syndicate 2003 relating to designated metal-on-metal hip claims, including but not limited to all claims asserted by our subsidiary WMT against Lloyd’s Syndicate 2003 in the Titanium Modular Neck Claims.previously disclosed insurance coverage litigation. On May 1, 2018, Lloyd’s Syndicate 2003 was dismissed from the Tennessee action described above. The parties have conducteddismissal of Lloyd’s Syndicate 2003 from the first round of arbitration andCalifornia action is in process.
During the second roundquarter of arbitration is scheduled2018, we resolved the previously reported insurance arbitration. See Note 13 to our condensed consolidated financial statements for later this year.additional information.
Wright/Tornier Merger Related Litigation
On November 26, 2014, a class action complaint was filed in the Circuit Court of Tennessee, for the Thirtieth Judicial District, at Memphis (Tennessee Circuit Court), by a purported shareholder of WMG under the caption City of Warwick Retirement System v. Gary D. Blackford et al., CT-005015-14. An amended complaint in the action was filed on January 5, 2015. The amended complaint names as defendants WMG, Tornier, Trooper Holdings Inc. (Holdco), Trooper Merger Sub Inc. (Merger Sub), and the members of the WMG board of directors. The amended complaint asserts various causes of action, including, among other things, that the members of the WMG board of directors breached their fiduciary duties owed to the WMG shareholders in connection with entering into the merger agreement, approving the merger, and causing WMG to issue a preliminary Form S-4 that allegedly fails to disclose material information about the merger. The amended complaint further alleges that Tornier, Holdco, and Merger Sub aided and abetted the alleged breaches of fiduciary duties by the WMG board of directors. The plaintiff is seeking, among other things, injunctive relief enjoining or rescinding the merger and an award of attorneys’ fees and costs.

On December 2, 2014, a separate class action complaint was filed in the Tennessee Chancery Court by a purported shareholder of WMG under the caption Paulette Jacques v. Wright Medical Group, Inc., et al., CH-14-1736-1. An amended complaint in the action was filed on January 27, 2015. The amended complaint names as defendants WMG, Tornier, Holdco, Merger Sub, Warburg Pincus LLC and the members of the WMG board of directors. The amended complaint asserts various causes of action, including, among other things, that the members of the WMG board of directors breached their fiduciary duties owed to the WMG shareholders in connection with entering into the merger agreement, approving the merger, and causing WMG to issue a preliminary Form S-4 that allegedly fails to disclose material information about the merger. The amended complaint further alleges that WMG, Tornier, Warburg Pincus LLC, Holdco and Merger Sub aided and abetted the alleged breaches of fiduciary duties by the WMG board of directors. The plaintiff is seeking, among other things, injunctive relief enjoining or rescinding the merger and an award of attorneys’ fees and costs.
In an order dated March 31, 2015, the Tennessee Circuit Court transferred City of Warwick Retirement System v. Gary D. Blackford et al., CT-005015-14 to the Tennessee Chancery Court for consolidation with Paulette Jacques v. Wright Medical Group, Inc., et al., CH-14-1736-1 (Consolidated Tennessee Action). In an order dated April 9, 2015, the Tennessee Chancery Court stayed the Consolidated Tennessee Action; that stay expired upon completion of the Wright/Tornier merger. On September 19, 2016, the Tennessee Chancery Court entered an agreed order, dismissing the Jacques case without prejudice.
Other
In addition to those noted above, we are subject to various other legal proceedings, product liability claims, corporate governance, and other matters which arise in the ordinary course of business.
ITEM 1A. RISK FACTORS.
There have been no material changes to the risk factors that were discussed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 25, 2016,31, 2017, as filed with the SEC on February 23, 2017,27, 2018, other than the new or updated risk factors below which update or replace the existing risk factors addressing the same topic.topic and the deletion of the risk factor entitled “Our obligation to settle substantially all the remaining outstanding metal-on-metal hip claims may be cancelled if the insurance recovery contingency contained in the Second Settlement Agreements is not satisfied, which would leave a substantial number of metal-on-metal hip claims unresolved.”
Product liability lawsuits could harm our business and adversely affect our operating results or results from discontinued operations and financial condition if adverse outcomes exceed our product liability insurance coverage.
The manufacture and sale of medical devices expose us to significant risk of product liability claims. We are currently defendants in a number of product liability matters, including those relating to the OrthoRecon business, which legacy Wright divested to MicroPort in 2014. Legacy Wright remains responsible, as between it and MicroPort, for claims associated with products sold before divesting the OrthoRecon business to MicroPort.
We have been named as a defendant, in some cases with multiple other defendants, in lawsuits in which it is alleged that as yet unspecifiedcertain defects in the design, manufacture, or labeling of certain metal-on-metal and other hip replacement products rendered the products defective. The pre-trial management of certain of thesethe metal-on-metal claims has beenwas consolidated in the federal court system, in the United States District Court for the Northern District of Georgia under multi-district litigation (MDL) and certain other claims by the Judicial Counsel Coordinated Proceedings in state court in Los Angeles County, California. AsCalifornia (JCCP). Pursuant to previously disclosed settlement agreements with the Court-appointed attorneys representing plaintiffs in the MDL and JCCP, the MDL and JCCP were closed to new cases effective October 18, 2017 and October 31, 2017, respectively. Excluding claims resolved in the settlement agreements, as of September 24, 2017,April 1, 2018, there were approximately 1,000 lawsuits pending in the multi-district federal court proceeding and consolidated California state court proceeding, and an additional 50110 metal-on-metal hip cases pending in variousU.S. courts. This number includes cases ineligible for settlement, cases which opted out of settlement, post-settlement cases, and existing state courts.court cases that were not part of the MDL or JCCP. As of April 1, 2018, we estimate there also was pending approximately 60 non-U.S. metal-on metal cases, 30 U.S. cobalt chrome modular neck corrosion cases, 20 U.S. titanium modular neck fracture cases, 60 non-U.S. titanium modular neck fracture cases, 5 U.S. cobalt chrome modular neck fracture cases, and 7 non-U.S. cobalt chrome modular neck fracture cases. We also estimate that date, we have also entered into approximately 850 so called "tolling agreements" with potential claimants who have not yet filed suit. Asas of September 24, 2017,April 1, 2018 there were also

approximately 50 non-U.S. lawsuits550 non-revision claims awaiting dismissal in the MDL and JCCP pursuant to the terms of the settlement agreements. Although there is a limited time period during which dismissed non-revision claims may be refiled, it is presently pending.unclear how many non-revision claimants will elect to do so. We believe we have data that supports the efficacy and safety of the metal-on-metalour hip replacement systems,products, and have been vigorously defending these cases.
While continuing to dispute liability, on November 1, 2016, WMT entered into a Master Settlement Agreement (MSA) with Court-appointed attorneys representing plaintiffs in the MDL and JCCP. Under the terms of the MSA, the parties agreed to settle 1,292 specifically identified claims associated with CONSERVE®, DYNASTY® and LINEAGE® products that meet the eligibility requirements of the MSA and are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a settlement amount of $240 million. Due to apparent demand from additional claimants excluded from settlement because of the 1,292 claim ceiling, but otherwise eligible for participation, on May 15, 2017, WMT agreed to settle an additional 53 such claims, on terms substantially identical to the MSA settlement terms, for a maximum additional settlement amount of $9.4 million.
On October 3, 2017, WMT entered into two settlement agreements (collectively, the Second Settlement Agreements) with the Court-appointed attorneys representing plaintiffs in the MDL and JCCP. Under the terms of the Second Settlement Agreements, the parties agreed to settle 629 specifically identified CONSERVE®, DYNASTY® and LINEAGE® claims that meet the eligibility requirements of the Second Settlement Agreements and are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a maximum settlement amount of $89.75 million. The comprehensive settlement amount is contingent on WMT’s recovery of new insurance payments totaling at least $35 million from applicable insurance carriers by December 31, 2017.
Claims for personal injury have also been made against us associated with fractures of legacy Wright's PROFEMUR® long titanium modular neck product. We believe that the overall fracture rate for the product is low and the fractures appear, at least in part, to relate to patient demographics, and have been vigorously defending these matters. While continuing to dispute liability, we have been open to settling these claims in circumstances where we believe the settlement amount is reasonable relative to the risk and expense of litigation.
Our material product liability litigation is discussed in Note 1213 to our consolidated financial statements. These matters are subject to many uncertainties and outcomes are not predictable. Regardless of the outcome of these matters, legal defenses are costly. We have incurred and expect to continue to incur substantial legal expenses in connection with the defense of these matters. We could incur significant liabilities associated with adverse outcomes that exceed our products liability insurance coverage, which could adversely affect our operating results or results from discontinued operations and financial condition. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, operating results or results from discontinued operations, and cash flows.

In the future, we may be subject to additional product liability claims. We also could experience a material design or manufacturing failure in our products, a quality system failure, other safety issues, or heightened regulatory scrutiny that would warrant a recall of some of our products. Product liability lawsuits and claims, safety alerts and product recalls, regardless of their ultimate outcome, could result in decreased demand for our products, injury to our reputation, significant litigation and other costs, substantial monetary awards to or costly settlements with patients, product recalls, loss of revenue, and the inability to commercialize new products or product candidates, and otherwise have a material adverse effect on our business and reputation and on our ability to attract and retain customers.
Our obligation to settle substantially all the remaining outstanding metal-on-metal hip claims may be cancelled if an insufficient number of eligible claimants choose to participate, which would leave a substantial number of metal-on-metal hip claims unresolved.
Each of the Second Settlement Agreements contains a 95% opt-in requirement meaning WMT may terminate either Settlement Agreement prior to any settlement disbursement if claimants holding greater than 5% of eligible claims in Tranches 1 and 2, collectively, or claimants holding greater than 5% of eligible claims in Tranche 3, elect to “opt-out” of the settlement. We believe a participation rate of at least 95% is necessary in order to realize the benefits of the Second Settlement Agreements. On January 2, 2018, we received notification that 100% of the claimants in Tranches 1 and 2 opted in. We reviewed proof of claim documentation for these claimants and confirmed a final opt-in percentage of 100%. On or about May 1, 2018, we received notice from plaintiffs that the 95% opt-in threshold has also been met for Tranche 3. We have until May 30, 2018 to confirm this. If a 95% participation rate is not achieved with respect to both Settlement AgreementsTranche 3 there is a significant risk the Tranche 3 Second Settlement AgreementsAgreement will be cancelled. If the Tranche 3 Second Settlement Agreements areAgreement is cancelled, we will be required to continue defending the 629541 claims that would otherwise be settled, and the previously disclosed risks, uncertainties and contingencies associated with these claims will remain unresolved.
Our obligationCertain of our settlement agreements with insurance carriers include broad releases of coverage for present and future claims of personal injury alleged to settle substantially allbe caused by metal-on-metal hip components or the release of metalions, which could result in inadequate insurance coverage to defend and resolve these claims. In addition, our settlements with these carriers do not resolve previously disclosed disputes with the remaining outstandingcarriers concerning the extent of coverage available for metal-on-metal hip claims.
On October 28, 2016, our WMT and WMG subsidiaries entered into a Settlement Agreement with a subgroup of three insurance carriers, Columbia Casualty Company (Columbia), St. Paul Surplus Lines Insurance Company and AXIS Surplus Lines Insurance Company (Three Settling Insurers), pursuant to which the Three Settling Insurers paid $60 million (in addition to $10 million previously paid) in full settlement of all potential liability of the Three Settling Insurers for metal ion and metal-on-metal hip claims, may be cancelled if the insurance recovery contingency containedincluding but not limited to all claims in the SecondMDL and the JCCP. As part of the settlement, the Three Settling Insurers repurchased their policies in the five policy years beginning with the 2007-2008 policy year.
On February 22, 2018, we and certain of our subsidiaries entered into a Settlement Agreementsand Release Agreement (Second Insurance Settlement Agreement) with Federal Insurance Company, a subsidiary of Chubb Insurance (Federal), pursuant to which Federal has paid us a single lump sum payment of $15 million (in addition to $5 million previously paid by Federal). This amount is not satisfied, which would leave a substantial numberin full satisfaction of all potential liability of Federal relating to designated metal-on-metal hip claims, unresolved.including but not limited to all claims asserted by our subsidiary WMT against Federal in the previously disclosed insurance coverage litigation.
UnderOn April 19, 2018, we and certain of our subsidiaries entered into a Settlement and Release Agreement (Third Insurance Settlement Agreement) with Catlin Underwriting Agencies Limited for and on behalf of Syndicate 2003 at Lloyd’s of London (Lloyd’s Syndicate 2003) pursuant to which Lloyd’s Syndicate 2003 has paid us a single lump sum payment of $1.9 million (in addition to $5 million previously paid by Lloyd’s Syndicate 2003). This amount is in full satisfaction of all potential liability of Lloyd’s Syndicate 2003 relating to designated metal-on-metal hip claims, including but not limited to all claims asserted by our subsidiary WMT against Lloyd’s Syndicate 2003 in the termspreviously disclosed insurance coverage litigation.
As a result of the Second Settlement Agreements,above-mentioned settlement agreements, we have no further coverage from the parties agreedThree Settling Insurers for present or future metal-on-metal or metal ion claims and we have no further coverage from Federal or Lloyd’s Syndicate 2003 for present or future metal-on-metal claims (as defined in the settlement agreements).
Our existing product liability insurance coverage may be inadequate to settle 629 specifically identified CONSERVEprotect us from any liabilities we might incur.
If the product liability claims brought against us involve uninsured liabilities or result in liabilities that exceed our insurance coverage, our business, financial condition, and operating results could be materially and adversely affected. Further, such product liability matters may negatively impact our ability to obtain insurance coverage or cost-effective insurance coverage in future periods. We remain in litigation with the insurance carriers with whom we have not settled (Lexington and Catlin, with remaining policy limits totaling $30 million and $5 million, respectively) concerning the amount of coverage available to satisfy potential liabilities associated with the metal-on-metal hip claims against us. An unfavorable outcome in this litigation could have an adverse effect on our financial condition and results from discontinued operations if we ultimately are subject to liabilities associated with these claims that exceed coverage amounts not in dispute.

MicroPort’s recall of certain sizes of its cobalt chrome modular neck devices due to alleged fractures could result in additional product liability claims against us. Although we have contested these claims, adverse outcomes could harm our business and adversely affect our results from discontinued operations and financial condition.
®, DYNASTYIn August 2015, MicroPort announced the voluntary recall of certain sizes of its PROFEMUR® Long Cobalt Chrome Modular Neck devices manufactured from June 15, 2009 to July 22, 2015. Because MicroPort did not acquire the OrthoRecon business until January 2014, many of the recalled devices were sold by legacy Wright prior to the acquisition by MicroPort. Under the asset purchase agreement with MicroPort, legacy Wright retained responsibility, as between it and LINEAGEMicroPort, for claims for personal injury relating to sales of these products prior to the acquisition. We were not consulted by MicroPort in connection with its recall, and we were aware of only twelve lawsuits alleging personal injury related to cobalt chrome neck fractures (five in the United States and seven outside the United States) as of April 1, 2018. However, if the number of product liability claims alleging personal injury from fractures of cobalt chrome modular necks we sold prior to the MicroPort transaction were to become significant, this could have an adverse effect on our results from discontinued operations and financial condition.
A competitor’s recall of its modular hip systems, and the liability claims and adverse publicity which ensued, could generate copycat claims against modular hip systems legacy Wright sold.
On July 6, 2012, Stryker Corporation announced the voluntary recall of its Rejuvenate Modular and ABG II modular neck hip stems citing risks including the potential for fretting and/or corrosion at or about the modular neck junction. Although Stryker’s recalled modular neck hip stems differ in design and material from the PROFEMUR® claims that meet the eligibility requirementsmodular neck systems legacy Wright sold before divestiture of the Second Settlement AgreementsOrthoRecon business, we have previously noted the risk that Stryker’s recall and are eitherthe resultant publicity could negatively impact sales of modular neck systems of other manufacturers, including the PROFEMUR® system, and that Stryker’s action has increased industry focus on the safety of cobalt chrome modular neck products. We have carefully monitored the clinical performance of the PROFEMUR® modular neck hip system, which combine a cobalt chrome modular neck and a titanium stem. With over 33,000 units sold since this version was introduced in 2009, and an extremely low complaint rate, we remain confident in the safety and efficacy of this product. Nevertheless, in light of Stryker’s recall, the resulting product liability claims to which it has been subject, and the general negative publicity surrounding “metal-on-metal” articulating surfaces (which do not involve modular hip stems), there remains a risk that, even in the absence of clinical evidence, claims for personal injury relating to sales of these products before divestiture of the OrthoRecon business could increase, which could have an adverse effect on our financial condition and results from discontinued operations since legacy Wright retained responsibility, as between it and MicroPort, for these claims. Since the 2012 Stryker recall, we have from time to time been subject to product liability claims alleging corrosion of cobalt chrome modular necks. We presently have approximately 30 such lawsuits pending in various U.S. courts.
As a result of different shareholder voting requirements in the MDLNetherlands relative to laws in effect in certain states in the United States, we may have less flexibility with respect to the issuance of our ordinary shares than companies organized in the United States.
Currently, our articles of association provide for an authorized share capital consisting of one class of shares, being 320,000,000 ordinary shares, each with a nominal value of €0.03. Under Dutch law, our authorized share capital can be increased by an amendment to our articles of association. Our articles of association can be amended upon a proposal of our board of directors by the general meeting of shareholders, which resolution can be adopted with a simple majority in a meeting where at least one-third of the outstanding shares are represented. New ordinary shares may be issued pursuant to a resolution of shareholders, or JCCP, orpursuant to such resolution of the board of directors if designated thereto by shareholders. Additionally, subject to court-approved tolling agreementsspecified exceptions, Dutch law grants statutory preemption rights to existing shareholders where shares are being issued for cash consideration. The right of our shareholders to subscribe for ordinary shares pursuant to preemptive rights may be limited or restricted by our shareholders and our shareholders may delegate such authority to the board of directors. Such designations of authority to our board of directors may remain in the MDL or JCCP,effect for up to five years and may be renewed for additional periods of up to five years.
Currently our board of directors is authorized to issue shares up to a maximum settlement amount of $89.75 million. The comprehensive settlement amount is contingent on WMT’s receiving new insurance payments

totaling at least $35 million from applicable insurance carriers by December 31, 2017. To date, the insurance carriers have not agreed to contribute this or any other amountequal to the settlement. WMT may cancel its obligationauthorized but unissued share capital and to settle 541 claims includedlimit or exclude pre-emptive rights in Tranche 3respect of such issue of shares until June 18, 2020, without further shareholder approval. We cannot provide any assurance that these authorizations will always be approved on a timely basis, especially since our shareholders did not approve these two authorizations the Second Settlement Agreements iflast time we submitted them to a vote of our shareholders at our annual general meeting in June 2016. The failure to renew these authorizations on a timely basis could limit our ability to issue equity and thereby adversely affect our ability to run our business and the foregoing insurance recovery contingency is not satisfied. If the obligation to settle these Tranche 3 claims is cancelled, we will be required to continue defending the Tranche 3 claims that would otherwise be settled in which case the previously disclosed risks, uncertainties and contingencies associated with these claims will remain unresolved.holders of our securities.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.

ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
ITEM 5. OTHER INFORMATION.
Not applicable.The following information included in this Quarterly Report on Form 10-Q is provided pursuant to Item 1.01 “Entry into a Material Definitive Agreement” and Item 2.03 “Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant” of Form 8-K:
General
On May 7, 2018 (Closing Date), Wright Medical Group N.V. amended and restated our previously disclosed Credit, Security and Guaranty Agreement, dated as of December 23, 2016 (as amended, ABL Credit Agreement) to add a $40 million term loan facility (Term Loan Facility). The parties to the Amended and Restated Credit, Security and Guaranty Agreement (Credit Agreement) are us, as a guarantor, Wright Medical Group, Inc. (Borrower Representative) and certain of our other wholly-owned U.S. subsidiaries, as borrowers (collectively, Borrowers), Midcap Funding IV Trust, as administrative agent (Agent) and a lender and the additional lenders from time to time party thereto.
In addition to continuing to provide for the $150.0 million senior secured asset based line of credit on substantially the same terms as set forth in the ABL Credit Agreement, the Credit Agreement also provides for the Term Loan Facility. The initial $20.0 million term loan tranche was funded on the Closing Date. We may at any time borrow the second $20.0 million term loan tranche, but will be required to do so no later than May 7, 2019 unless we meet certain adjusted EBITDA targets; in which case, we will be permitted to extend the borrowing requirement for up to an additional two years.
All borrowings under the Term Loan Facility are subject to the satisfaction of customary conditions, including the absence of default and the accuracy of representations and warranties in all material respects.
Interest, Amortization and Fees
The interest rate applicable to borrowings under the Term Loan Facility will be equal to one-month LIBOR plus 7.85%, subject to a 1.00% LIBOR floor.
Amortization payments under the Term Loan Facility are due in equal monthly installments beginning on May 1, 2019 unless we meet certain adjusted EBITDA targets; in which case, the amortization payments would not commence until May 1, 2021.
In addition to paying interest on the outstanding loans under the Term Loan Facility, the Borrowers will also be required to pay certain other customary fees related to Agent’s administration of the Term Loan Facility.
Prepayments
The Term Loan Facility requires mandatory prepayments, subject to the right of reinvestment and certain other exceptions, in amounts equal to 100% of the net cash proceeds from certain asset sales and casualty and condemnation events in excess of $10 million in any fiscal year. Any voluntary or mandatory prepayment under the Term Loan Facility, subject to certain exceptions, is subject to a 1.00% prepayment premium.
Final Maturity
The advances under the Term Loan Facility will be due and payable in full at the same time as the outstanding loans under the ABL Facility.
Collateral and Guarantors
All of the obligations under the Term Loan Facility and the ABL Facility are guaranteed jointly and severally by us and each of the Borrowers and are secured by a senior first priority security interest in substantially all existing and after-acquired assets of us and each Borrower on the terms set forth in the Credit Agreement.
Restrictive Covenants and Other Matters
In addition to financial and liquidity covenants consistent with those in the ABL Credit Agreement, while the Term Loan Facility is outstanding, we are required to maintain a minimum adjusted EBITDA, as described in the Credit Agreement. The Credit Agreement will not affect our ability to meet our existing contractual obligations, including payments under the Borrower Representative’s contingent value rights agreement, except in circumstances where an event of default (subject to certain exceptions) has occurred and is continuing.
The Credit Agreement also contains negative covenants, representations and warranties, affirmative covenants and events of default, in each case subject to grace periods, thresholds and materiality qualifiers consistent with the ABL Credit Agreement.
The foregoing represents only a summary of the material terms of the Credit Agreement, does not purport to be complete and is

qualified by the text of the Credit Agreement, which is expected to be filed as an exhibit to our Quarterly Report on Form 10-Q for the quarter ending July 1, 2018 and is incorporated herein by reference.
ITEM 6. EXHIBITS.
(a)Exhibits.
The following exhibits are being filed or furnished with this Quarterly Report on Form 10-Q:
Exhibit No. Exhibit Method of Filing
10.1Second Amendment to the Third Settlement Agreement dated as of February 23, 2018 between Wright Medical Technology, Inc. and the Counsel Listed on the Signature Pages Thereto
31.1Incorporated by reference to Exhibit 10.90 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (File No. 001-35065)
10.2Third Amendment to the Third Settlement Agreement dated as of March 29, 2018 between Wright Medical Technology, Inc. and the Counsel Listed on the Signature Pages Thereto
Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K as filed with the Securities and Exchange Commission on April 4, 2018 (File No. 001-35065)
10.3Omnibus Limited Consent and Amendment No. 3 to Credit, Security and Guaranty Agreement and Amendment No. 2 to Pledge Agreement dated as of February 13, 2018 among Wright Medical Group N.V. (as Guarantor), Wright Medical Group, Inc. (as Borrower), Certain Other Direct and Indirect Subsidiaries Listed on the Signature Pages Thereto (each as Borrower), Midcap Funding IV Trust (as Lender and Agent) and the Financial Institutions or other Entities Parties Thereto
Filed herewith
31.1 Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes‑Oxley Act of 2002 
Filed herewith
31.2
 Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes‑Oxley Act of 2002 
Filed herewith
32.1
 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002 
Furnished herewith
101 The following materials from Wright Medical Group N.V.’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 24, 2017,April 1, 2018, formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Balance Sheets as of September 24, 2017April 1, 2018 and December 25, 2016,31, 2017, (ii) the Consolidated Statements of Operations for the three and nine months ended September 24,April 1, 2018 and March 26, 2017, and September 25, 2016, (iii) the Consolidated Statements of Comprehensive Loss for the three and nine months ended September 24,April 1, 2018 and March 26, 2017, and September 25, 2016, (iv) the Consolidated Statements of Cash Flows for the ninethree months ended September 24,April 1, 2018 and March 26, 2017, and September 25, 2016, and (v) Notes to Consolidated Financial Statements Filed herewith


SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
November 1, 2017May 9, 2018    
WRIGHT MEDICAL GROUP N.V.
 
By:  /s/ Robert J. Palmisano
 Robert J. Palmisano
 President and Chief Executive Officer 
 (principal executive officer)
  
By:  /s/ Lance A. Berry
 Lance A. Berry
 Senior Vice President and Chief Financial Officer 
 (principal financial officer)






6359